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C H A P T E R  1

This thesis describes the outcomes of different treatment strategies in patients with 
early arthritis and is, for a large part, based on results of the IMPROVED-study (Induction 
therapy with Methotrexate and Prednisone in Rheumatoid Or Very Early arthritic Disease). 
First a general overview is given, starting with the clinical picture of rheumatoid and 
undifferentiated arthritis as known to date, followed by an introduction on currently 
available therapies and possible treatment strategies. Then an overview of the various 
outcome measures which are referred to in the thesis,  followed by a short discourse 
on the concept of treatment response and the prediction of that response. In the last 
section, the IMPROVED-study is explained in more detail.
RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a systemic auto-immune disease characterized by 
inflammatory arthritis.1 RA affects approximately 0.5-1% of the population worldwide 
and women are affected two to three times more often than men.2 The exact aetiology 
of RA is still unknown, but it appears that several genes and environmental factors act 
together to cause the disease.1 
Patients with RA can present with systemic symptoms such as fatigue, fever, malaise 
and weight loss and usually have complaints of morning stiffness and symptoms of 
joint swelling and pain of mainly the small joints of the hands and feet and often other 
peripheral joints.3 These symptoms cause impairments in functional capacity which 
frequently leads to a decreased work ability and restrictions in social activities and 
quality of life.4, 5 In early stages of RA, functional capacity is most impaired by disease 
activity (inflammation) while later in the disease course damage that has occurred in 
affected joints contributes to functional impairment which is then irreversible even with 
effective antirheumatic drugs.6 
The diagnosis of rheumatoid arthritis is based on patient assessment by a trained physician. 
To facilitate identification of patients with RA in clinical trials and scientific publications, 
classification criteria were formulated. In the 1950s, the first classification criteria for RA 
were published by the American College of Rheumatology (ACR),7 which were revised 
in 1987.8 With a growing awareness among rheumatologists that patients with RA need 
to start treatment as early as possible, it was felt that the old criteria were inadequate to 
identify patients in the earliest stages of the disease. Therefore, new classification criteria 
were published by the ACR and the European League Against Rheumatism (EULAR) in 
2010. These criteria allow classification of patients with arthritis of a short duration with 
clinical and/or laboratory features known to be associated with a risk of persistence of 
symptoms and/or structural joint damage. Classification of these patients as having RA 














Undifferentiated arthritis (UA) is a term commonly used for inflammatory arthritis where 
a specific rheumatic disease could not be diagnosed. There is an overlap with what 
was called ‘probable rheumatoid arthritis’ and ‘possible rheumatoid arthritis’, for which 
the ACR provided classification criteria in the 1950s.7 Several databases have included 
patients with UA to determine how symptoms, laboratory features and radiological 
outcomes might develop over time. The results, in part, depend on the initial definition 
of UA and the inclusion criteria.10
Spontaneous remission has been reported in 40-55% of UA patients and progression 
to RA in 17-32%.10, 11 Thus, in a subset of patients UA can be considered to be an early 
stage of RA. Radiographic progression, disease activity and functional capacity have 
shown to be similar in patients who present with UA but progress to RA in 1 year as in 
patients who present directly with classifiable early RA.12 Although several models have 
been developed to identify which UA patient has ‘very early RA’, it remains a challenge 
to predict progression, or alternatively spontaneous remission, in each individual UA 
patient correctly. This means that a decision to start antirheumatic treatment still largely 
depends on the physician’s insight or ‘gut feeling’. 
Table 1. The 2010 American College of Rheumatology/European League against Rheumatism classification 
criteria for rheumatoid arthritis.9
Target population: patients who have at least 1 joint with definite clinical synovitis (swelling)  
with the synovitis not better explained by another disease.
A score of ≥6/10 is needed for classification of a patient as having definite RA.
Joint involvement:
1 large joint 0
2-10 large joints 1
1-3 small joints 2
4-10 small joints 3
>10 joints (at least 1 small joint) 5
Serology:
Negative RF and negative ACPA 0
Low-positive RF or low-positive ACPA 2
High-positive RF or high-positive ACPA 3
Acute-phase reactants:
Normal CRP and normal ESR 0
Abnormal CRP or abnormal ESR 1
Duration of symptoms:
< 6 weeks 0
≥ 6 weeks 1















Non-biologic Disease-modifying antirheumatic drugs 
Non-biologic disease-modifying antirheumatic drugs (DMARDs) are still the initial 
treatment in most patients with RA and are sometimes also used in patients with UA. 
Methotrexate (MTX) is considered the ‘anchor drug’ in RA since it has proven to be 
effective with acceptable toxicity.13 Other synthetic DMARDs often used in the treatment 
of RA are sulphasalazine14 (SSZ), leflunomide15 and the moderately effective antimalarial 
hydroxychloroquine (HCQ).16, 17 DMARDs are often used in combination with other non-
biologic DMARDs, but also with (low dose) corticosteroids or biologic DMARDs (see 
below). In 1996 O’Dell and colleagues presented the ‘O’Dell scheme’ in patients with 
advanced RA who failed on previous DMARD monotherapy. O’Dell’s combination of 
MTX, SSZ and HCQ, proved to be superior to either MTX alone or combinations of SSZ 
plus HCQ, MTX plus SSZ, or MTX plus HCQ.18 Recently, the combination of MTX with 
SSZ and HCQ was shown to be no less effective than MTX with etanercept, a biologic 
DMARD, in patients with RA who had insufficient response on MTX alone19 and more 
effective than MTX monotherapy in patients with UA with a high risk of RA.20 
Corticosteroids
Parenteral and oral corticosteroids are often used in the treatment of RA, usually 
in combination with DMARDs. Steroids suppress inflammation leading to rapid 
improvement of clinical parameters and, as shown for oral corticosteroids and possibly 
also intra-articular corticosteroid injections, to a reduction in erosive joint damage.21-24 
Despite its benefits, doctors and patients often have concerns about the potential 
side effects of oral corticosteroids such as the Cushing face, osteoporosis, myopathy, 
glucose intolerance or cardiovascular disease.25, 26 It is therefore recommended to use 
oral corticosteroids in low doses and discontinue as soon as possible.27
Biologic DMARDs
Tumour Necrosis Factor (TNF) alpha, a cytokine produced by monocytes, macrophages 
and lymphocytes, stimulates and induces inflammation. It is found in the synovial 
fluid in the joints of patients with RA and is associated with synovitis and joint 
destruction.28, 29 TNF-alpha inhibitors, most often in combination with methotrexate, 
have shown to be effective anti-rheumatic drugs, suppressing symptoms as well as 
radiological joint damage progression in the majority of patients.30, 31 
Currently, there are five TNF-alpha inhibitors available for treatment of RA; infliximab 
(IFX), adalimumab (ADA), certolizumab, golimumab and etanercept. Current rules on 
reimbursement of the costs of these expensive drugs require that RA patients have had 
previous treatment with MTX and at least one other non-biologic DMARD but still have 
active disease. Other biologic DMARDs have also become available for patients with 













toculizumab (anti-IL-6), abatacept (a T-cell costimulation inhibitor) and rituximab (a 
B-cell depletor). These drugs do not feature in this thesis and are no further discussed. 
TREATMENT STRATEGIES
During the last decades, much has changed in the treatment of patients with arthritis 
with the aim to improve disease outcomes.32, 33 Until the 1980s, patients with RA were 
treated according to the ‘pyramid strategy’, first with either aspirin or other non-
steroidal anti-inflammatory drugs (NSAID). Only if joint damage occurred DMARDs 
were started, which were thought to be so potentially harmful that the way to use them 
was ‘go low, go slow’.34 Any improvement in clinical symptoms was considered a good 
response. When it became clear that DMARD toxicity was not significantly worse than 
NSAID toxicity, DMARDs were started earlier in the disease course and there were more 
treatment adjustments when the clinical response was insufficient.32, 35, 36 This so-called 
‘sawtooth strategy’ was superior to the ‘pyramid strategy’; more patients had adequate 
suppression of symptoms and also joint damage was better suppressed.37, 38  
After multiple decades of research, changing treatment paradigms, resulting in ever 
improving disease outcomes, there are a few concepts dominating the current treatment 
approaches in RA. The first concept is that treatment should be initiated directly after 
diagnosis.39, 40 This was one of the reasons why the classification criteria for RA were 
again revised in 2010, to be able to identify patients with early RA. Rheumatologists are 
recommended to start treatment in patients with any arthritis that is likely to progress, 
become chronic or lead to structural damage.9, 41 Second, many trials have shown that 
initial combination therapy, especially when including prednisone or a TNF-alpha 
inhibitor, leads to a better suppression of disease activity, better functional ability 
and less radiological damage progression without the burden of increased toxicity, 
when compared to monotherapy.18, 20, 21, 31, 42-44 This notwithstanding the fact that MTX 
monotherapy may be effective in a selection of patients, although it may take more 
time to achieve than with the aforementioned combinations of drugs.45, 46 Since it is 
not reliably possible to identify which patients would benefit from methotrexate alone, 
starting with a combination treatment in all patients allows more rapid response and 
avoids undertreatment. The third concept is that disease activity should be monitored 
frequently (‘tight control’) and that treatment should be adjusted in order to achieve 
and maintain a predefined target level of disease activity (for instance a threshold of a 
composite score that represents signs and symptoms of inflammation). This is called the 
‘treat to target’ approach.22, 47
The same principles are advocated for those patients with UA which is considered an 
early phase of RA. Initiation of treatment already in the phase of UA might possibly induce 
permanent remission or at least stop the disease process and prevent progression to RA. 
This early and restricted period of time in which alteration of the disease course might 













How to treat UA remains undecided. In the PROMPT study it was shown that one year 
of MTX monotherapy only postponed but did not prevent progression to RA.49 It might 
be possible that initial combination therapy with prednisone or early use of a TNF-alpha 
inhibitor in UA will prevent progression to RA and induce remission without joint 
damage and with restored functional ability.  
DISEASE OUTCOMES
Disease Activity Score (DAS)
The Disease Activity Score (DAS) is one of the composite measures to assess disease 
activity in patients with arthritis. It may be used in clinical trials to compare treatment 
response and in daily practice to register disease activity over time and to measure the 
response to treatment, intensifying treatment until the treatment target is achieved and 
tapering when disease activity is persistently low. 
The DAS combines the results of four components; the number of painful joints represented 
in a tender joint count which is called the Ritchie Articular Index (RAI)50, the number of swollen 
joints (the swollen joint count), global health as indicated by the patient on a 100 mm visual 
analogue scale (VAS) and the erythrocyte sedimentation rate (ESR). The DAS is calculated 
according to the following formula:  0.54√(RAI) + 0.065(swollen joint count) + 0.33ln(ESR) + 
0.0072VASgh. The DAS is based on evaluation of 44 joints for joint swelling and 53 joints for 
joint tenderness, compared to the DAS28 which is based on examination of only 28 joints.51
Remission 
Remission has become a realistic goal for many patients.52 According to the European 
League Against Rheumatism (EULAR) recommendations for the management of 
rheumatoid arthritis (2010), remission is the primary aim of treatment, especially in 
patients with early RA.27 The FIN-RACo trial was one of the first trials aiming for remission 
as a treatment goal.44 After 11 years follow-up they concluded that treatment targeted at 
remission has long term benefits when it comes to disease outcomes and that it greatly 
suppresses radiological joint damage progression.53 
Various definitions of remission are used and in general it can be defined as the absence 
of (troublesome) disease activity.54 The FIN-RACo trial used the old ACR remission criteria 
(≥ 5 of the following, for at least 2 consecutive months: morning stiffness <15 minutes, no 
fatigue, no joint pain, no joint tenderness or pain on motion, no soft tissue swelling in joints 
or tendon sheaths and an ESR <30 mm/hour for a female or <20 mm/hour for a male)55 
leaving out the absence of fatigue. A DAS <1.6 was found to be equivalent to absence 
of disease as represented by those ACR remission criteria.56 In 2011, a collaboration of 
the ACR, the EULAR and the Outcome Measures in Rheumatology (OMERACT) initiative 
resulted in a definition of remission in RA based on composite measures of disease 
activity (using the simplified disease activity index score (SDAI) which should be <3.3)) or 













has a tender joint count ≤1, a swollen joint count ≤1, a C-reactive protein (CRP) ≤1mg/dl 
and a patient global VAS-score ≤1 (on a scale of 0-10 centimeter).57
Ideally, after early and effective treatment, patients continue to be in remission while 
medication is tapered and finally stopped, to achieve drug free remission (DFR). In daily 
practice this is sometimes achieved and in one clinical trial (the BeSt study) aiming for 
DFR was integrated in the treatment protocol.45 In a previous evaluation of the predictors 
of DFR, it was found that a symptom duration less than 12 weeks and absence of anti-
citrullinated protein antibodies (ACPA) increased the chance of sustained DFR. There 
was no clear association between a targeted treatment strategy (aiming at low disease 
activity) and achieving DFR in that study.58
Functional ability 
Functional ability is one of the most reported outcome measures in clinical practice and 
in clinical trials. In the Netherlands it is measured with the Dutch version of the Health 
Assessment Questionnaire (HAQ).35, 59 The HAQ is a 24-item questionnaire to assess the 
level of difficulty the patient is having with activities of daily living. These activities are 
divided into eight categories; dressing, rising, eating, walking, personal hygiene, reach, 
grip and errands. Per question the score ranges between 0 (no difficulties doing this) and 3 
(unable to do this). By summing the highest score within each category and dividing it by 
8, the total score ranges from 0 to 3. The minimum clinically important difference is 0.22.60
In addition to the HAQ, the McMaster-Toronto Arthritis Patients Preference Questionnaire 
(MACTAR) also measures functional ability. Patients have to rank a maximum of five 
activities in which they are experiencing problems as a result of their arthritis. Over time, 
improvement or deterioration of these five activities can be monitored. The change scores 
from baseline vary between -38 (maximum deterioration) to +38 (maximum improvement). 
The MACTAR is sensitive to change and useful to detect small differences.61, 62 
Quality of life and psychological well being
Treatment to suppress disease activity may lead to symptom relief and this may result in 
improvement of patient reported outcomes (PROs) such as health related quality of life 
(HRQoL) and mental wellbeing.63
HRQoL can be assessed using the Short-Form 36 (SF-36). This widely used questionnaire 
measures eight domains of health; physical functioning, role limitations due to 
physical and due to emotional functioning, bodily pain, general health, vitality, social 
functioning and mental health. The total score ranges from 0 (worst) to 100 (best). Based 
on the scores in the different domains, a mental component score (MCS) and a physical 
component score (PCS) can be calculated. These component scores are standardized, 
based on the worldwide population norm, to a mean of 50 and a standard deviation 
of 10.64, 65 The minimum clinically important difference is a 5-10 point difference from 













Depressive symptoms are more common in patients with RA, compared to healthy 
individuals.67-70  The association between depression and arthritis may be explained 
by decreased functioning and pain, but may also be an effect of inflammatory 
processes.71, 72 Therefore, suppression of disease activity and especially achieving clinical 
remission may improve depressive symptoms.67 Depressive symptoms severity can be 
measured with the Beck Depression Inventory II (BDI-II). Based on the diagnostic criteria 
for major depression as described in the DSM-IV, a sum of scores is composed ranging 
from 0-63. A total score of 0-13 indicates minimal depressive symptoms, a score of 
14-19 denotes mild depressive symptoms, 20-28 moderate depressive symptoms and 
29-63 severe depressive symptoms.73 Another focus on mood is optimism, a trait which 
can be assessed with the 10-item Life Orientation Test Revised (LOT-R). The total score 
ranges between 0 and 24 and a higher score means a person is more optimistic.74 Low 
dispositional optimism has been defined as a total score <12.75 
Radiological joint damage
Radiological joint damage can be assessed on radiog raphs of the hands, wrists and 
feet with the modified Sharp-van der Heijde score (SHS). The proximal interphalangeal 
(PIP) and metacarpophalangeal (MCP) joints of the hands, six areas in each wrist, the 
metatarsophalangeal (MTP) and both hallux interphalangeal joints of the feet are scored 
for erosions and joint space narrowing. The maximum score is 448.76 
Progression of joint damage over time is often used as an outcome measure in clinical 
trials. Rapid Radiological Progression (RRP) is defined as an increase in SHS of ≥5 points 
in the first year after diagnosis and is associated with more severe damage progression 
in a later phase of the disease.77-79 Risk factors for rapid progression of joint damage may 
help guiding clinicians in their choice for the initial treatment step which may help to 
prevent RRP. In the BeSt study a matrix model to assess the risk of RRP was developed in 
patients with recent onset active RA. The model predicts the risk of RRP based on status 
for rheumatoid factor (RF) and/or ACPA, CRP, the number of erosions at baseline and 
initial treatment choice (either initial MTX monotherapy or initial combination therapy 
of MTX with SSZ and prednisone or with IFX).80 
As patients are treated in more early disease stages and according to treat-to-target 
strategies aiming at remission, fewer patients show radiological joint damage progression 
and damage is generally less severe.6, 47 Because of that, it may become difficult to 
compare the effect of various therapies on inhibition of structural joint damage.81 For 
individual patients radiological damage progression as treatment outcome may become 
increasingly irrelevant compared to symptoms of inflammation since the changes 
found on radiographs are too limited to have impact on, for instance, functional ability. 
Evaluating the effect of treatment on cartilage and bone is still scientifically relevant 
and may require other imaging techniques and/or serum biomarker studies where plain 













Bone mineral density measurement
Metacarpal osteopenia is a very early manifestation of RA not detected by conventional 
radiographs.83, 84 Subtle changes in metacarpal bone mineral density (mBMD) can be 
measured with Digital X ray Radiogrammetry (DXR). In patients with early RA, mBMD 
loss during the first year after diagnosis is predictive for radiological damage up to five 
years afterwards. mBMD loss is associated with persistent disease activity and mBMD 
gain is seen in patients in prolonged clinical remission.85-88 It may be possible that early 
mBMD loss, measured in the first few months of treatment, may represent a risk factor 
for joint damage progression already after 1 year. If so, very early mBMD loss may trigger 
early treatment adjustments in RA. 
RESPONSE TO TREATMENT
Individualized treatment would help to avoid both lack of response and delay in 
improvement with the risk of damage progression (undertreatment) as well as the risk 
of potential side effects and in some cases high costs of therapies which in retrospect 
would have been unnecessary (overtreatment). Individualized treatment would be 
possible if we could predict the response to treatment.89-92
Multiple predictors of response to treatment have been identified, mainly disease 
characteristics at baseline; disease activity, functional ability, radiological joint damage, 
acute phase reactants and the presence of autoantibodies like ACPA and RF.89, 91, 93  It 
appears that also body mass index (BMI) may be associated with treatment response, 
as it was reported that patients with a high BMI responded less well to combination 
therapy with MTX and IFX, than patients with low or normal BMI.94 
THE IMPROVED-STUDY
The IMPROVED-study (Induction therapy with Methotrexate and Prednisone in 
Rheumatoid Or Very Early arthritic Disease) is a multicentre, single-blind, randomized 
clinical trial in patients with recent-onset arthritis. In 12 centers in the Western part of the 
Netherlands, over 600 patients with UA and early RA were included between May 2007 
and September 2010. RA was defined according to the 2010 ACR/EULAR classification 
criteria9 with a symptom duration of ≤2 years. Patients were classified as UA if they had at 
least one joint with synovitis and one other painful joint which was clinically suspected 
for early RA, regardless of symptom duration. 
In patients with UA in the PROMPT-study it was shown that MTX monotherapy only postponed 
and not prevented progression to RA.49 In clinical trials in patients with RA, initial combination 
therapy including methotrexate and prednisone resulted in earlier improvement and better 
outcomes than monotherapy with non-biologic DMARDs.20, 21, 42, 95, 96 The IMPROVED-study 
was designed to start with such a combination both in very early RA and UA to see whether 













in the IMPROVED-study were initially treated with a combination of MTX (25mg/week) and 
a tapered high dose of prednisone (started at 60mg/day for one week and then tapered to 
7,5 mg/day in 7 weeks) during the first 4 months. 
The BeSt-study and the TICORA-trial have shown that a tight controlled treatment 
strategy targeted at low disease activity or remission leads to better disease outcomes.42, 47 
Up to 48% of the patients in the BeSt study achieved a DAS<1.6, while treatment was 
steered at a DAS≤2.4, and up to 14% achieved DFR.45 To try to improve these results, the 
IMPROVED treatment strategy is remission steered, with remission defined as a DAS<1.6 
(‘DAS-remission’).56 Every four months a DAS-evaluation was performed and based on 
the DAS, treatment was adjusted (figure 1). 
If DAS-remission was achieved, medication was tapered and or stopped. In case DAS-
remission was not achieved, medication was intensified (with a dose increase, drug 
switch or restart of medication that was previously discontinued). Patients who did not 
achieve DAS-remission after 4 months of initial combination therapy were randomized 
into 2 treatment strategy arms to answer which approach would result in more (drug 
free) remission. In arm 1, a combination of MTX, SSZ, HCQ and low dose prednisone 
was used, if that failed to induce DAS-remission adalimumab with MTX was started. 
In arm 2, adalimumab with MTX was started immediately. In both arms, adalimumab 
Figure 1. Study flow chart up until the second study year. MTX: methotrexate, HCQ: hydroxychloroquine, 
SSZ: sulfasalazine. Colours: orange=prednisone, green=MTX, dark blue=treatment left to decision 
of rheumatologist, aqua=HCQ, yellow=SSZ, purple=adalimumab biweekly, double thickness 














was to be increased (from 40 mg every 2 weeks to 40 mg weekly) if DAS-remission was 
not achieved. If DAS-remission was still not achieved on 40 mg weekly, the next choice 
of treatment was left to the decision of the treating physician, with DAS-remission 
as treatment target and the intention to taper and ultimately stop medication. The 
IMPROVED treatment strategy is visualized in figure 1. 
Radiological damage progression, mBMD changes, functional ability, quality of life and 
depressive symptoms severity were to be measured over time and compared in relation 
to remission rates and between patients with UA and RA and between patients with and 
without ACPA.
OUTLINE OF THIS THESIS
It remains a challenge to further optimize and improve treatment and treatment 
outcomes for patients with early (rheumatoid) arthritis. This thesis focuses on various 
treatment strategies as well as predictors for response to treatment and different 
kinds of outcome measures, varying from remission and joint damage progression to 
psychological wellbeing.
Chapter 2 describes disease outcomes in patients with undifferentiated arthritis (UA) 5 
years after initial treatment with methotrexate (MTX) or placebo in the PROMPT study. In 
chapter 3 the main outcomes together with predictors for early remission after the first 
four months of remission steered treatment in the IMPROVED-study are evaluated. In 
chapter 4 and chapter 5 the outcomes after respectively one and two years follow-up in 
the IMPROVED-study are described. In chapter 6 the influence of baseline characteristics 
on the possibility to achieve drug free remission (DFR), is investigated. In chapter 7 the 
association between high body mass index (BMI) and treatment response in patients 
with recent onset rheumatoid arthritis (RA) in the BeSt study is assessed. Chapter 9 
describes the performance of a matrix model to predict damage progression designed 
in the BeSt study and asks the question whether rapid radiological progression (RRP) 
still exists. In the last two chapters the associations between various patient reported 
outcomes (PROs) and disease activity and remission in the IMPROVED-study are 
described. Chapter 10 describes the severity of depressive symptoms and dispositional 
optimism both before and after the first four months of therapy. Follow-up of functional 
ability and health related quality of life (HRQoL) during the first study year and the 
association with remission are described in chapter 11.
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ABSTRACT
Objective: To assess long-term disease outcome of undifferentiated arthritis (UA) after 
initial treatment with methotrexate (MTX) or placebo.
Methods: 110 patients with UA were randomised to receive MTX (n=55) or placebo 
(n=55) for 1 year. After 5 years the outcomes for diagnosis (rheumatoid arthritis, 1987 
criteria (RA (1987)), UA or UA in remission) and radiographic progression were compared 
between treatment arms and anti-citrullinated protein antibody (ACPA)-positive and 
-negative patients. Outcomes were recalculated for patients who, with hindsight, might 
have been classified at baseline as having RA according to the 2010 criteria (RA (2010)).
Results: 25 patients in the MTX group and 29 in the placebo group progressed to RA (1987) 
(p=0.45). MTX delayed progression from UA to RA (1987) but only in ACPA-positive patients. 
Drug-free remission was achieved in 35 patients, 20 of whom were initially treated with MTX, 
and 32 were ACPA-negative. ACPA-positive patients had more radiographic progression, 
regardless of treatment. Forty-three patients (39%) could be reclassified as having had RA 
(2010) at baseline, 6/24 (25%) of whom achieved remission after placebo treatment.
Conclusions: After 5 years there is no lasting benefit of a 1 year initial course of MTX for 
patients with undifferentiated arthritis, compared with initial placebo. Progression to 
classifiable RA was not suppressed, drug-free remission not induced and the progression 
of radiological damage was similar in both groups. Reclassification at baseline with 










































Patients with inflammatory arthritis may present with undifferentiated arthritis (UA) 
not fulfilling any classification criteria.1 Although UA may be a self-limiting disease, a 
considerable proportion of patients with UA has an early manifestation of rheumatoid 
arthritis (RA). For patients with recent-onset RA, a timely start of treatment with disease-
modifying antirheumatic drugs (DMARDs) has proved to be crucial for achieving better 
clinical and radiographic outcomes. Therefore starting antirheumatic treatment already 
in UA might result in even more sustained benefits and potentially a chance for cure.2, 3
In the PROMPT study, we showed that treatment with methotrexate (MTX) compared 
with placebo for 1 year did not prevent, but (in anti-citrullinated protein antibody 
(ACPA)-positive patients at least) delayed, the development of UA into RA.4 MTX reduced 
signs and symptoms at 12 months and radiographic progression at 18 months—again, 
particularly in ACPA-positive patients with UA. It remains to be determined whether this 
very early introduction of MTX has benefits in the long term.
In this study, the effect of early MTX treatment on clinical and radiological outcomes was 
assessed after 5 years. In addition, we identified predictors for disease progression to 
classifiable RA and for persistent remission in patients with UA. Finally, we re-evaluated 
current and previous study results using the 2010 classification criteria for RA to see 
whether MTX monotherapy in patients who fulfil the 2010 criteria and have relatively 
low disease activity is sufficient to achieve remission.5
PATIENTS AND METHODS
Study setting and design
The PROMPT study is a prospective double-blind, randomised, placebo-controlled 
multicentre trial evaluating the effect of 1 year MTX versus placebo treatment.4 All 110 
patients fulfilled the 1958 classification criteria for probable RA6, were DMARD-naïve 
and had a symptom duration of <2 years.
Patients started treatment with MTX 15 mg/week (6 tablets of 2.5 mg) or the equivalent 
number of placebo tablets. No other DMARDs or steroids were allowed during the 
first year of treatment. Every 3 months, medication was increased by 5 mg MTX or 
two tablets placebo to a maximum of 30 mg or 12 tablets placebo a week as long as 
the Disease Activity Score (DAS) was >2.4. As soon as a patient fulfilled the 1987 ACR 
classification criteria for RA7 (RA (1987)) during the first year, medication was switched 
to open-label MTX. After 12 months, the study drug was tapered and discontinued in 
the patients who had not developed RA (1987). IgM rheumatoid factor (RF) and ACPA 
were measured retrospectively in serum samples taken at baseline using commercial 
kits (Euro-Diagnostica, Arnhem, The Netherlands). ACPA levels >25 U/ml and RF levels 
>5 IU/ml were considered positive. Further details of the study and results of the primary 








































To substantiate the PROMPT study results, the patients were reclassified at baseline 
according to the 2010 American College of Rheumatology/ European League Against 
Rheumatism (ACR)/EULAR criteria for RA.
Outcomes
At 3, 6, 9, 12, 30 and 60 months the diagnosis was recorded as classifiable RA (1987)7 or UA 
(UA not fulfilling the 1987 ACR criteria), drug-free remission (DFR) without progression 
to RA (1987) or other (lost to follow-up or other diagnosis). Remission was defined as 
a DAS≤1.68 or the absence of synovitis or self-reported absence of symptoms without 
use of DMARDs. Radiographs of the hands and feet were obtained at inclusion and at 
6, 12, 18, 30 and 60 months. Radiographic progression was scored by two independent 
readers using the Sharp–van der Heijde scoring (SHS) method9 with radiographs blinded 
for patient identity, treatment group and time order.
Statistical analysis
Baseline and disease characteristics were compared between the two treatment arms, 
between ACPA-positive and ACPA-negative patients and between patients with RA 
(1987) and patients in DFR using the χ2  test, Student’s t test and the Mann–Whitney 
U test. To assess differences in time to reach one of the endpoints (RA (1987) or DFR), 
Kaplan–Meier curves with a log rank test were used.
In a large proportion of patients the readers independently scored no radiological 
damage progression (71% and 73%, respectively). Consequently, interobserver and 
intraobserver intraclass correlation coefficients were not suitable for measuring 
reliability.10 In 71% of patients both readers scored the same progression. A consensus 
score was reached for the radiographs with inter-reader differences ≥1, based on a 
median (IQR) difference in progression score between readers of 0 (0–2). The mean 
score of the readers was used for the analyses. We performed a completers’ analysis, 
then repeated the analyses with imputed values according to last observation carried 
forward, for incomplete series.
Univariate logistic regression analysis was used to identify potential predictors for 
fulfilling the criteria of RA (1987) after 60 months and for DFR, including age, sex, 
symptom duration, baseline SHS, baseline erosion score, baseline DAS, baseline Health 
Assessment Questionnaire, ACPA status and RF status. The univariate predictors that 
reached statistical significance (p≤0.1) were entered stepwise in a multivariate model. 
Age and gender, as known predictors, were forced into the model. To avoid problems of 
colinearity, separate analyses were done with either ACPA or RF.
RESULTS
After 5 years, seven patients were lost to follow-up because they had either moved away 








































Baseline and disease characteristics of the 110 patients with UA (55 receiving MTX, 55 
placebo) are shown in table 1. 
Diagnosis at 60 months
1987 RA criteria
After 60 months 54/110 patients (49%) had disease progression and fulfilled the 1987 
RA classification criteria. In the MTX group 25/55 patients (45%) progressed to RA (1987), 
in the placebo group 29/55 (53%) patients (p=0.45) (table 2). All the 29 patients in the 
placebo group who progressed to RA (1987) did so within 1 year, compared with 11/25 
in the MTX group. Yet, possibly owing to small numbers, Kaplan–Meier analyses showed 
no significant difference in time to progression to RA between the treatment groups 
(p=0.11) (figure 1A). Of the patients who progressed to RA (1987), the 25 patients in 
the MTX group used a median of 1 (1–2) DMARDs in 5 years, compared with a median 
of 2 (1–3) DMARDs in the 29 patients of the placebo group. ACPA-positive patients 
progressed significantly faster to RA (1987) than ACPA-negative patients (p<0.001). 
Initial MTX treatment delayed progression to RA (1987) in the ACPA-positive group but 
not in the ACPA-negative group (p<0.001) (figure 1B,C).
Drug-free remission and persistent UA
In the MTX group 25/55 patients (45%) did not progress to RA (1987). At 5 years, of 
those 25 patients, 19 were in persistent DFR since 1 year, and one was in DFR after 
using hydroxychloroquine for 35 months. Five were still diagnosed as having active 
UA (table 2). In the placebo group 17/55 (31%) patients did not progress to RA (1987) 
and 15 were in DFR after 60 months, two still had arthritis (table 2). None of these 15 
patients had used DMARDs since 1 year. Of the total group, 35/110 patients (32%) were 
Table 1. Baseline and disease characteristics for both randomization groups.
MTX (n=55) Placebo (n=55) p
Age in years 51 (42-60) 51.3 (42-56) 0.39
Female 35 (64) 38 (69) 0.55
Symptom duration in days 312 (195-507) 263 (169-432) 0.29
Morning stiffness in minutes 30 (10-60) 30 (10-60) 0.95
RF positive 20 (36) 19 (35) 0.96
ACPA positive 12 (22) 15 (27) 0.51
DAS 2.72 (0.78) 2.52 (0.76) 0.19
HAQ 0.79 (0.51) 0.78 (0.58) 0.90
Sharp-van der Heijde score 0 (0-2) 0 (0-2) 0.93
Fulfilled ACR-EULAR 2010 RA criteria 19 (35) 24 (44) 0.33
Data are presented as means ± standard deviations (SD), medians and interquartile ranges (IQR), 
or numbers and percentages (%) when appropriate.  RF: rheumatoid factor, ACPA: anti-citrullinated 
protein antibody, HAQ: Health Assessment Questionnaire, DAS: disease activity score, SHS: Sharp-van 








































in DFR at 60 months. The survival analysis did not show a difference in time to achieve 
DFR between the MTX and the placebo group (p=0.34) (figure 1D). Most patients who 
achieved DFR were ACPA negative (32/35), and achieved DFR significantly earlier than 
the three ACPA-positive patients (p=0.008).
2010 RA criteria
Based on signs and symptoms, 43/110 patients with UA (39%) fulfilled the 2010 ACR/
EULAR classification criteria for RA (RA (2010)) at baseline (table 1). Nineteen of these 
patients were randomised to the MTX group. Of these patients, 12/19 (63%) had disease 
progression to fulfilling the 1987 classification criteria, 5/19 (26%) achieved DFR. Of the 
24 RA (2010) patients randomised to the placebo group, 17/24 (71%) progressed to RA 
(1987) and 6/24 (25%) achieved DFR.
Predictors of drug-free remission and fulfilling the criteria for RA
The univariate predictors for fulfilling the 1987 classification for RA after 60 months 
were, separately tested, ACPA positivity (OR=9.7, 95% CI 3.1 to 30.5) and RF positivity 
(OR=3.0, 95% CI 1.3 to 6.8). Multivariate analyses including ACPA or RF, age, gender, SHS 
and DAS at baseline, showed ACPA (OR=8.9 95% CI 2.7 to 29.1), SHS at baseline (OR=1.3, 
Figure 1. Kaplan-Meier survival analysis for (A) the time to diagnosis of rheumatoid arthritis in the total group, 
(B) in ACPA (anti-citrullinated protein antibody)-positive patients, (C) in ACPA-negative patients, (D) the time 








































95% CI 1.01 to 1.6) and RF (OR=2.9, 95% CI 1.2 to 7.1) as independent predictors for 
progression to RA (1987).
Absence of ACPA (OR=5.0, 95% CI 1.4 to 18.0) was identified as the only independent 
predictor for DFR (OR=5.1, 95% CI 1.4 to 18.5, in the multivariate analysis including 
ACPA, age and gender).
Radiographic damage
Completers
After 60 months, 67 patients had completed the radiographic follow-up. Patients who 
completed follow-up were more often ACPA positive (36% versus 7% in non-completers) 
and more had progressed to RA (1987) (66% versus 23% in non-completers). In 39/67 
patients (58%) there was no radiological progression at all. Radiological damage progression 
was comparable in patients who had progressed to RA (1987) and those who were in DFR 
after 5 years (p=0.08). There was significantly more damage progression in the ACPA-positive 
than in the ACPA-negative patients (median (IQR) 1.8 (0–6) versus 0 (0–0.5); p=0.001).
Total group
Imputation of missing values by last observation carried forward was done in 107 patients 
(no imputation in three patients with only baseline scores). In 73/110 (66%) patients 
were estimated to have no progression. In the 34 patients who showed progression, 
median progression was 2 (1–7). The median (IQR) progression of patients initially 
treated with MTX was 0 (0–1) and in the placebo group 0 (0–1) (p=0.78). After 5 years, 
patients who progressed to RA (1987) had more progression than patients in DFR 
(respectively 0 (0–2) versus 0 (0–0); p=0.02). Again, ACPA-positive patients showed more 
radiological progression than ACPA-negative patients (1.5 (0–3) points progression in 
SHS versus 0 (0–0), p<0.001), regardless of initial treatment (figure 2). Two ACPA-positive 
patients who initially received placebo showed rapid radiological progression, defined 
Table 2. Diagnosis after 30 and 60 months follow up in patients initially treated with 1 year MTX or 1 
year placebo.
Diagnosis
30 months 60 months
MTX Placebo MTX Placebo
RA (1987 criteria) 22 29 25 29 
UA (active arthritis) 10 4 5 2 
Drug free remission 15 13 20 15 
Other diagnosis 3* 4** 3* 4**
Lost to follow up 5 5 2 5
Total 55 55 55 55
Values indicate the number of patients. 
* 2 osteoarthritis, 1 autoimmune hepatitis. ** 3 osteoarthritis and 1 diabetic arthropathy. RA: rheumatoid 








































as an increase in SHS of ≥5 points in year 1 (figure 2A).77, 78 None of the other patients 
showed rapid radiological progression.
DISCUSSION
The PROMPT study, a randomised clinical trial in patients with UA, was set up to establish 
whether very early treatment with MTX could induce drug-free remission or prevent 
progression to RA (1987). Early study results showed that MTX can postpone progression 
from UA to RA and suppresses radiological damage progression, in particular in ACPA-
positive patients.4 In this study we have found that after 5 years there is little lasting 
benefit of early MTX treatment. Overall, patients with UA treated with MTX did not 
achieve more DFR, did not progress less often to RA (1987) and had comparable damage 
progression compared with patients with UA who initially were treated with placebo. 
Only in ACPA-positive patients did initial MTX postpone progression to RA (1987). These 
results indicate that early treatment with MTX is ineffective in altering the disease course 
of UA. This may be owing to inefficacy of the drug, duration of treatment, characteristics 
of the targeted illness, inadequate timing of treatment, or all of the above.
Figure 2. Sharp- van der Heijde Score at every time point for individual patients who were either A) anti-
citrullinated protein antibody (ACPA) positive and treated with placebo (n=15), B) ACPA positive and treated 
with MTX (n=12), C) ACPA negative and treated with placebo (n=40), or D) ACPA negative and treated with 








































MTX may be seen as the cornerstone of antirheumatic treatment,13, 14 yet MTX 
monotherapy as initial treatment in patients with RA is often inferior to initial 
combination treatment with corticosteroids or biological DMARDs.15-18 It may be 
that such initial combination treatment in our population would have been more 
successful in altering the disease course than MTX monotherapy. It is also possible that 
discontinuation of MTX after 1 year was too soon, but longer treatment cannot be seen 
as induction therapy, which was the target of the PROMPT study.
The finding that initial treatment with MTX delayed progression to 1987 classifiable 
RA only in ACPA-positive patients suggests that the effect of treatment may depend 
on the type of illness presenting as UA. We found that ACPA and RF are independent 
predictors for disease progression to RA (1987) after 60 months. Time to progress to 
RA (1987) was significantly shorter in ACPA-positive patients than in the ACPA-negative 
patients. Absence of ACPA was the only independent predictor of drug-free remission 
after 5 years. ACPA-positive patients showed more radiographic progression, despite the 
fact that having progressed to classifiable RA many started treatment with open-label 
MTX, after which damage progression was suppressed. Overall, we found no difference 
in radiographic progression between the MTX- or placebo-treated groups. These results 
suggest that ACPA-positive and ACPA-negative early arthritis are different disease 
entities, which may require different treatments. In addition, the persistence of remission 
in the majority of ACPA-negative patients (also those treated with placebo) suggests 
that these had a temporary disease, which could not be identified at presentation, by 
symptom duration or characteristics other than ACPA status.
It might be that we started initial treatment with MTX too late. We included and treated 
patients who were at the time considered to have UA, but who now would be classified as 
RA, based on the 2010 classification criteria for RA.5 In retrospect, 43 patients (39%) of the 
patients included as UA fulfilled the 2010 ACR/EULAR criteria at baseline, 23 of whom were 
ACPA positive. It is possible that for these patients the opportunity to achieve a change in 
the disease course by whatever treatment, might already have been lost. On the other hand, 
the new criteria may also misclassify some patients as having RA, and lead to overtreatment. 
Twenty-four of the 43 patients fulfilling the 2010 criteria were randomised to initial placebo 
treatment, and six of those 24 achieved clinical remission. This means that, had we started 
MTX in all patients who fulfilled the 2010 criteria, we would have overtreated these six 
patients (25%). We also started MTX treatment in 36 patients who in retrospect did not fulfil 
the 2010 classification criteria, which may also qualify as overtreatment. Of these patients, 
13 did progress to RA (1987), which more effective treatment might have prevented.
In summary, in this randomised clinical trial comparing the outcomes after 5 years of initial 
MTX treatment and placebo in patients with UA, there is no lasting effect of MTX treatment 
given in the first year. A positive ACPA status and radiological damage at baseline are 
independent predictors for progression to RA and a negative ACPA status is a predictor 








































patients, demonstrates that initiation of MTX treatment in all patients who fulfil the 2010 
ACR/EULAR criteria would constitute overtreatment in 25% of patients. On the other 
hand, mostly in ACPA-positive patients, initial MTX monotherapy is insufficient to prevent 
disease progression. Further research should focus on early and correct recognition of RA, 
as well as identifying a treatment that might truly alter the disease process.
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C H A P T E R  3
REMISSION INDUC TION THERAPY 
WITH METHOTREXATE AND PREDNISONE 
IN PATIENTS WITH EARLY RHEUMATOID 
AND UNDIFFERENTIATED ARTHRITIS
Ann Rheum Dis 2012 71(9):1472-7
K.V.C. Wevers-de Boer, K. Visser, L. Heimans,  H.K. Ronday, 
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ABSTRACT
Aim: Classifying more patients as rheumatoid arthritis (RA) (2010 American College 
of Rheumatology/European League Against Rheumatism criteria for RA) may improve 
treatment outcomes but may cause overtreatment in daily practice. The authors 
determined the efficacy of initial methotrexate (MTX) plus prednisone treatment in 
patients with 1987 or 2010 classified RA and undifferentiated arthritis (UA).
Methods: 610 recent onset RA or UA patients started with MTX 25 mg/week and 
prednisone 60 mg/day tapered to 7.5 mg/day in 7 weeks. Percentage remissions after 
4 months were compared between RA (1987 or 2010 criteria) and UA. Predictors for 
remission were identified.
Results: With the 2010 criteria, 19% more patients were classified as RA than with the 
1987 criteria, but similar remission rates were achieved: 291/479 (61%) 2010 classified RA 
and 211/264 (58%) 1987 classified RA patients (p=0.52), and 79/122 (65%) UA patients 
(p=0.46). Anti-citrullinated protein antibody (ACPA) positive RA patients achieved more 
remission (66%) than ACPA negative RA patients (51%, p=0.001), but also had a lower 
mean baseline Disease Activity Score (DAS) (3.2 versus 3.6, p<0.001). Independent 
predictors for remission were male sex, low joint counts, DAS and Health Assessment 
Questionnaire, low body mass index and ACPA positivity.
Conclusions: Initial treatment with MTX and a tapered high dose of prednisone results in 
similarly high remission percentages after 4 months (about 60%) in RA patients, regardless 
of fulfilling the 1987 or 2010 criteria, and in UA patients. Independent predictors indicate 















































Starting treatment earlier in the disease course of rheumatoid arthritis (RA) has 
improved functional and radiological outcome as compared with delayed treatment.1-6 
New RA classification criteria support this trend,7 but have triggered concerns that some 
patients may now be misclassified and overtreated as a result.8
Remission has increasingly become a treatment goal in clinical trials, resulting in 
remission rates that vary between 26% and 42%.9
It is hypothesised that starting treatment already in the phase of undifferentiated arthritis 
(UA) may prevent progression to classified RA and increase permanent remission rates. 
However, methotrexate (MTX) monotherapy for patients with probable RA postponed 
but did not prevent progression to RA. Similar drug free remission rates (about 25%) 
were achieved in the MTX and placebo groups.10
Since in RA initial combination treatment with prednisone leads to a more rapid clinical 
improvement and less radiological progression of joint damage than disease modifying 
antirheumatic drug monotherapy,3, 11-14 treatment with combination possibly in the 
phase of UA may increase remission and drug free remission rates, as well as improve 
short-term functional outcome and long-term joint damage progression.
To investigate this, we designed the IMPROVED (Induction therapy with Methotrexate 
and Prednisone in Rheumatoid Or Very Early arthritic Disease) study, the first clinical trial 
in patients with UA and early RA, with an induction phase with MTX and a tapered high 
dose of prednisone, aimed at achieving remission. This trial allowed us to evaluate the 
effect of classifying patient groups according to the old and the new RA classification 
criteria and to identify predictors of remission.
PATIENTS AND METHODS
Study design
The IMPROVED study is a multicentre, clinical trial in recent onset RA and UA patients. 
All patients were initially treated for 4 months with MTX 25 mg/week and a tapered high 
dose of prednisone, starting with 60 mg/day, tapered in 7 weeks to 7.5 mg/day, and 
continued in this dose up to 4 months. Later, this introduction phase will be followed 
by a single blind randomised controlled trial where those patients who did not achieve 
remission will be treated according to two treatment strategies: one starting with a 
combination of MTX, sulfasalazine, hydroxychloroquine and low dose prednisone and 
the other with a combination of MTX with adalimumab.
Rheumatologists participating in the Foundation for Applied Rheumatology Research 
designed and conducted the study. Patients were recruited between March 2007 and 
September 2010 in 12 hospitals in the Western part of the Netherlands. The Medical 














































patients gave written informed consent. The IMPROVED trial was registered in the 
ISRCTN Register (number 11916566) and the EudraCT (number 2006-006186-16).
Patients/subjects
Patients with RA classified according to the 1987 American College of Rheumatology 
(ACR) criteria15 with a symptom duration of <2 years and UA, defined as likely to have 
early RA according to the treating rheumatologist, with at least one arthritic joint and 
one other painful joint, regardless of symptom duration, were included in the trial. All 
patients had a Disease Activity Score (DAS)≥1.6.16
Exclusion criteria included previous therapy with disease modifying antirheumatic 
drugs or corticosteroids, pregnancy or pregnancy wish during the study, malignancy 
within the last 5 years, bone marrow hypoplasia, elevated liver enzyme levels (aspartate 
transaminase (AST) and/or alanine transaminase (ALT)>3 times the normal value), serum 
creatinine level >150 umol/l or estimated creatinine clearance of <75%, uncontrolled 
diabetes mellitus, uncontrolled hypertension, heart failure (New York Heart Association 
class III/IV), alcohol or drug abuse, serious infections in the previous 3 months or chronic 
infectious disease, opportunistic infections within previous 2 months, active or latent 
hepatitis B infection, documented HIV infection or AIDS, lymphoproliferative disease 
and multiple sclerosis. All patients with active tuberculosis (TB) were excluded, as well 
as UA patients with latent TB. RA patients with latent TB could be included if they started 
adequate antituberculous therapy (according to local TB specialists) prior to initiation of 
high dose prednisone.
Reclassification according to the 2010 ACR/EULAR classification criteria
After inclusion was complete the new classification criteria were published. Unless 
specified otherwise (by adding the year of classification criteria between brackets), ‘RA’ 
in the text denotes RA classified according to the 2010 criteria, and ‘UA’ denotes not 
fulfilling the 2010 criteria.
Outcomes
Primary outcomes after 4 months were percentage clinical remission, defined as a 
DAS<1.6, disease activity measured by DAS, functional ability measured by the Health 
Assessment Questionnaire (HAQ)17 and radiological progression using the Sharp/van 
der Heijde scoring method (SHS).18
Radiological damage was assessed by two independent readers using SHS, blinded 
for patient identity and time order of the radiographs.Progression was defined as 
an increase in SHS score of ≥0.5 points. Due to the small distribution of SHS scores, 
caused by a large proportion of patients without progression, the interobserver 
and intraobserver intraclass correlation coefficients were not suitable for measuring 














































others, the median (IQR) difference in progression score between readers was 2(2-3). 
A consensus score was reached for radiographs with inter-reader differences ≥ median 
difference in progression score (n=41).
Percentage remissions according to ACR/European League Against Rheumatism (EULAR) 
preliminary definition20were compared with percentage remissions based on the DAS.
Statistical analysis
All outcomes were calculated according to the intention-to-treat (ITT) principle. 
Percentages remission in the RA and the UA group were compared using the  χ2 test. 
Categorical variables were compared between groups using the χ2 test, normally 
distributed outcome measures with the independent samples t-test and skewed 
outcome measures using the Mann-Whitney U-test.
Independent predictors for remission were identified using univariate followed by 
multivariate logistic regression with achieving or not achieving remission as binominal 
dependent variable. All available clinical variables were entered in a univariate 




Between March, 2007 and September, 2010, 730 patients signed informed consent and 
were screened for inclusion (figure 1). We included 610 patients: 364 RA patients (1987 
classification criteria) or 479 RA patients (2010 classification criteria) and 122 UA patients 
(i.e. not fulfilling the 2010 classification criteria) (table 1).
During 4 months, 12 patients left the trial: two patients because of a revised diagnosis 
(one osteoarthritis, one lupus), two because of comorbidity, six withdrew consent and 
two died (figure 1).
Table 1. Classification of patients according to the 1987 ACR and the 2010 ACR/EULAR criteria for RA.
Inclusion 1987 criteria, n (%) RA (1987): 364 (60%) UA: 246 (40%)
Reclassification 2010 criteria, n (%)* RA (2010): 479 (79%) UA (2010):122 (20%)
RA(2010) UA(2010)
RA (1987), n (%) 324/364 (89%) 34/364 (9%)
UA n (%) 155/246 (63%) 88/246 (36%)
RA(1987): RA according to the 1987 classification criteria for RA.8 UA: at least one swollen and one painful 
joint, at risk of developing RA according to the rheumatologist. RA(2010): included in trial as RA(1987) 
or UA, reclassified as RA according to the 2010 classification criteria for RA.9 UA(2010): included in trial 
as RA(1987) or UA, not fulfilling the 2010 classification criteria for RA















































RA (1987) patients had a higher mean DAS based on more affected joints, higher 
erythrocyte sedimentation rate and higher serum C-reactive protein than RA (2010) 
patients. UA patients included fewer female subjects, were less often rheumatoid factor 
and anti-citrullinated protein antibody (ACPA) positive, and had lower disease activity 
and HAQ. There was no significant difference between RA (1987 or 2010 classified) and 
UA patients in baseline damage scores or erosiveness (table 2).
After 4 months, DAS <1.6 was achieved in 58% of the RA (1987), 61% of the RA (2010) 
(p=0.52) and 65% of the UA patients (p=0.46 compared with RA 2010).
DAS improved more in the RA (2010) group than in the UA group and was similar as in 
the RA (1987) group, resulting in comparable mean (SD) DAS levels after 4 months: 1.4 
(0.9) in UA, 1.6 (0.9) in RA (1987) and 1.5 (0.9) in RA (2010) patients. Also HAQ improved 
more in the RA patients than the UA patients, resulting in HAQ levels of 0.44 both in UA 
and RA patients (p=0.96) after 4 months.
Baseline and 4-month radiographs of hands and feet were available for 546 patients. 
After 4 months, 61 patients (10%) showed radiological progression, without a difference 
between UA and RA patients. In those with progression the median (IQR) SHS progression 
was 1 (1–1) point.
Patients who did not achieve remission after 4 months treatment had a higher baseline 
DAS and higher DAS components, and were more often ACPA negative than patients 
















































Table 2. Baseline characteristics and clinical outcomes after 4 months of RA patients classified either by 








Age, years mean ± SD 53.5 (14) 52 (13) 0.08 52 (16) 0.90
Female, n (%) 256 (70) 333 (70) 0.8 74 (61) 0.06
Symptom duration, weeks, median (IQR) 17 (8-32) 18 (9-34) 0.25 16 (8-28) 0.14
RF positive, n (%) 254 (67) 330 (69) 0.59 5 (4) <0.001
ACPA positive, n (%) 228 (63) 324 (68) 0.15 4 (3) <0.001
ESR mm/hr, median (IQR) 29 (15-45) 26 (12-41) 0.04 16 (9-38) 0.01
CRP mg/l, median (IQR) 13 (6-36) 11 (5-28) 0.046 10 (4-24) 0.25
DAS, mean ± SD 3.50 (0.9) 3.34 (0.9) 0.02 2.70 (0.65) <0.001
Swollen Joint Count, median (IQR) 8 (4-12) 7 (3-11) 0.02 3 (2-6) <0.001
Tender Joint Count, median (IQR) 7 (5-11) 7 (4-10) 0.18 5 (3-8) <0.001
HAQ, mean ± SD 1.26 (0.65) 1.19 (0.67) 0.11 1.03 (0.62) 0.02
BMI, mean ± SD 25.5 (4.1) 25.9 (4.5) 0.18 25.8 (4.0) 0.88
Total SHS, median (IQR) 0 (0-1) 0 (0-0.5) 0.33 0 (0-0.4) 0.98
Erosive, n (%) 49 (13) 60 (13) 0.62 12 (9) 0.46
Follow up (4 months)
DAS, mean ± SD 1.56 (0.89) 1.52 (0.89) 0.56 1.43 (0.85) 0.30
HAQ, mean ± SD 0.45 (0.51) 0.44 (0.53) 0.81 0.44 (0.51) 0.96
Improvement DAS, mean ± SD 1.93 (1.04) 1.82 (1.04) 0.11 1.26 (0.88) <0.001
Improvement HAQ, mean ± SD 0.80 (0.64) 0.74 (0.66) 0.16 0.59 (0.61) 0.03
Total SHS, median (IQR) 0 (0-1) 0 (0-0.5) 0.37 0 (0-0) 0.85
Erosive, n (%) 48 (13) 64 (13) 0.98 11 (9) 0.22
SHS progression, median (IQR) 0 (0-0) 0 (0-0) 0.75 0 (0-0) 0.93
Remission (DAS<1.6), n (%) 211 (58) 291 (61) 0.52 79 (65) 0.46
SD: standard deviation, IQR: interquartile ranges, n: number, RF: rheumatoid factor, ACPA: anti-
citrullinated protein antibody, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, DAS: 
disease activity score, HAQ: Health Assessment Questionnaire, BMI: body mass index, SHS: Sharp- van 
de Heijde Score, SHS progression: increase in SHS ≥0.5 points, remission: DAS<1.6.16 Erosive denotes the 
presence of at least 1 erosion on radiographs of hands and feet. *   p-value based on difference between 
RA1987 and RA2010. ** p-value based on difference between RA2010 and UA.
who did achieve remission (table 3). Of the ACPA positive RA patients, 66% achieved 
remission compared with 51% of the ACPA negative RA patients (p=0.001). ACPA positive 
RA patients had a lower baseline DAS (mean (SD) 3.19 (0.89)) than ACPA negative RA 
patients (mean (SD) 3.64 (0.94), p<0.001). ACPA negative RA patients who achieved 
remission had a shorter median (IQR) symptom duration (12 weeks) (8–26) than those 
who did not (20 weeks (10–31), p=0.02). In the whole study population, there was a 
trend for more remission in patients with shorter symptom duration.
The distribution of joints was different in patients with RA and UA. All RA patients had 














































(p<0.001). Large joint (all other joints) involvement was found in similar percentages 
of RA and UA patients (73% versus 68%, p=0.22). Patients with large joint involvement 
had more affected small joints (median (IQR) 10 (6–17) versus 7 (4–11), p<0.001) and 
achieved remission less often than patients without large joint involvement (57% versus 
76%, p<0.001).
Predictors for remission
Significant univariate clinical predictors for achieving remission in the total study 
population were baseline DAS, HAQ, symptom duration, male sex, ACPA positivity, 
number of affected small joints, number of affected large joints and body mass index 
Table 3. Baseline characteristics and clinical characteristics after 4 months of patients achieving 






DAS, mean ± SD 2.99 (0.85) 3.57 (0.92) <0.001
Swollen joint count, median (IQR) 5 (2-9) 7 (3-12) 0.001
Tender joint count, median (IQR) 5 (3-8) 8 (6-14) <0.001
VAS general health in mm mean ± SD 42 (24) 52 (21) <0.001
ESR mm/hr, median (IQR) 23 (10-38) 25 (13-41) 0.20
HAQ, mean ± SD 1.03 (0.65) 1.37 (0.62) <0.001
Small joints,* median (IQR) 8 (4-13) 12 (7-18) <0.001
Large joints,** median (IQR) 1 (0-2) 2 (1-4) <0.001
Age, years, mean ± SD 52 (14) 51 (14) 0.54
Symptom duration, weeks median (IQR) 16 (9-30) 21 (9-37) 0.08
Female, n (%) 231 (62) 172 (78) <0.001
RF positive, n (%) 219 (58) 111 (50) 0.09
ACPA positive, n (%) 220 (59) 106 (48) 0.007
Diagnosis RA(2010), n (%) 291 (78) 177 (80) 0.46
BMI, mean ± SD 25.4 (3.9) 26.6 (5.1) 0.001
Follow up (4 months)
DAS, mean ± SD 0.94 (0.36) 2.45 (0.65) <0.001
Swollen joint count, median (IQR) 0 (0-0) 1 (0-4) <0.001
Tender joint count, median (IQR) 0 (0-1) 4 (3-8) <0.001
VAS general health in mm, mean ± SD 13 (14) 36 (21) <0.001
ESR mm/hr, median (IQR) 6 (3-13) 11 (6-22) <0.001
HAQ, mean ± SD 0.23 (0.33) 0.82 (0.59) <0.001
Remission: DAS<1.6.16 SD: standard deviation, IQR: interquartile ranges, n: number, DAS: disease 
activity score, VAS: visual analogue scale, ESR: erythrocyte sedimentation rate, HAQ: Health Assessment 
Questionnaire, RF: rheumatoid factor, ACPA: anti-citrullinated protein antibody, RA(2010): rheumatoid 
arthritis according to the 2010 classification criteria, BMI: body mass index.
*number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal 
joints, thumb interphalangeal joinst, wrists, second through fifth metacarpophalangeal joints)














































(BMI) (table 4). Fulfilling the 1987 or 2010 classification criteria for RA was not a predictor 
for remission. In a multivariate regression analysis including baseline DAS and excluding 
number of affected small and large joints, independent predictors were baseline DAS, 
HAQ, symptom duration, ACPA positivity, male sex and BMI. In a model including the 
baseline numbers of affected small and large joints instead of the DAS, the number of 
affected small and large joints were both predictive, independently of each other. In this 
analysis, ACPA positivity was not an independent predictor (table 4).
ACR/EULAR preliminary definition of remission
According to the preliminary ACR/EULAR definition,57157/610 (26%) of the patients achieved 
remission after 4 months (34 patients could not be defined because of missing data), without 
a difference between UA and RA patients (29/122 (24%) versus 126/479 (26%), p=0.45).
Mean (SD) DAS after 4 months of patients in ACR/EULAR remission is 0.82 (0.41).
Table 4. Univariate and multivariate logistic regression analyses with remission as dependent variable
Univariate regression Odds ratio 95% CI
Classified RA 0.85 0.56 - 1.30
Baseline DAS 0.49 0.40 - 0.60
Baseline HAQ 0.43 0.33 - 0.57
Small joints*  0.93 0.90 - 0.95
Large joints** 0.72 0.65 - 0.79
Symptom duration (wks) 0.99 0.99 - 1.00
ACPA positivity 1.59 1.14 - 2.23
Age (years) 1.00 0.99 - 1.02
Male sex 2.19 1.50 - 3.20
BMI (kg/m2) 0.94 0.90 - 0.98
Multivariate regression
Analysis with DAS Analysis with small and large joints
Odds ratio 95% CI Odds ratio 95% CI
Baseline DAS 0.61 0.47-0.78 - -
Small joints* - - 0.96 0.93-0.99
Large joints** - - 0.81 0.72-0.90
Baseline HAQ 0.66 0.46-0.94 0.63 0.46-0.88
Symptom duration (wks) 0.99 0.98-0.997 0.99 0.98-0.997
ACPA positivity 1.59 1.09-2.33 1.44 0.98-2.12
Male sex 2.03 1.34-3.08 2.01 1.32-3.07
BMI (kg/m2) 0.94 0.90-0.98 0.94 0.90-0.98
Classified RA: rheumatoid arthritis according to the 2010 classification criteria for RA, DAS: disease 
activity score, HAQ: Health Assessment Questionnaire, ACPA: anti-citrullinated protein antibody, BMI: 
body mass index. 
*number of swollen and/or tender small joints (metacarpophalangeal joints, proximal interphalangeal 
joints, thumb interphalangeal joinst, wrists, second through fifth metacarpophalangeal joints)














































In all, 206/610 (34%) patients did achieve DAS remission but were not in ACR/EULAR 
remission. They had a median (IQR) tender joint count of 0 (0–1), a median (IQR) swollen 
joint count of 0 (0–0), a median (IQR) C-reactive protein of 5 (3–9) and a mean (SD) Visual 
Analogue Scale general health of 21 (14).
A total of 152/610 (25%) patients achieved remission by both criteria, 201/610 (33%) did 
not achieve remission according to either and 5/610 (0.8%) patients were in ACR/EULAR 
remission but not DAS remission, based on arthritis in the feet (not included in the ACR/
EULAR remission definition).
The data suggest that the ACR/EULAR definition of remission is more stringent than DAS 
remission, resulting in lower remission percentages. Clinical and radiological follow-up 
are needed to show which definition is most adequate.
Adverse events
During 4 months of treatment, 341/610 (56%) of the patients reported one or more 
adverse events (table 5). There were 16 serious adverse events in 16 (3%) of 610 patients 
(8 per 100 patient-years). Two patients died: a 70-year-old female subject from a 
myocardial infarction later found to be caused by giant cell arteriitis (incorrect inclusion 
due to alternative diagnosis) and an 85-year-old female subject after refusing treatment 
for pneumonia. Fourteen hospital admissions were reported for patients with bacterial 
coxarthritis, pneumocystis carinii pneumonia (a patient with pre-existing non-specific 
interstitial pneumonia), other pneumonia (three patients), viral pneumonitis, urothelial 
cell carcinoma, surgery for carcinoma of the caecum, diverticulitis, bleeding from a 
benign intestinal polyp, supraventricular tachycardia, hypertension, peripheral arterial 
occlusion and pulmonary embolism.
DISCUSSION
Initial treatment with MTX and a tapered high dose of prednisone results in similar 
remission rates in 2010 classified and 1987 classified RA patients and in UA patients after 
4 months. The majority (90%) of the patients showed no radiological progression after 4 
months. Independent predictors for remission were low baseline DAS, low numbers of 
affected large and small joints, ACPA positivity, male sex and BMI.
The early remission rate of 61% is higher than previously reported in cohorts such as 
COBRA (Combinatietherapie Bij Reumatoide Artritis) and BeSt (Behandel Strategieën), 
where patients also received MTX and a tapered high dose of prednisone, combined with 
sulfasalazine.3, 11 This is most likely explained by our intentional inclusion of patients with 
milder disease activity and not (yet) fulfilling the classification criteria for RA. Also, our 
patients had on average a shorter symptom duration. Thus, the higher remission rate in 
this study would support the window of opportunity theory. However, earlier inclusion 














































explanations are the initial dose of MTX (25 mg/week compared with 7.5 mg/week in 
the other cohorts) and the absence of sulfasalazine in the initial drug combination.
The 2010 ACR/EULAR classification criteria were formulated to classify patients earlier in 
disease course.7 In this study however, the symptom duration of patients classified as RA 
according to the 1987 or the 2010 criteria is comparable, which might explain why we 
found no difference in clinical response and remission rates between the groups, even 
though the 2010 criteria classified 19% more patients.
Also, we found no difference in remission rates between RA and UA patients, although 
we hypothesised that UA patients, as presumably very early RA, would benefit more 
from early combination therapy, and despite the fact that UA patients had a lower mean 
baseline disease activity and were predominantly male subjects. This may be explained 
by the comparable symptom duration in UA and RA patients. Of the UA patients, 64% 
had a symptom duration >12 weeks, thus possibly missing the so-called window of 
opportunity.21Also, only a few UA patients were ACPA positive, compared with 68% 
Table 5. numbers of adverse events reported during the first four months of treatment with MTX and a 
tapered high dose of prednisone
Numbers of adverse events
Gastro-intestinal symptoms 98
Nausea 47/98
Liver enzyme elevations 45
Infectious 80




Urinary tract infection 7/80
Influenza/fever 7/80



























































in the RA group, and ACPA positivity in the total study population was found to be a 
predictor of achieving remission. ACPA negative RA and ACPA negative UA both may 
represent or include illnesses that do not sufficiently respond to combination therapy 
with MTX and prednisone and require different treatments.22 Previously, in the PROMPT 
(Probable rheumatoid arthritis: Methotrexate versus Placebo Treatment) study ACPA 
negative UA patients did not benefit from treatment with MTX monotherapy.10
The baseline characteristics in this study population suggest that classifying patients 
as RA by the new classification criteria rests predominantly on numbers of (small) joints 
involved and ACPA positivity, with UA patients having less joints involved and almost 
all UA patients being ACPA negative. ACPA negative patients who were still classified as 
RA had a higher disease activity and a longer symptom duration than ACPA positive RA 
patients. These characteristics may explain why ACPA negative RA patients achieve less 
remission than ACPA positive RA patients. It is possible that they might have benefited 
more from treatment if they were treated earlier.
As shown in previous studies, male patients achieve more remission than female 
patients.23 Our results show that male sex is an independent predictor of remission 
and not associated with a lower pain score or tender joint count. Also, a lower BMI was 
found to be an independent predictor of remission, which may be related to relative 
underdosing of patients with a high BMI.
The early and intensive treatment with a high dose of MTX and a tapered high dose of 
prednisone in this study was accompanied by adverse events in more than half (56%) of the 
patients. Although most adverse events were mild, serious adverse events were reported in 
3% of patients. Two older patients died, one from pneumonia that may have been treatment 
related and on the patient’s request remained untreated, and one of a vasculitis related 
cardiac event. This patient thus was misdiagnosed and, since the lethal event occurred 
during treatment with the tapered dose of prednisone, possibly underdosed.
In conclusion, initial therapy with MTX and a tapered high dose of prednisone results 
in high remission percentages (about 60%) both in early RA patients (regardless of 
classification according to the 1987 or 2010 criteria) and in UA patients after 4 months of 
treatment. Independent predictors for remission, besides male sex and low BMI, indicate 
that initiation of treatment while disease activity is relatively low results in more remission, 
regardless of whether patients fulfil the classification criteria for RA. ACPA negative patients 
may benefit from early treatment, but on the whole achieve less remission on MTX with 
prednisone than ACPA positive patients. This may indicate that this subgroup of patients 














































1. Egsmose C, Lund B, Borg G et al. Patients with 
rheumatoid arthritis benefit from early 2nd 
line therapy: 5 year followup of a prospective 
double blind placebo controlled study. J 
Rheumatol 1995;22(12):2208-2213.
2. Finckh A, Liang MH, van Herckenrode CM, de 
Pablo P. Long-term impact of early treatment 
on radiographic progression in rheumatoid 
arthritis: A meta-analysis. Arthritis Rheum 
2006;55(6):864-872.
3. Goekoop-Ruiterman YP, de Vries-Bouwstra 
JK, Allaart CF et al. Clinical and radiographic 
outcomes of four different treatment strategies 
in patients with early rheumatoid arthritis (the 
BeSt study): a randomized, controlled trial. 
Arthritis Rheum 2005;52(11):3381-3390.
4. Klarenbeek NB, Guler-Yuksel M, van der 
Kooij SM et al. The impact of four dynamic, 
goal-steered treatment strategies on the 
5-year outcomes of rheumatoid arthritis 
patients in the BeSt study. Ann Rheum Dis 
2011;70(6):1039-1046.
5. Lard LR, Visser H, Speyer I et al. Early versus 
delayed treatment in patients with recent-
onset rheumatoid arthritis: comparison of 
two cohorts who received different treatment 
strategies. Am J Med 2001;111(6):446-451.
6. van der Heide A, Jacobs JW, Bijlsma JW et 
al. The effectiveness of early treatment 
with “second-line” antirheumatic drugs. A 
randomized, controlled trial. Ann Intern Med 
1996;124(8):699-707.
7. Aletaha D, Neogi T, Silman AJ et al. 2010 
rheumatoid arthritis classification criteria: 
an American College of Rheumatology/
European League Against Rheumatism 
collaborative initiative. Ann Rheum Dis 
2010;69(9):1580-1588.
8. Cader MZ, Filer A, Hazlehurst J, de Pablo P, 
Buckley CD, Raza K. Performance of the 2010 
ACR/EULAR criteria for rheumatoid arthritis: 
comparison with 1987 ACR criteria in a 
very early synovitis cohort. Ann Rheum Dis 
2011;70(6):949-955.
9. Ma MH, Scott IC, Kingsley GH, Scott DL. 
Remission in early rheumatoid arthritis. J 
Rheumatol. 2010 Jul;37(7):1444-53.
10. van Dongen H, van Aken J, Lard LR et al. 
Efficacy of methotrexate treatment in patients 
with probable rheumatoid arthritis: a double-
blind, randomized, placebo-controlled trial. 
Arthritis Rheum 2007;56(5):1424-1432.
11. Boers M, Verhoeven AC, Markusse HM et 
al. Randomised comparison of combined 
step-down prednisolone, methotrexate 
and sulphasalazine with sulphasalazine 
alone in early rheumatoid arthritis. Lancet 
1997;350(9074):309-318.
12. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. 
Effects of glucocorticoids on radiological 
progression in rheumatoid arthritis. Cochrane 
Database Syst Rev 2007;(1):CD006356.
13. Mottonen T, Hannonen P, Leirisalo-Repo M 
et al. Comparison of combination therapy 
with single-drug therapy in early rheumatoid 
arthritis: a randomised trial. FIN-RACo trial 
group. Lancet 1999;353(9164):1568-1573.
14. Landewe RB, Boers M, Verhoeven AC et al. 
COBRA combination therapy in patients 
with early rheumatoid arthritis: long-term 
structural benefits of a brief intervention. 
Arthritis Rheum 2002;46(2):347-356.
15. Arnett FC, Edworthy SM, Bloch DA et al. 
The American Rheumatism Association 
1987 revised criteria for the classification 
of rheumatoid arthritis. Arthritis Rheum 
1988;31(3):315-324.
16. Prevoo ML, van Gestel AM, van ‘t Hof MA, 
van Rijswijk MH, van de Putte LB, van Riel 
PL. Remission in a prospective study of 
patients with rheumatoid arthritis. American 
Rheumatism Association preliminary remission 
criteria in relation to the disease activity score. 
Br J Rheumatol 1996;35(11):1101-1105.
17. Siegert CE, Vleming LJ, Vandenbroucke JP, 
Cats A. Measurement of disability in Dutch 
rheumatoid arthritis patients. Clin Rheumatol 
1984;3(3):305-309.
18. van der Heijde D. How to read radiographs 
according to the Sharp/van der Heijde 
method. J Rheumatol 2000;27(1):261-263.
19. Shrout PE, Fleiss JL. Intraclass correlations: 
uses in assessing rater reliability. Psychol Bull 
1979;86(2):420-428.
20. Felson DT, Smolen JS, Wells G et al. American 
College of Rheumatology/European League 
against Rheumatism provisional definition of 
remission in rheumatoid arthritis for clinical 
trials. Ann Rheum Dis 2011;70(3):404-413.
21. van der Linden MP, le Cessie S, Raza K et al. 
Long-term impact of delay in assessment of 
















































22. Daha NA, Toes RE. Rheumatoid arthritis: Are 
ACPA-positive and ACPA-negative RA the 
same disease? Nat Rev Rheumatol. 2011 
Apr;7(4):202-3
23. Katchamart W, Johnson S, Lin HJ, Phumethum 
V, Salliot C, Bombardier C. Predictors for 
remission in rheumatoid arthritis patients: 

















































A T WO-STEP TREATMENT STRATEGY TRIAL 
IN PATIENTS WITH EARLY ARTHRITIS 
AIMED AT ACHIEVING REMISSION: 
THE IMPROVED-STUDY
Accepted for publication in Annals of the Rheumatic Diseases
L. Heimans*, K.V.C. Wevers-de Boer*, K. Visser, R.J. Goekoop, 
M. van Oosterhout, J.B. Harbers, C. Bijkerk, I. Speyer, P.D.M. de Buck, 
P.B.J. de Sonnaville, B.A.M. Grillet, T.W.J. Huizinga, C.F. Allaart
*Both authors contributed equally
C H A P T E R  4
ABSTRACT
Objectives: To assess which treatment strategy is most effective in inducing remission 
in early (rheumatoid) arthritis.
Methods: 610 patients with early rheumatoid arthritis (RA 2010 criteria) or undifferentiated 
arthritis (UA) started treatment with methotrexate (MTX) and a tapered high dose of 
prednisone. Patients in early remission (Disease Activity Score <1.6 after 4 months) tapered 
prednisone to zero and those with persistent remission after 8 months, tapered and 
stopped MTX. Patients not in early remission were randomised to receive either MTX plus 
hydroxychloroquine plus sulfasalazine plus low-dose prednisone (arm 1) or to MTX plus 
adalimumab (ADA) (arm 2). If remission was present after 8 months both arms tapered to 
MTX monotherapy; if not, arm 1 changed to MTX plus ADA and arm 2 increased the dose 
of ADA. Remission rates and functional and radiological outcomes were compared between 
arms and between patients with RA and those with UA.
Results: 375/610 (61%) patients achieved early remission. After 1 year 68% of those were 
in remission and 32% in drug-free remission. Of the randomised patients, 25% in arm 1 
and 41% in arm 2 achieved remission at year 1 (p<0.01). Outcomes were comparable 
between patients with RA and those with UA.
Conclusions: Initial MTX and prednisone resulted in early remission in 61% of patients 
with early (rheumatoid) arthritis. Of those, 68% were in remission and 32% were in 
drug-free remission after 1 year. In patients not in early remission, earlier introduction 
of ADA resulted in more remission at year 1 than first treating with disease-modifying 




































The way in which patients with rheumatoid arthritis (RA) are treated has changed 
dramatically over recent decades. Early and tightly controlled treatment with disease-
modifying antirheumatic drugs (DMARDs), targeted at low disease activity, suppresses 
inflammation better than previously, resulting in improved functional ability and 
minimised radiological joint damage.1-6 Even remission can be achieved. Early 
combination therapy with synthetic DMARD treatment plus prednisone or a tumour 
necrosis factor (TNF) alpha inhibitor is effective in most patients.7-9 
It is thought that there is a ‘window of opportunity’ during which initiation of effective 
treatment may prevent inflammatory symptoms from becoming chronic and damaging 
to bone and joint tissues. To enable earlier diagnosis and treatment initiation, classification 
criteria for rheumatoid arthritis (RA) were revised in 2010.10 Starting antirheumatic treatment 
at the stage of undifferentiated arthritis (UA), when RA is still unclassifiable, might be useful.7
Treatment of patients with UA with methotrexate (MTX) was successful in postponing, 
but not preventing, progression to RA.11 It is possible that, as in patients with RA, initial 
combination therapy with MTX and prednisone might be more effective.8 If patients 
do not achieve remission with initial combination therapy, the best follow-up strategy 
needs to be determined: either expansion of DMARDs or switching to MTX with a 
TNF-alpha inhibitor; both proved effective in established RA.6, 9
We designed a two-step treatment strategy study (remission induction therapy followed 
by randomisation for patients who did not achieve remission) in patients with recent-
onset RA or UA, to determine how often remission or even drug-free remission (DFR) can 
be achieved. Here we report clinical and radiological outcomes after 1 year.
METHODS
Study design and patients
The IMPROVED study (acronym for Induction therapy with MTX and Prednisone in 
Rheumatoid Or Very Early arthritic Disease, ISRCTN Register number 11916566 and EudraCT 
number 2006-006186-16) is a multicentre, randomised, single-blinded clinical trial designed 
by Dutch rheumatologists participating in the Foundation for Applied Rheumatology 
Research. Patients were recruited between March 2007 and September 2010 in 12 hospitals 
in the western area of the Netherlands. Medical ethics committees of each participating 
centre approved the study protocol and all patients gave written informed consent.
Patients with both UA and early RA were included. Detailed inclusion and exclusion criteria 
have been previously published.8 Recent-onset RA was defined according to the ACR/
EULAR 2010 classification criteria,10 with symptom duration ≤2 years. Patients with UA had 
at least one joint clinically assessed as ‘arthritis’ and at least one other tender joint, which 




































The treatment target was clinical remission, defined as a Disease Activity Score (DAS)<1.6.12 
Four-monthly assessments of DAS were performed by trained nurses who were blinded to the 
allocated treatment. Patients and doctors were not blinded for practical reasons. All patients 
started with 4 months of open-label MTX 25 mg/week (dose escalated from 7.5 mg/week in 
4 weeks) and prednisone tapered in 7 weeks from 60 mg/day to a stable dose of 7.5 mg/day. 
Patients in ‘early DAS remission’ (defined as DAS<1.6 at 4 months) tapered prednisone to zero 
in 3 weeks and when still in remission at 8 months, also tapered MTX to zero in 9 weeks. If DAS 
was ≥1.6 after stopping prednisone, it was restarted at 7.5 mg/day (figure 1).
Patients not in early remission at 4 months were randomised either to MTX 25 mg/wk plus 
hydroxychloroquine (HCQ) 400 mg/day, sulfasalazine (SSZ) 2000mg/day and prednisone 
7.5 mg/day (arm 1) or to MTX 25 mg/week plus adalimumab (ADA) 40 mg/2 weeks 
(arm 2). If in remission at 8 months, patients in arm 1 started tapering prednisone and 
subsequently SSZ and HCQ to MTX monotherapy, patients in arm 2 tapered ADA to MTX 
monotherapy. If not in remission at 8 months, patients in arm 1 switched to MTX+ADA 
(40 mg/2 weeks), patients in arm 2 increased ADA to 40 mg/week (figure 1).
Patients who did not regain remission after restarting prednisone, were also randomised 
(‘delayed randomisation’) as described above.
Variable block randomisation stratified for each centre and diagnosis ensured the 
same number in the two randomisation arms. Randomisation sequence was obtained 
Figure 1. Study flow chart with percentages DAS-remission after the first study year. MTX: methotrexate, 



































by computer. At the local centres, allocation was performed by the rheumatologists 
drawing opaque envelops.
Study outcomes and assessments
Primary outcomes after 1 year were percentages of clinical remission and DFR based on a 
DAS<1.6.  A provisional Boolean-based remission definition, published by ACR/EULAR,13 
based on the 44-joint count was used to recalculate remission percentages at 4, 8 and 12 
months. Secondary outcomes collected 4 monthly were DAS, functional ability measured 
with the Health Assessment Questionnaire (HAQ, ranging from 0 (best) to 3 (worst), ≥0.2 
points’ change is clinically relevant),14 radiological damage progression measured with 
Sharp–van der Heijde score (SHS, ranging from 0 to 448, progression was defined as an 
increase in SHS≥0.5 point)15 and toxicity. Radiographs of hands and feet, blinded for patient 
identity, were scored for the presence of erosions and joint space narrowing in time random 
order by two trained, independent readers (KW and LH). Since 88% of patients showed no 
progression, intraclass correlation coefficients were not suitable for measuring reliability.16 
In 83% of patients both readers scored the same progression. In 54 patients with inter-
reader differences ≥2 (the median difference in progression score of patients for which 
both readers scored different progression) a consensus score was reached.
Outcomes were reported separately for patients who achieved early DAS remission 
and those randomised, and were compared between randomisation arms. Additional 
comparisons were made between patients with RA and those with UA. Patients who 
were not in early DAS remission and who were not randomised according to the protocol 
were analysed in the outside of protocol (OP) group. Reasons for protocol deviation 
were not inventoried.
Statistical analysis
With a power calculation we assessed the number of patients needed in each 
randomisation arm to detect differences between arms of at least 50% in remission 
rates and 0.2 points in HAQ with a power of 80%. Based on previous studies,6, 9, 17 we 
estimated that 30% of the patients would achieve early remission. We needed 535 
patients to randomise at least 100 patients in each arm. Because during the study early 
DAS remission rates were higher, the inclusion number was extended to 610 patients.
We performed intention-to-treat analyses. Outcomes were analysed using a Student’s 
t test, Mann–Whitney U tests and χ2 tests. DAS and HAQ were compared over time 
using linear mixed models, with treatment strategy (arms 1 and 2) and time (study 
visit) as fixed effects, in an unstructured covariance structure. Statistical analyses were 





































In total 610 patients were included, 479 (79%) with RA and 122 (20%) with UA; nine 
patients could not be classified because of missing values. Over the year 23 patients 
withdrew consent, three discontinued because of a revised diagnosis and six because of 
comorbidity. Twelve of these patients dropped out during the first 4 months.
After 4 months, 375/610 patients (61%) had a DAS<1.6 (early DAS remission). Twelve 
other patients with a marginally high DAS at 4 months were by protocol reassessed 
after 1 month. All then had a DAS<1.6 and were included in the early remission group, 
bringing it to a total of 387 patients: 291/479 (61%) patients with RA and 79/122 (65%) 
patients with UA were in early remission (12 patients were lost to follow-up and five 
were not classifiable because of missing data). A total of 144/387 (37%) (114/291 (39%) 
with RA and 28/79 (35%) with UA, two had missing data) also fulfilled the proposed ACR/
EULAR remission definition.
In total, 161/610 (26%) patients not in DAS remission were randomised, 83 patients into arm 
1 and 78 to arm 2. None fulfilled the proposed ACR/EULAR remission definition. Two patients 
with a missing DAS at 4 months and 48 other patients with a DAS≥1.6 at 4 months who 
did not follow the protocol were analysed in the OP group. Thirty-three of these patients 
tapered prednisone and for 17 patients various other treatment decisions were made.
Clinical characteristics at baseline and 4 months
Patients who achieved early DAS remission had lower mean baseline DAS, HAQ and 
DAS components, were more often male and anti-citrullinated protein antibody (ACPA)-
positive and had a shorter symptom duration than randomised patients.8 Clinical 
characteristics at baseline and 4 months were comparable in arms 1 and 2 (table 1). 
After 4 months 12 patients were lost to follow-up and 598 patients were categorised a 
described in this table.
Outcomes after 1 year
After 1 year, 328/610 (54%) patients achieved DAS remission (253/479 (53%) patients 
with RA versus 71/122 (58%) patients with UA (p=0.10), four patients were not classifiable. 
Proposed ACR/EULAR remission was achieved in 144/610 (24%). DFR after 1 year was 
achieved in 130/610 (21%) patients (93/479 (19%) patients with RA versus 36/122 (30%) 
patients with UA, one patient was not classifiable). Patients most often achieved DAS 
remission in the group with early remission. Patients in arm 1 achieved DAS remission 
less often than patients in arm 2 (p=0.01) (table 1).
After 1 year, mean HAQ and DAS were lower in the group with early DAS remission than 
in arms 1 and 2. Over time, no significant difference in DAS and HAQ between arms 1 
and 2 was found (mean DAS difference of 0.03 95% CI -0.16 to 0.22, mean HAQ difference 







































treatmentArm 1 Arm 2
Baseline characteristics n = 387 n = 83 n = 78 n = 50
DAS, mean ± SD 3.0 ± 0.8 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
HAQ, mean ± SD  1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.6 1.3 ± 0.7
Swollen Joint Count, median (IQR) 5 (2-9) 6 (3-10) 8 (4-12) 7 (3-13)
Tender Joint Count, median (IQR) 5 (3-8) 8 (6-13) 9 (6-13) 8 (6-14)
Age in years, mean ± SD 52 ± 14 49 ± 14 51 ± 14 54 ± 14
Female, n (%)   240 (62) 64 (77) 58 (74) 42 (84)
Symptom duration in weeks, median (IQR) 17 (9-30) 22 (9-41) 21 (8-31) 18 (9-42)
Symptom duration <12 weeks, n (%) 247 (64) 59 (71) 49 (63) 28 (56)
RF positive, n (%) 224 (58) 41 (49) 43 (55) 23 (46)
ACPA positive, n (%)   225 (58) 40 (48) 37 (47) 25 (50)
RA(2010), n (%) 298 (77) 66 (80) 66 (85) 40 (80)
Total SHS, median (IQR) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
Erosive, n (%) 63 (16) 10 (12) 13 (17) 3 (6)
Follow-up – 4 months
DAS, mean ± SD 1.0 ± 0.4 2.5 ± 0.6 2.6 ± 0.7 2.3 ± 0.6
HAQ, mean ± SD 0.2 ± 0.3 0.9 ± 0.6 0.9 ± 0.6 0.8 ± 0.7
Swollen Joint Count, median (IQR) 0 (0-0) 1 (0-4) 2 (1-5) 0 (0-2)
Tender Joint Count, median (IQR) 0 (0-1) 4 (3-7) 5 (3-9) 4 (2-6)
ESR mm/hr, median (IQR) 6 (3-12) 13 (7-22) 11 (6-19) 15 (9-28)
VAS global health in mm, mean ± SD 14 ± 14 37 ± 21 38 ± 21 30 ± 21
Follow up – 1 year
DAS, mean ± SD 1.3 ± 0.8 2.1 ± 0.9  1.8 ± 0.9 2.1 ± 0.8
HAQ, mean ± SD 0.4 ± 0.5 0.9 ± 0.6 0.8 ± 0.7 0.8 ± 0.6
Swollen Joint Count, median (IQR) 0 (0-1) 0 (0-3) 0 (0-1) 1 (0-2)
Tender Joint Count, median (IQR) 0 (0-2) 3 (1-7) 3 (0-6) 4 (1-8)
ESR mm/hr, median (IQR) 8 (4-15) 9 (5-18) 9 (4-16) 14 (7-31)
VAS global health in mm, mean ± SD 20 ± 21 33 ± 23 27 ± 20 33 ± 24
Total SHS, median (IQR) 0 (0-0.5) 0 (0-0.5) 0 (0-0) 0 (0-0)
Erosive, n (%) 65 (17) 12 (15) 12 (16) 2 (4)
DAS-Remission, n (%) 263 (68) 21 (25) 32 (41)* 12 (24)
Drug free remission, n (%) 124 (32) 1 (1) 0 (0) 5 (10)
ACR/EULAR remission, n (%) 122 (32) 9 (11) 13 (17) 4 (8)
SHS progression, median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
After 4 months 12 patients were lost to follow up and 598 patients were categorized a described in this 
table. SD: standard deviation, IQR: interquartile ranges, n: number, DAS: disease activity score, HAQ: 
Health Assessment Questionnaire, RF: rheumatoid factor, ACPA: anti-citrullinated protein antibody, 
RA(2010): rheumatoid arthritis according to the 2010 classification criteria, VAS: visual analogue scale, 
ESR: erythrocyte sedimentation rate, SHS: Sharp- van de Heijde Score, Progression: increase in SHS ≥0.5 
points, DAS-remission: DAS<1.612, ACR/EULAR remission: provisional Boolean based remission definition 
published by the American College of Rheumatology and the European League Against Rheumatism 
based on a 44 joint count 13. Erosive denotes the presence of at least 1 erosion on radiographs of hands 



































Median (IQR) SHS progression score in all groups was 0 (0–0), with no difference between 
patients with UA and those with RA. Of the total study population, 33/610 (5%) had 
radiological progression defined as an increase in SHS≥0.5 point, 20/387 (5%) in the early 
remission group, 5/83 (6%) in arm 1, 6/78 (8%) in arm 2 and 2/50 (4%) in the OP group. Only 
one patient, in the early DAS remission group and losing remission at 8 months, had rapid 
radiological progression (defined as a progression score of≥5 points in 1 year) of 18 points.
Loss of early DAS remission after prednisone discontinuation
Fifteen of 387 patients who achieved early DAS remission did not taper and stop 
prednisone. Of the other 372 patients, 109 (29%) lost DAS remission at 8 months of 
whom, 67 restarted prednisone at 7.5 mg/day. In 40 patients the protocol was not 
followed and various other steps were taken. Two patients had missing data. After 
1 year, 48/67 (72%) patients re-treated according to protocol and 22/40 (55%) treated 
otherwise had again achieved remission.
Results at 8 months
DAS remission at 8 months was achieved in 30/83 (36%) in arm 1 and 27/78 (35%) in arm 
2 (p=0.99). In arm 1, 30 patients tapered to monotherapy, 33 switched to ADA and in 
19 patients other steps were taken (one patient had missing data). In arm 2, 26 patients 
tapered to monotherapy, 28 increased ADA and in 21 patients other steps were taken 
(three patients had missing data). More patients in arm 2 who increased ADA achieved DAS 
remission after 1 year, than patients in arm 1 who switched to ADA (8/28 (29%) versus 6/33 
(18%) (p=0.29)). In addition, more patients in arm 2 retained DAS remission after tapering 
to MTX monotherapy than in arm 1 (17/26 (65%) versus 11/30 (37%), respectively, p=0.02).
Subgroups
During the first year of the study 96/610 (16%) patients never achieved DAS remission, 
462/610 (76%) achieved DAS remission at least once and 52 patients had one or more 
missing DAS values during the first year. Compared with those who achieved DAS 
remission at least once, patients who never achieved DAS remission had a higher mean 
baseline DAS (mean (SD) 3.7 (0.9) versus 3.1 (0.9), p<0.001), a longer median symptom 
duration (median (IQR) 24 (12–44) versus 17 (8–31) weeks, p=0.002), included more 
women (85/96 (89%) versus 291/462 (63%), p<0.001) and fewer were ACPA-positive 
(45/96 (47%) versus 265/462 (57%), p=0.047).
Adverse events
During the first 4 months there were 471 adverse events (AE) in 341/610 (56%) patients, 
including two deaths and 14 other serious adverse events (SAE) in 14 patients.8
From 4 months to 1 year, 346/610 (57%) patients reported 527 AE, 53% in the early 
DAS remission patients, 74% in arm 1, 68% in arm 2 (arm 1 versus arm 2, p=0.41) and 



































Table 2. Number of adverse events reported between 4 months and 1 year for patients in the early 









Patients with AE*, no (%) 205/387 (53%) 61/83 (74%) 52/78 (68%) 28/50 (56%) 
Total number of AE
Type of AE
298 101 88 40
Cardiovascular 9 5 6 1
Pulmonary 11 - 2 1
Gastrointestinal 62 18 20 8
Nausea/emesis 15 6 5 2
Increased liver enzymes 33 5 9 3
Other 14 7 6 3
Neuropsychiatric 22 17 2 4
Headache 2 7 - -
Dizzyness 10 1 - 2
Mood disorders 6 5 1 -
Other 4 4 1 2
Urogenital 5 2 2 1
Skin/mucous membranes 51 6 13 3
Rash 20 5 6 2
Hair thinning/loss 8 1 2 1
Sicca complaints 5 - 1 -
Stomatitis 4 - - -
Other 14 - 4 - 
Infections 76 23 27 11
Upper airway tract 17 4 8 5
Gastro-intestinal 4 - 3 -
Skin/mucosa 11 2 1 1
Pneumonia / bronchitis 8 3 1 1
Urinary tract 9 6 5 1
Flu/unspecified fever 10 2 2 2
Other 17 6 7 1
Trauma/injury 15 3 - 2
Surgical procedures 
without hospitalization
9 3 2 2
Other 38 24 14 7
AE: adverse event. *One or more adverse events possible per patient. 
nausea, upper airway and skin/mucosa infections and skin rashes (table 2). In 26/610 
(4%) patients, SAE were reported. Three patients died: one of a squamous cell carcinoma 
of the tongue (early remission group), one of a cerebral tumour (arm 2, treated with ADA 
40 mg/2 weeks for 4 months) and one patient of an ovarian carcinoma (OP group; in 



































for 4 months). Three other malignancies were reported, all in the early remission group 
(breast carcinoma, basal cell carcinoma of the skin, malignant mesothelioma). Twenty-
five hospital admissions were reported in 23/610 (4%) patients, 10 in the early remission 
group, seven in arm 1, six in arm 2 and two in the OP group. Reasons for admission 
to hospital were complications of malignancy (the three patients, described above), 
pneumonia (four patients; two in arm 1, one in arm 2 and one in the OP group), suspicion 
of septic arthritis (arm 1, cultures remained negative), cellulitis of the lower leg (two 
patients; early remission group and arm 1), percutaneous coronary intervention for 
cardiac ischaemia (two patients; early remission group and arm 2), cardiac arrhythmia 
(two patients in the early remission group), urosepsis (arm 1), myocardial infarction 
(early remission group), femoral fracture (early remission group), total hip replacement 
for osteoarthritis (arm 1), lower leg amputation for peripheral vascular disease due 
to diabetes mellitus (OP group), exacerbation of chronic obstructive pulmonary 
disease (arm 2), surgery for cervical spinal disc herniation (early remission group), 
cerebrovascular accident (arm 2), Nissen fundoplication (arm 2), femoral head necrosis 
(arm 2) and trauma due to a car accident (arm 1).
DISCUSSION
In patients with early arthritis, remission defined by Disease Activity Score can be 
achieved in 54% after 1 year with initial treatment with MTX and a tapered high dose 
of prednisone followed by remission-steered adjustments to treatment. Radiological 
damage progression was effectively suppressed in almost all patients. Of the 61% of 
patients who started tapering medication after being in remission after 4 months, 
68% were in remission and 32% in drug-free remission (DFR) after 1 year. These results 
suggest that combination therapy with MTX and a tapered high dose of prednisone can 
halt the potentially chronic disease course of RA, prevent damage and induce DFR.
Remission is more difficult to achieve if the initial treatment was unsuccessful. For 
those patients who did not achieve early remission, an early switch to a combination of 
MTX with ADA resulted in more remission (41% versus 25%) than treatment expansion 
with SSZ and HCQ, reserving ADA as possible next step. Functional ability, radiological 
damage progression and toxicity were similar.
This study is the first to steer according to remission in patients with early RA, and taper 
and stop medication as soon and as long as this is achieved. The overall remission rate 
of 54% after 1 year is high. Few other studies have reported similar percentages, and 
in those studies treatment was continued for longer and none tapered medication or 
achieved early DFR.17-20 
A possible explanation for the high (drug-free) remission rates and the minimal 
radiological damage progression is that we included patients in a relatively early, and 
possibly reversible, disease stage, which may represent the ‘window of opportunity’.21 



































possible that some patients with UA or even classified as RA might have had a self-
limiting type of arthritis.22 A second explanation might be that we included patients with 
relatively low disease activity, who will more easily achieve the target of a DAS<1.6.8, 23 
The final explanation might be the treatment chosen, initially with a rapidly built up 
high dose of MTX and a high dose of prednisone tapered to 7.5 mg/day -a combination 
which has been proved to be better than DMARD monotherapy in patients with RA6,24,25-
followed after randomisation by progressive treatments either with multiple DMARDs or 
with a TNF inhibitor, which proved to be effective both in early and established RA.26-28
We used the DAS criteria to define remission. These criteria are less stringent than 
the provisional remission criteria proposed by ACR and EULAR. Nonetheless, we have 
shown that our patients in DAS remission have good functional ability and virtually no 
progression of damage.
After 1 year significantly more patients in arm 2 had achieved DAS remission than in arm 1, 
although after 8 months the remission rates were similar. The 1-year difference is explained 
by more patients losing remission after tapering low-dose prednisone and poly-DMARDs 
to MTX monotherapy and fewer patients achieving remission after switching from poly-
DMARDs and prednisone to ADA (both in arm 1). This suggests that if remission is not 
achieved with initial combination therapy, it is better to introduce ADA early. It appears 
that patients for whom prednisone and poly-DMARDs fail, may respond less well to any 
other treatment, as was previously shown in a comparison of initial or delayed treatment 
with infliximab in patients with recent-onset RA (1987 classification criteria).29
Although prednisone in the initial treatment combination appears to be very effective, it 
may also have several side effects and therefore our results may come at a price. Fourteen 
SAE (infections, cardiovascular disease, femoral head necrosis, diabetic complications) 
might be related to the use of prednisone. Thirty-six per cent of our patients did not 
achieve DAS remission with the initial treatment, and 16% did not achieve DAS remission 
with any treatment. Other (biological) treatments may be more effective and less toxic.
In this trial, which integrated treatment adjustments by protocol with daily practice, the 
treating rheumatologist sometimes disagreed with required treatment steps based on 
DAS evaluations by nurses who were blinded to treatment. In some cases the patients 
refused to take the next treatment step. Despite the protocol deviations that ensued, in 
general, treatment remained steered according to DAS remission or clinical remission, 
and follow-up visits continued as before. Because we included all data in our analyses, 
no information was lost.
In conclusion, most patients with early RA can achieve remission with initial combination 
therapy followed by treatment targeted at remission early in the disease course. Of the 
61% of patients who achieve remission with the initial treatment and start tapering 
medication, 68% are in remission and 32% are in DFR after 1 year. For patients not in 
early remission, combination therapy including ADA resulted in significantly more 
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ABSTRACT
Background: To assess 2-year clinical and radiological outcomes of remission steered 
treatment in patients with early arthritis.
Methods: 610 patients with early rheumatoid arthritis (RA) or undifferentiated arthritis 
(UA) were treated with methotrexate (MTX) and tapered high dose of prednisone. 
Patients in early remission (disease activity score (DAS44<1.6) after 4 months 
tapered and stopped medication. Patients who did not achieve early DAS-remission 
were randomized to either MTX, hydroxychloroquine, sulphasalazine and low dose 
prednisone (arm 1) or to MTX and adalimumab (arm 2). During follow-up, medication 
was increased, switched or restarted in case of no remission and tapered and stopped in 
case of remission. Proportions of (drug free) remission (DFR) were analyzed separately 
for the treatment strategies and patients with RA and UA.
Results: After 2 years, 301/610 (49%) of the patients were in DAS-remission and 131/610 
(21%) in DFR. In the early remission group 241/387 patients (62%) achieved DAS-remission 
and 111/387 (29%) DFR. In arm 1 22/83 (27%) achieved remission and 7/83 (8%) DRF. In 
arm 2 24/78 (31%) achieved remission and 7/78 (9%) DFR. Patients with RA and with 
UA achieved DAS-remission in comparable percentages (RA: 234/479 (49%), UA: 64/122 
(52%), p=0.25). UA patients more often achieved DFR (42/122 (34%)) than RA patients 
(88/479 (18%), p<0.001). Median (IQR) radiological progression in all groups was 0 (0-0).
Conclusions: After 2 years remission steered treatment, patients in the early remission group 
more often achieved (drug) free remission than patients who needed additional treatment 






























In rheumatoid and undifferentiated arthritis (RA and UA) it is preferable to initiate 
treatment early after onset of symptoms to induce early remission and maybe reverse 
the disease process.1-3
In the IMPROVED-study we have shown that it is possible for 61% of the RA patients and 
65% of the UA patients to achieve early remission (Disease Activity Score DAS<1.6) after 4 
months treatment with methotrexate (MTX) and tapered high dose of prednisone.4 In case 
of early remission, medication was tapered until drug free remission (DFR) was achieved. 
Those patients who did not achieve early remission were randomized. In all patients, 
treatment adjustments, including drug tapering, were made every 4 months aiming at a 
DAS<1.6. Here, the clinical and radiological outcomes after 2 year follow-up are presented. 
METHODS
Study design and patients 
The IMPROVED-study (ISRCTN Register number 11916566 and EudraCT number 2006-
006186-16) is a multicenter, randomized, single-blinded clinical trial designed by Dutch 
rheumatologists participating in the Foundation for Applied Rheumatology Research 
(FARR). Patients were recruited between March 2007 and September 2010 in 12 hospitals 
in the Western part of the Netherlands. The study protocol was approved by the Medical 
Ethics Committee of each participating center, all patients gave written informed consent. 
Patients were ≥18 years, with recent onset RA or UA, a DAS≥1.6 and no previous 
antirheumatic therapy. RA was defined as fulfilling the 2010 the American College 
of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) 
classification criteria 5 with a symptom duration ≤2 years. UA was defined as at least one 
joint with clinical synovitis and one other painful joint, clinically suspected for early RA, 
regardless of symptom duration. Exclusion criteria were published previously.4, 6
Intervention 
All patients started with 4 months of MTX 25 mg/week and prednisone 60 mg/day which 
was tapered to 7.5 mg/day in 7 weeks. Every 4 months the DAS was assessed by a trained 
research nurse, blinded for treatment allocation. The treatment target of the study was 
a DAS<1.6 which was considered to denote remission (figure 1).7  
Patients in early remission after 4 months tapered prednisone to 0. When still in 
remission after 8 months, MTX was also tapered to 0. In case of a DAS≥1.6 after 8 months, 
prednisone was restarted at 7.5 mg/day. 
Patients with a DAS≥1.6 after 4 months were randomized, either hydroxychloroquine (HCQ) 
400mg/day and sulphasalazine (SSZ) 2000mg/day were added to MTX and prednisone 
(arm 1) or they switched to MTX 25mg/week plus adalimumab (ADA) 40mg/2weeks (arm 





























remission and restarted prednisone without achieving remission, were also randomized 
(‘delayed randomization’) (figure 1). In arm 1, if remission after 8 months was achieved, 
prednisone, SSZ and then HCQ were stopped. MTX was stopped if remission remained 4 
months later. If remission was not achieved at 8 months, patients switched to MTX+ADA 
(40mg/2weeks, increased to 40 mg/week if DAS remained ≥1.6). Patients in arm 2 tapered 
ADA in case of remission after 8 months and increased ADA to 40mg/week in case of no 
remission. In both arms, if patients did not achieve remission on a combination of MTX+ADA 
40mg/week, further treatment decisions were left to the opinion of the rheumatologist 
(figure 1). A detailed description of the randomization procedure was published previously.6
Primary and secondary outcomes
Primary outcomes were percentages of patients in remission and DFR based on a 
DAS<1.6 or on the proposed remission definition published by the ACR/EULAR in 2011.8 
Secondary outcomes were mean DAS, mean functional ability as measured by the 
Dutch version of the Health Assessment Questionnaire (HAQ 9), toxicity and radiological 
damage progression of the joints in hands and feet (defined as an increase of ≥0.5 point 
in Sharp-van der Heijde score (SHS) 10).
Baseline and yearly radiographs of hands and feet were blinded for patient identity and 
scored in time random order for the presence of erosions and joint space narrowing by 2 
Figure 1. Study flow chart with percentages DAS- and drug free remission after the second study 
year. DFR: drug free remission,  MTX: methotrexate,  HCQ: hydroxychloroquine, SSZ: sulfasalazine. 
Colours: orange=prednisone, green=MTX, dark blue=treatment left to decision of rheumatologist, 
aqua=HCQ, yellow=SSZ, purple=adalimumab biweekly, double thickness purple=adalimumab weekly, 





























trained, independent readers (LH and GA). Only 8% of the patients showed progression 
and therefore intra-class correlation coefficients were not suitable for measuring 
reliability.11 In 443 of 496 patients who had radiographs taken after 2 years follow-up, 
there was an inter-reader difference of <2 between the progression scores of both 
readers. For the other 53 a consensus score was reached.  
Outcomes were reported separately for patients who achieved early DAS-remission 
and those randomized and were compared between the randomization arms, as well 
as between patients with RA and patients with UA and between patients in or not in 
remission after 2 years.
Statistical analysis 
We performed intention-to-treat analyses. Outcomes were analyzed using students 
t-tests, Mann Whitney U tests and χ2 tests. DAS and HAQ over time were compared using 
linear mixed models, with treatment strategy (arm 1 and 2) and time (study visit) as fixed 
effects, in an unstructured covariance structure. All statistical analyses were conducted 
with SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL).
RESULTS
Study population
Of the 610 patients included in the IMPROVED-study, 479 (79%) had classifiable RA and 
122 (20%) UA (9 patients could not be classified because of missing data). During the 
first 2 years 79 patients were lost to follow-up; 54 withdrew consent, 9 discontinued 
because of a revised diagnosis and 8 because of co-morbidity. Eight patients died,4, 6 3 of 
those in the second year of the study (supplementary table S1).
Of 610 patients, 387 (63%) achieved early remission, 375 (61%) at 4 months, 12 (2%) 
more after a reassessment 4-6 weeks later (if the rheumatologists disagreed with the 
DAS after 4 months). One-hundred-sixty-one of 610 patients (26%) were randomized; 83 
patients into arm 1 and 78 to arm 2. Fifty patients with a DAS≥1.6 after 4 months were 
not randomized as the protocol required and were analyzed in the outside of protocol 
(OP) group. Twelve patients left the study before the assessment at 4 months (table 1).
Remission and drug free remission
In 50/610 patients (8%) remission had never been achieved during 2 years follow-up. 
Most patients at least once achieved remission which was lost again and medication 
was reintroduced. At the next evaluation, remission had been achieved again in >70% 
of those patients. Fifty-five patients (9%) (37 with RA, 17 with UA, p=0.01. One patient 
was unclassifiable because of missing data) were in sustained remission from 4 months 
through to 2 years (and therefore in DFR from 8 months to 2 years). After 2 years follow 
up, 301/610 (49%) patients were in remission and 131/610 (21%) were in DFR. In the 





























2 years. In arm 1, 22/83 (27%) were in remission compared to 24/78 (31%) in arm 2 
(p=0.76). DFR was achieved by 7/83 patients in arm 1 (8%) and in 7/78 patients in arm 
2 (9%) (p=0.90). Remission defined according to the proposed ACR/EULAR remission 
criteria was achieved in 138/610 (23%) patients; 117/387 (30%) in the early remission 
group, 2/83 (2%) in arm 1 and 14/78 (18%) in arm 2 (arm 1 versus arm 2: p=0.001). 
After 2 years, comparable percentages of ACPA positive and ACPA negative patients were 
in remission (ACPA positive: 172/333 (52%), ACPA negative: 125/262 (48%), p=0.68) but 
more ACPA negative patients achieved DFR than ACPA positive patients: 74/262 (28%) 
versus 54/333 (16%), p<0.001. Comparable percentages of patients with UA or with RA 
achieved remission after 2 years (UA: 64/122 (52%) and RA: 234/479 (49%), p=0.25) but 
significantly more patients with UA, of whom 94% were ACPA-negative, achieved DFR 
(41/122 (34%) compared to 89/479 (19%) in RA patients, p<0.001). 
Patients who were not in remission at 2 years, had a higher tender joint count than 
patients who were in remission (median (IQR) 4 (2-6) versus 0 (0-1) p<0.001) and also 
higher scores on the visual analogue scale (VAS) for pain (mean (SD) 41 (24) versus 11 (16) 
p<0.001), higher ESR (13 (9-22) versus 6 (3-13) p<0.001) and a higher swollen joint count 
(1 (0-3) versus 0 (0-0), p<0.001). Except for ESR and swollen joint count, the statistical 
significant differences between these patients were already present at baseline.









DAS, mean ± SD 3.0 ± 0.8 3.6 ± 0.9 3.6 ±1.0 3.6 ±0.9
HAQ, mean ± SD 1.0 ± 0.7 1.4±0.6 1.4±0.6 1.3 ±0.7
Age in years, mean ± SD 52±14 49±14 51±14 54±14
Female, n (%) 240 (62) 64 (77) 58 (74) 42 (84)
Symptom duration (weeks), median (IQR) 17 (9-30) 22 (9-41) 21 (8-31) 18 (9-42)
RF positive, n (%) 224 (58) 41 (49) 43 (55) 23 (46)
ACPA positive, n (%) 225 (58) 40 (48) 37 (47) 25 (50)
RA(2010), n (%) 298 (77) 66 (80) 66 (85) 40 (80)
Swollen Joint Count, median (IQR) 5 (2-9) 6 (3-10) 8 (4-12) 7 (3-13)
Tender Joint Count, median (IQR) 5 (3-8) 8 (6-13) 9 (6-13) 8 (6-14)
ESR mm/hr, median (IQR) 23 (8-38) 28 (13-41) 22 (11-41) 29 (16-42)
VAS global health in mm, mean ± SD 43 ± 24 53 ± 20 54 ± 22 49 ± 23
Total SHS, median (IQR) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
Erosive, n (%) 63 (16) 10 (12) 13 (17) 3 (6)
After 4 months 12 patients were lost to follow up and 598 patients were categorized as described in this table. 
OP outside of protocol, SD: standard deviation, IQR: interquartile ranges, n: number, DAS: disease activity 
score, HAQ: Health Assessment Questionnaire, RF: rheumatoid factor, ACPA: anti-citrullinated protein 
antibody, RA(2010): rheumatoid arthritis according to the 2010 classification criteria, ESR: erythrocyte 
sedimentation rate, VAS: visual analogue scale, SHS: Sharp- van de Heijde Score, Erosive: at least 1 erosion.
Arm 1: randomized at 4 months to methotrexate, sulphasalazine, hydroxychloroquine and low dose 





























Remission rates were comparable between patients who at baseline had <12 weeks 
symptom duration and patients who had symptoms for ≥12 weeks, 106/204 (52%) versus 
192/397 (50%) (p=0.31), as were DFR rates 50/204 (25%) versus 80/397 (20%) (p=0.19).
DAS and HAQ after 2 years
At 2 years, mean (SD) DAS was 1.25 (0.77) in the early remission group, 2.02 (0.70) in 
arm 1 and 1.92 (0.85) in arm 2 (arm 1 versus arm 2: p=0.45). Patients treated outside 
the protocol had a mean DAS of 1.9 (0.7) (table 2). Mean (SD) HAQ at 2 years was 0.38 
(0.48) in the early remission group, 0.90 (0.66) in arm 1 and 0.83 (0.67) in arm 2 (arm 
1 versus arm 2: p=0.55) (table 2). Compared to baseline, in all groups improvement 
in mean HAQ was >0.20 and therefore clinically relevant.9 Mean (SD) HAQ in patients 
who were in remission at 2 years was 0.29 (0.39) compared to 0.94 (0.63) in patients 
who were not in remission (p<0.001). Mean (SD) HAQ at 2 years of patients in ACR/
EULAR remission was 0.14 (0.28). 
Over time, DAS or HAQ were not significantly different between arm 1 and 2 (mean 
difference (95%CI) LMM for DAS 0.01 (-0.2;0.2) and for HAQ 0.1 (-0.1;0.2)). 
Radiological joint damage
Of the total study population, 50/610 (8%) patients showed radiological progression 
defined as an increase in SHS of ≥0.5; in the early remission group 33/387 (9%) patients 
showed progression, in arm 1 9/83 (11%), in arm 2 5/78 (6%) (arm 1 versus arm 2: p=0.31) 
and in the OP-group 3/50 (6%). Median SHS progression in all groups was 0 (range 0-22). 
There was no significant difference in progression scores between patients who at 2 
years were in DAS-remission and patients who were not. Eight patients (1%) after 2 
years had radiological damage progression of ≥5 points which represents the minimal 
clinically important difference.12 Seven of these 8 patients had achieved early remission 
and one patient was in persistent remission from 4 months.
Compared to the results after 1 year we found less erosions after 2 years, probably due 
to differences in interpretation of the minimal changes on radiographs. The differences 
were found across the scores of both readers, one of whom had also scored year 1 while 
the new reader used the same scoring method and had received the same training. In 
the early remission group 39/387 (10%) showed erosions after 2 years compared to 65 
(17%) after year 1, in arm 1 2/83 (2%) after 2 years compared to 12 (15%) after year 1, in 
arm 2 8/10 (6%) after 2 years and 12 (16%) after year 1 and in the OP-group 1/50 (2%) 
after 2 years and 2 (4%) after year 1.
Therapy 
Of the 400 patients not in DFR at 2 years, 196 patients were on DMARD monotherapy, 
12 used a combination of multiple non-biologic DMARDs, 37 a combination of non-





























agent. In 16 patients therapy at 2 years was unknown because of missing data and 42 
patients were drug free but not in remission. 
During 2 years follow-up, 43/83 (52%) of the patients in arm 1 switched to ADA+MTX 
and after 2 years 28 patients still used ADA+MTX.
Toxicity
During the second year of the study, 337/610 (55%) patients reported 704 adverse 
events (AE): 53% of the patients in the early remission group, 64% in arm 1, 67% in arm 
2 (arm 1 versus arm 2: p=0.71) and 54% in the OP-group. The most common AE were 
gastro-intestinal complaints, upper airway infections and skin rashes (table 3). Twenty-
five serious adverse events (SAE) were reported in the early remission group, 5 in arm 1, 
8 in arm 2 and 3 in the OP group (table S1).
DISCUSSION
Two years after initial therapy with MTX and a tapered high dose of prednisone, 
followed by remission steered treatment including drug tapering and discontinuation, 
49% of the patients with early RA or UA were in remission and 21% were in DFR. Patients 








arm 1 vs 2
OP group
n = 50
DAS, mean + SD 1.3 ± 0.8 2.0 ± 0.7 1.9 ± 0.9 0.45 1.9 ± 0.7
HAQ, mean + SD 0.4 ± 0.5 0.9 ± 0.7 0.8 ± 0.7 0.55 0.8 ± 0.7
Swollen Joint Count, median (IQR) 0 (0-1) 1 (0-2) 0 (0-2) 0.25 0 (0-2)
Tender Joint Count, median (IQR) 0 (0-2) 3 (2-5) 3 (1-6) 0.84 2 (1-4)
ESR mm/hr, median (IQR) 8 (4-16) 11 (6-20) 9 (6-17) 0.19 14 (7-25)
VAS global health in mm, mean + SD 18 ± 21 30 ± 21 28 ± 24 0.61 32 ± 22
Total SHS, median (IQR) 0 (0-0.5) 0 (0-1.1) 0 (0-0) 0.12 0 (0-0.3)
Erosive, n (%) 39 (10) 2 (2) 8 (10) 0.04 1 (2)
SHS progression, n (%) 33 (9) 9 (11) 5 (6) 0.31 3 (6)
DAS-remission, n (%) 241 (62) 22 (27) 24 (31) 0.76 15 (28)
Drug free remission, n (%) 111 (28) 6 (7) 7 (9) 0.73 7 (14)
ACR/EULAR remission, n (%) 117 (30) 2 (2) 14 (18) 0.001 5 (10)
After 4 months 12 patients were lost to follow up and 598 patients were categorized.
OP: outside of protocol, SD: standard deviation, IQR: interquartile ranges, n: number, DAS: disease 
activity score, HAQ: Health Assessment Questionnaire, ESR: erythrocyte sedimentation rate, VAS: visual 
analogue scale, SHS: Sharp- van de Heijde Score, Erosive: at least 1 erosion, Progression: increase in 
SHS ≥0.5 points, DAS-remission: DAS<1.67, ACR/EULAR remission: provisional Boolean based remission 
definition published by the American College of Rheumatology and the European League Against 
Rheumatism based on a 44 joint count 13. 
Arm 1: randomized after 4 months to methotrexate, sulphasalazine, hydroxychloroquine and low dose 






































Patients with AE, no (%) 205/387 (53%) 53/83 (64%) 52/78 (67%) 27/50 (54%)
Total number of AE 408 129 109 58
Cardiovascular 25 5 8 4
Pulmonary 17 5 2 2
Gastrointestinal 67 16 14 12
GI complaints 8 2 2 -
Nausea/emesis 23 2 4 4
Increased liver enzymes 15 7 3 4
Other 21 5 5 4
Neuro-psychiatric 37 5 7 3
Headache 14 - 4 1
Dizziness 7 1 - 1
Mood disorders 4 - - 1
Other 12 4 3 -
Urogenital 7 3 2 3
Skin/mucous membranes 45 18 15 3
Rash 19 8 5 -
Hair loss/thinning 4 1 1 1
Sicca complaints 3 - - 1
Eczema 3 1 - -
Other 16 8 9 1
Infections 106 38 41 18
Upper airway tract 29 11 16 10
Gastro-intestinal 4 1 - 2
Skin/mucosa 14 2 4 2
Pneumonia/bronchitis 9 1 1 1
Urinary tract 15 7 5 1
Flu/unspecified fever 25 10 6 1
Other 10 6 9 1
Trauma/injury 13 5 2 3
Infusion reaction 3 1 - -
Malaise 9 5 1 1
Surgical procedures without hospitalization 13 5 4 1
Other 65 23 12 8
AE: adverse event. *One or more adverse events possible per patient. 
who achieved early remission after 4 months more often achieved remission (62%) and 
DFR (29%) at 2 years than patients who did not (29% remission and 9% DFR, without 
differences between the two treatment strategies). Radiological damage progression 
was seen in only 8% of the patients and functional ability improved up to the normal 





























The radiological results are better than previously reported in patients with early RA.14-17 For 
example, 7-33% of the patients in the BeSt study showed progression after 1 year and 20-47% 
of the patients in the NEO-RACo study showed progression after 2 years.14, 18 Still, the overall 
remission rates in the IMPROVED-study are only slightly higher than what we observed in the 
BeSt study.14, 19 At baseline, those patients had active RA (1987 criteria20) with high disease 
activity, were more often ACPA positive patients and had longer symptom duration. 
Furthermore, only half of the BeSt study population received initial combination therapy 
and the target of treatment was low disease activity (DAS≤2.4) instead of remission 
(DAS<1.6). That only half of the patients achieved remission in the IMPROVED-study may 
in part be explained by rapid tapering and discontinuation of drugs as soon as DAS<1.6 
was achieved. There were only 55 patients who had been in remission from 4 months 
onwards. Together with the exception of 50 patients who never achieved remission, 
all others had achieved but lost remission at least once. It is possible that steering at a 
treatment target of remission defined by DAS<1.6 is hampered by some patients reporting 
pain and joint tenderness where no joint swelling was found. One may argue that using 
DAS<1.6 as the treatment target is unrealistic, as with a DAS just above the threshold 
of 1.6 inflammation is equally well suppressed, resulting in equally well prevented joint 
damage. Still, patients not in remission had a mean HAQ approaching 1 whereas patients 
in remission had near-normal functional ability. This, however, may have come at the cost 
of relatively high usage of medications with potential side effects and high costs. 
We found the highest remission and DFR rates in patients who had achieved early 
remission. It may be that patients who fail to achieve remission on initial combination 
treatment are a selected group with less responsive disease. After 1 year follow-up we 
have reported there was a statistically significant difference in remission rates between 
the randomization arms.6 After 2 years, the remission rates were comparable and this 
is probably due to remission steered treatment adjustments in both arms and due to 
treatment overlap in the treatment strategies during follow-up. 
Remission rates were comparable between patients with RA and UA. This could either 
indicate that we missed the ‘window of opportunity’ and therefore the opportunity 
to alter the disease course. However, the outcomes between patients with <12 weeks 
symptom duration and those with ≥12 weeks symptom duration are comparable. It 
could also indicate that early RA and UA, when effectively treated, result in comparable 
outcomes. On the other hand, UA patients more often achieved DFR than RA patients. 
This may suggest that, although it is possible to achieve remission in RA and UA in 
comparable percentages, the possibility to taper and stop medication when remission 
is achieved, is not. These same arguments probably also explain the higher DFR rates in 
ACPA negative patients, compared to ACPA positive patients.
We found less erosive joint damage after 2 years than after 1 year. Our data suggest that this 
is not due to repair, which has been shown to occur more often in damaged joints.21 Joint 





























from early abnormalities. Furthermore, the radiographs taken at baseline, after 1 year and 
after 2 years, were scored in random order. It has been demonstrated that chronological 
scoring is more sensitive to change and may lead to an increased detection of clinically 
relevant progression.22, 23 Since the overall progression rates are so low and for most patients 
below the minimal clinically important difference, it is unlikely that the small difference 
between the erosion scores after 1 and 2 years affect the main radiological outcomes. 
In conclusion, in patients with recent onset RA or UA, 2 years of remission targeted 
treatment results in 49% of the patients being in remission and 21% in DFR and virtually 
no radiological damage progression. Patients who achieved early remission also 
achieved more remission and DFR after 2 years than the patients who had not achieved 
early remission and were randomized to 2 treatment strategies, between which no 
differences in outcomes were found. These results suggest that initial treatment with 
MTX and prednisone followed by remission steered treatment is effective in suppressing 
disease activity and in particular in suppressing joint damage progression. 
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ABSTRACT
Objective: To assess if baseline characteristics in patients with undifferentiated or early 
rheumatoid arthritis affect the possibility to achieve drug free remission after one year 
(DFR1year) of early remission induction therapy.
Methods: We included 375 patients participating in the IMPROVED study, who achieved 
remission (DAS<1.6) after four months (early remission) and were by protocol able to 
achieve DFR1year. Having started with methotrexate (MTX) plus prednisone, patients tapered 
prednisone to zero and after 8 months, those still in remission tapered MTX to zero, while 
those not restarted prednisone. Characteristics of patients achieving and not achieving 
DFR1year were compared. Logistic regression was performed to identify predictors of DFR1year. 
Results: After one year, 119 patients (32%) were in DFR. Presence of Rheumatoid Factor 
(RF), fulfilling the 2010 criteria for RA and a low tender joint count were associated 
with achieving DFR1year, whereas presence of ACPA was not. None of the baseline 
characteristics were independently associated with DFR1year.  DFR1year was sustained for 4 
months in 65% patients. ACPA positive patients less often had sustained DFR than ACPA 
negative patients (58% versus 80%, p=0.013).
Conclusion: After 1 year of remission steered treatment, 32% of the patients who had 
achieved early remission after 4 months, were able to taper medication and achieved 
drug free remission. Neither presence of ACPA nor other baseline characteristics were 
independently associated with achieving drug free remission after 1 year but in ACPA 






















With the current treatment strategies, remission has become a realistic goal in patients with 
rheumatoid arthritis (RA).1-3 It remains to be seen whether achieving drug free remission 
(DFR) after tapering medication is also a realistic goal. In recent cohort studies and clinical 
trials in patients with RA, DFR rates vary between 17 and 29% 4-6 and DFR was sustained 
for 1-4 years in 9-16%.4, 7 Previously reported independent predictors for sustained DFR are 
absence of anti-citrullinated protein antibody (ACPA),  rheumatoid factor (RF) and shared 
epitope, short symptom duration and low disease activity until remission.6, 7
In the IMPROVED study, patients with recent onset RA or undifferentiated arthritis (UA) 
clinically suspected for RA received initial treatment with a combination of MTX and a 
tapered high dose of prednisone. If remission (DAS<1.6) was achieved after 4 months, 
medication was stepwise tapered until DFR could be achieved already after 1 year (DFR1year). 
We previously reported that 61% of the patients achieved early remission after 4 months. 
Surprisingly, these patients were more often ACPA positive than the patients who did not 
achieve early remission.8 Here, we aimed to assess whether ACPA status also influenced the 
likelihood to achieve DFR1year and to identify possible other determinants of achieving DFR1year. 
METHODS 
Patients, study design and outcomes 
IMPROVED is a multi-center clinical trial in 122 patients with undifferentiated arthritis (UA) 
and 479 patients with recent onset rheumatoid arthritis (RA, 2010 criteria), treated according 
to a tight controlled, remission (DAS<1.69) steered protocol. Details on in- and exclusion 
criteria were previously published.10 Initially, all patients were treated with MTX 25mg/wk 
plus prednisone 60mg/day tapered in 7 weeks to 7.5mg/day, continued up to 4 months. 
Patients not in remission after 4 months by protocol could not achieve DFR1year because they 
had to take additional treatment steps before tapering was possible, and thus were left out 
of the current analysis. Patients who achieved remission after 4 months (early remission) first 
tapered prednisone to zero in 4 weeks and if still in remission after 8 months also tapered 
MTX to zero in 2 months. Patients who lost remission while still on MTX restarted prednisone 
and patients who already discontinued MTX restarted MTX. DFR1year was defined as having 
a DAS<1.6 from 4 months to 1 year while both prednisone and methotrexate (MTX) were 
subsequently tapered and stopped. Because DFR1year was only achieved about 2 months 
before the end of year 1, we included 16 months follow up data to see if DFR could be 
sustained. Details on study protocol and scoring methods were previously published.11
Statistical analysis
Clinical, radiological and laboratory variables during the first year were compared between 
patients achieving and not achieving DFR1year using the student’s t test, Mann Whitney U 





















were entered as covariates in univariate logistic regression analyses, with DFR1year as 
binomial dependent variable. Using a significance level of 0.10, univariate significant 
variables were entered in a multivariable model to indentify independent predictors. 
RESULTS 
After 4 months, 375 (61%) patients achieved early remission, of which 291 (78%) fulfilled 
the 2010 classification criteria for RA. Compared to patients not in early remission, patients 
in early remission had lower mean baseline DAS and HAQ levels, more were ACPA positive 
and fewer were female.8 After one year, 119/375 patients (32%) were in DFR and 245 
(65%) were not, although 138 (56%) of those were in remission but on medication. Eleven 
patients had insufficient data. Whether patients fulfilled the 198712 and/or the 2010 RA 
classification criteria10 did not significantly affect the DFR1year rate (DFR1year was achieved by 
51 (28%) patients who fulfilled both classification criteria, 33 (34%) who fulfilled the 2010 
but not the 1987 criteria and 21 (37%) who fulfilled neither (p=0.4)). Similar proportions 
of patients in DFR1year and not in DFR1year were ACPA positive (66 (55%) versus 150 (61%) 
respectively, p=0.2). There were no differences in baseline DAS, symptom duration and 
percentage of females between patients in and not in DFR1year. Patients in DFR1year were 
more often RF negative, and after 4 months as well as after 1 year, they had lower mean 
DAS and HAQ values than patients not in DFR1year (table 1).
Results of the univariate regression analysis are shown in table 2. Baseline DAS and 
HAQ values, ACPA status, age, male sex and symptom duration were not associated 
with achieving DFR1year. RF positivity, high baseline TJC and fulfilling the 2010 criteria 
for RA were univariate predictive for less often achieving DFR1year. In a multivariate 
regression model none of these variables were independently predictive for less often 
achieving DFR1year (adjusted OR (95%CI) RF positivity 0.6 (0.4-1.1), baseline TJC 0.9 (0.9-
1.0), fulfilling the 2010 criteria for RA 0.9 (0.5-1.8)). After leaving out the least significant 
variable, fulfilling the 2010 criteria for RA (p=0.8), RF positivity was predictive for less 
often achieving DFR1year, independently of TJC.
Seventy seven (65%) patients in DFR1year were still in DFR after 16 months (DFR16mo), 36 
(30%) were not and 6 patients had missing data. Those who lost remission were more 
often ACPA positive than those who sustained DFR (26 (72%) versus 36 (47%), p=0.01), 
and ACPA positive patients less often sustained remission than ACPA negative patients 
(36 (58%) versus 40 (80%), p=0.013). Regardless of achieving DFR1year, 107 (29%) patients 
achieved DFR16mo. Patients in DFR16mo were less often ACPA positive than those not in 
DFR16mo (47 (44%) versus 159 (67%), p<0.001) (figure 1).
DISCUSSION
In the IMPROVED-study, 32% of the early arthritis patients who had achieved remission 





















Table 1. Baseline characteristics and clinical outcomes of patients who are and are not in drug free 






DAS 2.9±0.9 3.0±0.8 0.3
Swollen joint count 4 (2-10) 5 (3-9) 0.2
Tender joint count 5 (3-8) 6 (4-8) 0.1
VAS global health, mm 41±25 43±24 0.3
ESR, mm/hr 21 (11-36) 24 (10-38) 0.5
HAQ 1.0±0.7 1.0± 0.6 0.5
Age, years 52±13 51±14 0.5
Symptom duration, weeks 16 (8-30) 17 (9-32) 0.4
Female 67 (56) 158 (64) 0.1
RF positive 60 (50) 152 (62) 0.03
ACPA positive 66 (55) 150 (61) 0.2
Diagnosis RA(2010) 87 (74) 196 (80) 0.1
Diagnosis RA(1987) 61 (51) 138 (56) 0.4
SHS total score 0(0-1) 0(0-0) 0.08
Erosive 20 (17) 31 (13) 0.3
4 months
DAS 0.8±0.4 1.0±0.4 <0.001
Swollen joint count 0 (0-0) 0 (0-0) 0.3
Tender joint count 0 (0-1) 0 (0-1) 0.07
VAS global health, mm 12±14 15±13 0.1
ESR, mm/hr 6 (2-11) 7 (4-13) 0.08
HAQ 0.2±0.3 0.3±0.3 0.006
ACR/EULAR remission 57 (48) 86 (35) 0.006
1 year
DAS 0.9±0.4 1.5±0.8 <0.001
Swollen joint count 0 (0-0) 0 (0-2) <0.001
Tender joint count 0 (0-0.5) 1 (0-3) <0.001
VAS global health, mm 12±15 25±22 <0.001
ESR, mm/hr 6 (3-11) 9 (4-18) 0.01
HAQ 0.2±0.3 0.5±0.5 <0.001
DAS remission 119 (100) 138 (56) <0.001
Data are presented as means ± standard deviations (SD), medians and interquartile ranges (IQR), or 
numbers and percentages (%) when appropriate. Eleven patients had missing data after 1 year. 
DFR1year: drug free remission defined as DAS<1.6 and all medication tapered after 1 year, RF: rheumatoid 
factor, ACPA: anti-citrullinated protein antibody, HAQ: Health Assessment Questionnaire, DAS: disease 
activity score, VAS: visual analogue scale, ESR: erythrocyte sedimentation rate, RA(2010): Rheumatoid 
Arthritis according to the 2010 ACR/EULAR classification criteria, RA(1987): RA according to the 1987 
ACR classification criteria, SHS: Sharp-van der Heijde score, Erosive: number of patients having one or 
more erosions, DAS-remission: defined as a DAS<1.6, ACR/EULAR remission according to the Boolean 





















Table 2. Univariate logistic regression analyses with DFR after 1 year (yes or no) as dependent variable.
Baseline characteristics Crude OR 95%CI p-value
Age, years 1.0 0.99-1.0 0.3
Male sex 1.4 0.9-2.2 0.13
DAS 0.8 0.6-1.0 0.10
HAQ 0.9 0.6-1.2 0.5
TJC 0.9 0.9-1.0 0.08
SJC 0.99 0.95-1.0 0.6
ESR, mm/hr 0.996 0.99-1.0 0.4
Symptom duration, weeks 0.997 0.99-1.0 0.6
ACPA positivity 0.7 0.5-1.2 0.2
RF positivity 0.6 0.4-0.96 0.03
Diagnosis RA(2010) 0.6 0.4-1.1 0.099
OR: odds ratio, 95% CI: 95% confidence interval, DAS: disease activity score at baseline,  HAQ: health 
assessment questionnaire at baseline, ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, TJC: 
tender joint count at baseline, SJC: swollen joint count at baseline, ESR: erythrocyte sedimentation rate (mm/
hr) baseline, RA(2010): rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria. 
remission after 1 year (DFR1year), regardless of fulfilling the 1987 and/or 2010 classification 
criteria for RA. Baseline characteristics in the past associated with chronic and/or 
progressive disease, such as a positive RF and fulfilling criteria for RA, were associated 
with less often achieving DFR1year, although not independently of each other. Also a 
high tender joint count at baseline was, non-independently, associated with less often 
achieving DFR1year. ACPA status and symptom duration were not associated with DFR1year. 
In 65% of patients in DFR1year, DFR was sustained for 4 more months. Although DFR was 
achieved in ACPA positive patients as often as in ACPA negative patients, ACPA positive 
patients less often sustained in DFR than ACPA negative patients.  
To our knowledge, IMPROVED is the first study in which DFR was a treatment goal. A 
DFR rate of 32% after 1 year is probably high, although 29% of the total IMPROVED 
population did not achieve early remission after 4 months and by protocol were not 
able to achieve DFR already after 1 year. 
Given the fact that we included both RA and UA patients, clinically suspect for RA but 
not fulfilling the criteria, we may have included and treated patients who might have 
remitted spontaneously. This was a reason why we introduced a rapid drug tapering 
scheme in our protocol. However, if the 32% mainly represented non-chronic types of 
arthritis, one would expect that these patients more often were auto-antibody negative, 
possibly had shorter disease duration or less often fulfilled the criteria sets for RA than 
patients not achieving DFR, which was not the case. 
Interestingly, presence of ACPA was not associated with less DFR1year. Previously we 
reported that presence of ACPA was associated with achieving more remission after 4 





















that presence of ACPA is associated with a less favorable disease course.13, 14 In a study 
comparing DFR in the Leiden Early Arthritis Clinic and the BeSt study, absence rather 
than presence of ACPA was an independent predictor of sustained DFR.7 That ACPA 
positive patients achieve DFR1year in similar numbers as ACPA negative patients may 
be explained both by the initial combination with MTX and prednisone and the early 
remission steered treatment in the IMPROVED-study. 
However, after treatment was stopped 30% of patients lost remission and had to restart 
medication within 4 months after achieving DFR, and ACPA positive patients more often 
Figure 1. Percentages ACPA positive patients 
achieving drug free remission after 1 year versus 
not, sustaining drug free remission versus not and 
achieving drug free remission after 16 months 
versus not. DFR 1 year: drug free remission after 1 
year, sustained DFR: patients in DFR after 1 year and 
after 16 months, DFR 16 months: patients in DFR 
after 16 months regardless of being in DFR after 1 





















lost DFR than ACPA negative patients. This suggests that compared to ACPA negative 
patients, ACPA positive patients have a similar likelihood of achieving and maintaining 
remission, even while medication is tapered. But after having successfully tapered 
and discontinued medication, ACPA positive patients show more relapses in disease 
activity in the next 4 months, and this may even increase with follow up. Reasons why 
sustaining drug free remission was achieved less often in ACPA positive patients may 
be that we have tapered medication too soon or too fast or have not used the optimal 
initial treatment within the optimal time frame. In the future we will also be able to see 
which patients who did not achieved early remission after 4 months, may achieve late 
drug free remission in the randomization arms and whether this is sustained over time. 
In conclusion, 32% of patients with early arthritis who achieved remission after 4 months 
of initial combination therapy can taper medication until DFR is achieved after one year. 
Achieving DFR is possible regardless of ACPA status or other baseline disease characteristics, 
but DFR is sustained less often in ACPA positive than in ACPA negative patients.
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C H A P T E R  7
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ABSTRACT
Objective: To assess the association between high body mass index (BMI) and treatment 
response in recent-onset rheumatoid arthritis.
Methods: In the Behandelstrategieën voor Reumatoide Artritis (Treatment Strategies 
for Rheumatoid Arthritis) study, 508 patients were randomized to initial monotherapy 
or combination therapy with prednisone or infliximab (IFX). The response to Disease 
Activity Score (DAS) ≤2.4–steered treatment (first dose and after 1 year) was compared 
between patients with a BMI <25 kg/m2 and ≥25 kg/m2, using relative risk (RR) regression 
analyses. DAS, components of DAS, and functional ability during the first year were 
compared using linear mixed models.
Results: High BMI was independently associated with failure to achieve a DAS ≤2.4 on initial 
therapy (RR 1.20 [95% confidence interval (95% CI) 1.05, 1.37]). The effect for combination 
therapy with prednisone was RR 1.55 (95% CI 1.06, 2.28) and for combination therapy with 
IFX 1.42 (95% CI 0.98, 2.06). The RRs for failure after 1 year were 1.46 (95% CI 0.75, 2.83) and 
2.20 (95% CI 0.99, 4.92), respectively. High BMI was also associated with failure on delayed 
combination therapy with IFX, after adjustment for selection bias related to previous failure 
on disease-modifying antirheumatic drugs. No significant association was observed in the 
initial monotherapy groups. In the first year, patients with a high BMI had higher DAS and 
worse functional ability, with more tender joints and a higher visual analogue scale global 
health, but not more swollen joints and similar systemic inflammation.
Conclusion: High BMI was independently associated with failure to achieve low DAS on initial 
combination therapy with prednisone and on initial and delayed treatment with IFX. Patients 


































An association between treatment response to tumour necrosis factor (TNF) blockers 
and body mass index (BMI; kg/m2) was described in a group of patients with established 
rheumatoid arthritis (RA) who had failed treatment on disease-modifying antirheumatic 
drugs (DMARDs). Patients with a high BMI responded less well to treatment with a fixed 
dose of the TNF blocker infliximab (IFX).1 This finding was replicated in patients who 
had failed on methotrexate (MTX) and were treated with a fixed dose of adalimumab, 
etanercept, or IFX.2 Patients with a high BMI and thus a higher fat mass might show more 
inflammation.3, 4 Yet, clinical synovitis might be less easy to assess in RA patients with a 
high BMI. It has also been described that patients with various conditions and a high BMI 
report more pain than patients with a normal or low BMI.5-7
In the Behandelstrategieën voor Reumatoide Artritis (Treatment Strategies for Rheumatoid 
Arthritis) (BeSt) trial, a treatment to target trial in early RA patients, treatment response in 
terms of Disease Activity Score (DAS) and patient-reported outcomes was assessed every 
3 months and yearly radiographs were taken. Because different treatment strategies were 
used, we were able to analyze the association between BMI and different components 
of treatment response not only to TNF blockers, but also to conventional DMARD 
monotherapy or combination therapy.
METHODS
Patients from the BeSt cohort, a study originally designed to compare 4 different 
treatment strategies in early DMARD-naive RA patients, were analyzed. Patients were 
randomized to 1 of 4 treatment groups: 1) sequential monotherapy starting with MTX, 2) 
step-up combination therapy starting with MTX, 3) initial combination therapy, with the 
COBRA (Combinatietherapie Bij Reumatoïde Artritis) scheme: MTX, sulfasalazine (SSZ), 
and tapered high dose prednisone, or 4) a combination of MTX and IFX.
Treatment was DAS-steered and aimed at a DAS of ≤2.4, resulting in 3 monthly treatment 
adjustments as long as the DAS was >2.4. Thus, in groups 1–3, delayed IFX treatment 
was initiated if treatment had failed on at least 3 synthetic DMARDs, including MTX, SSZ, 
leflunomide (in arm 1) or hydroxychloroquine (in arm 2), and prednisone (in arms 2 and 3). 
In all arms, DMARD treatment was changed or added to at least twice in case of insufficient 
response (DAS >2.4) before MTX + IFX combination therapy was started. Patients treated 
with MTX + IFX started IFX in a dosage of 3 mg/kg/every 8 weeks, but if the DAS remained 
>2.4, the IFX dosage was escalated from 3 mg/kg/2 months to 6 mg, 7.5 mg, and finally 
10 mg/kg if necessary. If the highest dose did not lead to a low DAS, MTX + IFX were 
abandoned and the next treatment initiated. At any stage of the protocol, if patients 
achieved a DAS ≤2.4 for ≥6 months, treatment was tapered to maintenance dose: MTX 
monotherapy in groups 1 and 2, SSZ monotherapy in group 3, and MTX + IFX 3 mg/kg/2 

































Treatment response (failure was defined as not achieving a DAS ≤2.4) was compared 
between normal weight patients (BMI <25 kg/m2) and overweight or obese patients 
(BMI ≥25 kg/m2).9 Both height and weight were assessed at baseline and were measured 
by a research nurse, using professional calibrated scales to measure weight and wall-
based measure rods to measure height. Treatment response was assessed at 2 time 
points. First, we looked at whether or not patients achieved a DAS ≤2.4 after the first 
3 months of treatment. Second, we looked at failing responses (DAS >2.4) in year 1, on 
treatment step 1 and 2: MTX monotherapy (15 mg/week, if necessary increased to 25 
mg/week) in groups 1 and 2, on combination therapy with prednisone (MTX 7.5 mg, if 
necessary increased to 25 mg/week) in group 3, and on treatment steps 1, 2, or 3 (MTX + 
IFX increased from 3 mg, 6 mg to 7.5 mg/kg/2 months) in group 4. The different cut-off for 
group 4 was chosen because, based on DAS evaluations before each IFX dose, treatment 
could be intensified every 2 months as compared to every 3 months in the other groups. 
We also looked for a relation between BMI and clinical response to treatment with MTX 
+ IFX in patients who had failed treatment on previous synthetic DMARDs in groups 1–3. 
After 8 years of treatment, the number of protocolized treatment steps that patients had 
failed on was recorded in the initial treatment groups. Radiologic damage progression 
was assessed using the Sharp/van der Heijde score, taking the mean of the scores of 2 
independent readers, blinded for patient identity, who evaluated all the radiographs of 
hands and feet in non-chronological order.
Statistical analyses were performed with the software program SPSS, version 17.0 (SPSS 
Inc., Chicago, IL), and STATA, version 12. Baseline characteristics were compared between 
patients with normal and high BMI using the Student’s  t-test, the Mann-Whitney U 
test, or the χ2 test. To determine whether a higher BMI was associated with impaired 
response to therapy according to the definitions above, a relative risk (RR) regression 
model was used, where the parameters were estimated using a modified Poisson 
regression approach with robust SEs.10 These analyses give risk ratios, which are easier 
to interpret than odds ratios. The analyses were adjusted for sex, age, smoking habits, 
rheumatoid factor (RF), and baseline DAS. Then the regression analyses for treatment 
response were repeated and stratified for treatment group (groups 1 and 2, group 3, 
and group 4). The association between BMI and failure to achieve a DAS ≤2.4 on delayed 
IFX was examined in patients from groups 1–3 who received MTX + IFX after failing on 
several DMARDs. Differences in baseline characteristics in this group, associated with 
response to DMARDs, were observed between patients with low or normal and high BMI, 
indicating that there might be a selection bias. Therefore, propensity scores with age, RF, 
alcohol use (yes/no), treatment group, baseline erythrocyte sedimentation rate (ESR), 
number of swollen joints, visual analogue scale (VAS) global and morning stiffness as 
predictors, and high BMI as outcome were calculated using logistic regression. Then, to 
correct for the differences between patients with normal and high BMI, a risk regression 
model was fitted with the weighting based on the estimated propensity score, i.e., 1/

































normal BMI. Weights >5 were truncated at 5. We repeated the analyses with BMI as a 
(linear) continuous variable. There was no evidence of a nonlinear association (tested by 
comparing likelihoods of different models and by using fractional polynomials). To find 
out whether there was a difference in disease manifestation in the first year of treatment 
between the BMI categories of the various DAS components or in patient-reported 
outcomes, linear mixed models were fitted. The following dependent variables were 
used in the different models: tender joint count, swollen joint count, ESR, C-reactive 
protein (CRP) level, patients’ assessment of global health (VAS global) and of pain (VAS 
pain), and Health Assessment Questionnaire (HAQ) score. In each of the models, time 
and BMI category were entered as categorical covariates and the baseline value of the 
dependent variable as continuous covariate. The interaction between time and BMI was 
not significant in any of the analyses, therefore it was not included in the final models. 
The estimates were adjusted for sex, age, RF, and smoking habits.
The number of treatment steps on which patients had failed after 8 years was compared 
using the Mann-Whitney U test.
RESULTS
Patients with a BMI ≥25 kg/m2  were older than patients with a BMI <25 kg/m2 (56 
years versus 53 years; p=0.03) and were less often smokers (31% versus 41%; p=0.01) 
(table 1). No other significant differences in baseline characteristics were observed. A 
BMI ≥30 kg/m2 was observed in 15% of all patients.
High BMI was an independent predictor of failing (not achieving a DAS ≤2.4) on the first 
treatment step with an RR of 1.20 (95% confidence interval 95% CI 1.05;1.37) (table 2). A minor 
effect was observed for failing on treatment steps in year 1 (steps 1 and 2 in groups 1−3 or 
steps 1, 2, and 3 in group 4) with an RR of 1.15 (95% CI 0.92;1.43). Analyses were repeated 
with BMI as a continuous variable, and these results confirm the findings of the dichotomized 
analyses. High BMI was again an independent predictor of failing on the first step (RR 1.03, 
95% CI 1.01;1.06) and for failing on treatment steps in year 1 (RR 1.02, 95% CI 1.01;1.04) 
(table 3). Adding nonlinear terms in BMI to the model did not improve the fit (p=0.99).
After 8 years of DAS-steered treatment, the median (interquartile range) number of 
treatment steps patients had failed on was 1 (0–3) for patients with a BMI <25 kg/m2 and 
2 (1-4) for patients with a BMI ≥25 kg/m2  (p<0.001). The percentage of patients who 
after 8 years were no longer treated according to protocol due to failing on all treatment 
steps was not different (26% versus 22%; p=0.4).
Treatment groups
In groups 3 and 4, a higher risk of impaired response to therapy for patients with a 
high BMI was found with RRs of 1.55 (95% CI 1.06;2.28) and 1.42 (95% CI 0.98;2.06) for 

































in year 1 was 1.46 (95% CI 0.75;2.83). The effect of impaired response in patients with 
a high BMI was stronger in group 4 (RR 2.20, 95% CI 0.99;4.92). In groups 1 and 2, no 
significant association between treatment response and BMI was observed.
Delayed IFX
For patients initially treated with MTX + IFX in group 4 (n=120), demographic or disease 
characteristics between patients with a high and low BMI were similar at baseline (data 
not shown). In contrast, patients with a BMI ≥25 kg/m2 who received MTX + IFX in groups 
1–3 were less often positive for anti-citrullinated protein antibody and RF (57% versus 
83% and 66% versus 90%; p=0.004 and 0.002, respectively) (table S1). They were older 
than patients with a BMI <25 kg/m2 (mean age 51 years versus 46 years; p=0.02). There 
were 32 patients with a BMI >30 kg/m2. Of these, only 9 patients (28%) responded well 
to medication after 1 year. Of the patients in groups 1–3 with a BMI <30 kg/m2, 89 of 193 
(46%) responded well.
However, in crude analyses no association was seen between BMI and response to 
treatment in patients from groups 1–3 who received delayed MTX + IFX (RR 1.11, 95% CI 
0.71;1.73) for response to first dose, and a trend was seen for response after 1 year (RR 
1.56, 95% CI 0.80;3.04). After adjusting for the misbalance in the baseline characteristics 





Female, n(%) 155 (72) 188 (64) 0.08
Age 53 ± 15 56 ± 13 0.03
BMI 23 ± 2 29 ± 3 <0.001
Symptom duration, median (IQR) 23 (13-57) 23 (14-47) 0.7
ACPA positive, n(%) 131 (65) 160 (59) 0.2
RF positive, n(%) 149 (69) 180 (62) 0.09
DAS 4.4 ± 0.8 4.4 ± 0.9 0.4
HAQ 1.4 ± 0.6 1.4 ± 0.7 0.4
CRP, median (IQR) 20 (8-55) 21 (9-50) 0.96
ESR, median (IQR) 38 (20-56) 34 (18-56) 0.4
TJC, median (IQR) 13 (9-17) 13 (9-19) 0.3
SJC, median (IQR) 13 (10-19) 14 (9-18) 0.8
VAS global health 51 ± 20 54 ± 20 0.09
VAS physician 58 ± 18 57 ± 18 0.6
VAS pain 54 ± 21 55 ± 22 0.3
Smoking, n(%) 88 (41) 89 (31) 0.02
Unless indicated otherwise, values are mean ± SD.
ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, DAS: disease activity score, HAQ: 
Health Assessment Questionnaire, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, TJC: 

































using propensity weighting, the RR of failure to the first dose changed to 1.37 (95% CI 
0.81;2.31), and the RR of failure after 1 year changed to 2.09 (95% CI 0.97;4.49).
Disease activity components
In year 1 and adjusted for baseline differences, patients with high BMI had higher disease 
activity (difference in DAS 0.30, 95% CI 0.15;0.45), a higher HAQ score (difference 0.14, 
95% CI 0.05;0.23), and a higher VAS pain (difference 6.2 mm [95% CI 3.0;9.4]). For DAS 
components, a difference was found in tender joints (difference 1.4, 95% CI 0.6;2.2) and 
patient’s assessment of global health (VAS difference 4.9 mm, 95% CI 1.9;7.8), but not for 
swollen joints (difference 0.6, 95% CI -0.02;1.2) (table 4 and figure 1). Radiologic damage 
Table 2. Risk of not achieving a DAS ≤2.4 (on the first dose and during year 1) in patients with a high BMI
Crude RR Adjusted RR*
Fail on initial treatment step (all) 1.20 (1.04-1.38)** 1.20 (1.05-1.37)**
Fail on first dose MTX monotherapy 1.10 (0.96-1.25) 1.10 (0.97-1.25)
Fail on initial dose MTX+SSA+prednisone 1.57 (1.02-2.41)** 1.55 (1.06-2.28)**
Fail on initial dose MTX+infliximab 1.37 (0.93-2.02) 1.42 (0.98-2.06)
Fail in year 1 (all) 1.13 (0.89-1.43) 1.15 (0.92-1.43)
Fail in year 1 (groups 1+2) 1.04 (0.82-1.31) 1.05 (0.84-1.30)
Fail in year 1 (group 3) 1.37 (0.68-2.75) 1.46 (0.75-2.83)
Fail in year 1 (group 4) 2.12 (0.93-4.83) 2.20 (0.99-4.92)
First dose: MTX monotherapy in groups 1 and 2, MTX+sulfasalazine+prednisone in group 3, 
MTX+infliximab in group 4 
Year 1: failing on treatment step 1 and 2: methotrexate monotherapy (15 or 25 mg/week) in groups 1 and 2, on 
combination therapy with prednisone (methotrexate 7.5 or 25 mg/week) in group 3, and on treatment steps 
1, 2 or 3 (methotrexate 25 mg/week plus infliximab increased from 3, 6 to 7.5mg/kg/2 months) in group 4.
Reference: patients with a BMI <25
*adjusted for gender, age, smoking habits, rheumatoid factor (RF) and baseline DAS
** p-value <0.05
Table 3. Relative risk of not achieving a DAS ≤2.4 (on the first dose and during year 1) per unit increase 
of BMI (BMI as continuous variable) 
Crude RR Adjusted RR*
Fail on initial treatment step (all) 1.025 (1.011-1.040)* 1.023 (1.010-1.037)*
Fail on first dose MTX monotherapy 1.016 (1.002-1.030)* 1.016 (1.003-1.029)*
Fail on initial dose MTX+SSA+prednisone 1.052 (1.014-1.092)* 1.049 (1.014-1.085)*
Fail on initial dose MTX+infliximab 1.029 (0.99-1.071) 1.028 (0.99-1.064)
Fail in year 1 (all) 1.032 (1.008-1.056)* 1.029 (1.005-1.055)*
Fail in year 1 (groups 1+2) 1.022 (1.002-1.043)* 1.020 (0.998-1.043)*
Fail in year 1 (group 3) 1.063 (0.97-1.165) 0.99 (0.99-1.160)
Fail in year 1 (group 4) 1.039 (0.97-1.114) 1.041 (0.98-1.112)

































Figure 1. Disease Activity Score, Health Assessment Questionnaire, VAS global health, erythrocyte 
sedimentation rate, Tender joint count, Swollen joint count, patient’s assessment of pain (on a visual 
analogue scale) and physician’s assessment of disease activity in year 1 for patients with a BMI<25 and 

































Table 4. Differences in disease activity and its components for patients with a BMI≥25 compared to 
patients with a BMI<25 over the first year (analyzed using linear mixed models). 
Unadjusted difference Adjusted difference*
DAS 0.25 (0.10-0.40) 0.30 (0.15-0.45)
HAQ 0.13 (0.04-0.21) 0.14 (0.05-0.23)
VAS global 4.4 (1.5-7.3) 4.9 (1.9-7.8)
ESR 0.9 (-1.3-3.1) 1.3 (-0.9-3.5)
CRP 0.1 (-2.2-2.3) 0.7 (-1.5-2.9)
TJC 1.1 (0.4-1.9) 1.4 (0.6-2.2)
SJC 0.5 (-0.1-1.1) 0.6 (-0.02-1.2)
VAS pain 5.4 (2.3-8.6) 6.2 (3.0-9.4)
*Adjusted for rheumatoid factor, age, gender and smoking habits. 
DAS: Disease Activity Score, HAQ: Health Assessment Questionnaire score, VAS: visual analogue scale, ESR: 
erythrocyte sedimentation rate, CRP: C-reactive protein, TJC: tender joint count, SJC: swollen joint count.
Figure 2. Cumulative probability plot of joint damage progression in year 0-1 and in years 0-8 for patients 
with a BMI<25 and ≥25. BMI: body mass index, SHS: Sharp/ van der Heijde Score
progression in year 1 and over 8 years follow-up was similar in patients with high or low/
normal BMI (figure 2). 
DISCUSSION
In this DAS-steered treated cohort with early RA patients, high BMI was associated with 
failure to achieve a low DAS (≤2.4) on antirheumatic therapy, including after adjustment 
for confounders. This was most noticeable in patients who were treated with initial 
combination therapy with MTX, either combined with prednisone and SSZ, or with IFX. 
The association between high BMI and failure of treatment remained if the dose of MTX 
or IFX was increased. After stratification for initial therapy (initial monotherapy with 
MTX in groups 1–2, initial combination therapy with MTX, SSZ, and prednisone in group 

































combination therapy were more likely to show a decreased response to treatment than 
patients with a normal BMI. This association was still seen after 1 year, after failure on the 
initial treatment had led to dose increases (of MTX in group 3 and of IFX in group 4), but 
less so in group 3 than in group 4. High BMI was also associated with failure to achieve 
a low DAS on delayed treatment with IFX in patients who had failed treatment on at 
least 3 conventional DMARDs. Due to more failure to achieve a low DAS on treatment, 
patients with high BMI went through significantly more treatment steps over 8 years 
of DAS-targeted treatment than patients with a low/normal BMI. Failure to achieve a 
low DAS depended mainly on the pain and joint tenderness scores, which were higher 
in the patients with a high BMI, whereas joint swelling and laboratory parameters of 
inflammation were similar in patients with high or low/normal BMI.
Recently, Klaasen et al reported that patients with a high BMI responded less well to 
delayed treatment with fixed-dose IFX after failure on a median of 2 DMARDs.1 It has been 
suggested that this may be due to high levels of proinflammatory cytokines produced 
by adipocytes.3, 4 Our results confirm that patients with a high BMI fail treatment more 
often on IFX, also as initial treatment, and also if the dosages are increased up to 10 mg/
kg/every 8 weeks. Thus, a failure to respond on IFX in patients with higher BMI is not due 
to underdosing, which is also theoretically unlikely, since IFX is dosed per kilogram and 
the drug remains mainly in the intravascular space,11 the volume of which can increase 
with higher BMI.12 However, our data also show patients with a high BMI fail more often 
on treatment with a combination of MTX, SSZ, and prednisone and on subsequent 
treatment steps during 8 years of DAS ≤2.4–targeted treatment. Only in patients treated 
with initial MTX monotherapy, patients with higher BMI did not fail to achieve a low 
DAS more often than patients with low/normal BMI. This might be related to the fact 
that, in general, failure on initial MTX monotherapy was more common than on initial 
combination therapy, which makes it harder to analyze the role of individual risk factors.
Rather than being the result of a high ESR or swollen joint counts, the higher DAS scores in 
patients with higher BMI appear to depend on pain. Higher pain scores and worse global 
health were also reported in patients with a high BMI in a large Swedish cohort.13 In that 
study, patients with a BMI ≥30 kg/m2 also had a higher ESR and CRP level at follow-up. We 
found no association between a high BMI and higher parameters of inflammation or more 
joint swelling, but there were very few patients with a BMI ≥30 kg/m2.
It is possible that we underestimated joint swelling in patients with a high BMI. The higher 
tender joint counts in patients with a high BMI might still reflect more local inflammation. 
We previously reported that local joint tenderness is a predictor of local joint damage 
after 1 year, independent of swelling.14 This in fact supports the practice of using a 
composite score such as the DAS as treatment target, not merely joint swelling. We found 
no differences in joint damage progression after 8 years of DAS-targeted treatment in 
patients with high or low/normal BMI. This may be due to more treatment adjustments 

































patients with high BMI appear to be protected against joint damage progression.15, 
16 It may also be that the pain experienced by patients with high BMI does not reflect 
inflammation. We did not do routine assessments of fibromyalgia features, but we cannot 
exclude that a fibromyalgia component was present in part of these patients. Self-reported 
pain, especially musculoskeletal pain, is higher in patients with a high BMI, in particular 
with a BMI ≥30 kg/m2, and they are more likely to report pain in multiple locations.5, 6 The 
mechanism of the relationship between obesity and pain is unclear, but it is suggested that 
disturbances in neurotransmitters and hormones might be, at least partially, responsible.7 
This relation between BMI and pain may also influence the association between high BMI 
and functional disability, which was found in this cohort. Pain and body size itself may 
both interfere with the daily activities that are listed in the HAQ.17
In conclusion, in the DAS ≤2.4–targeted BeSt study we found that RA patients with a higher 
BMI fail more often than patients with low/normal BMI to achieve a low DAS on antirheumatic 
treatment. This resulted in more treatment adjustments over time. The higher DAS scores 
were mainly dependent on joint tenderness and self-reported pain and well-being, and were 
associated with less functional ability, but not with more damage progression over time.
In treatment to target strategies, finding a high DAS based on inflammation or on non-
inflammatory pain may have different therapeutic consequences. Additional research, 
including advanced imaging techniques and biomarker studies, may further elucidate 
the relation between BMI and failure to treatment, thus helping us to decide how we can 
best treat our individual patients.
REFERENCE LIST
1. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. 
Body mass index and clinical response to 
infliximab in rheumatoid arthritis. Arthritis 
Rheum 2011;63(2):359-364.
2. Gremese E, Carletto A, Padovan M et al. 
Obesity reduces the response rate to anti 
TNFalpha in rheumatoid arthritis. an approach 
to a personalized medicine. Arthritis Care Res 
(Hoboken ) 2013 Jan;65(1):94-100.
3. Camhi SM, Bray GA, Bouchard C et al. The 
relationship of waist circumference and BMI 
to visceral, subcutaneous, and total body 
fat: sex and race differences. Obesity (Silver 
Spring) 2011;19(2):402-408.
4. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, 
Spiegelman BM. Increased adipose tissue 
expression of tumor necrosis factor-alpha in 
human obesity and insulin resistance. J Clin 
Invest 1995;95(5):2409-2415.
5. Hitt HC, McMillen RC, Thornton-Neaves T, 
Koch K, Cosby AG. Comorbidity of obesity 
and pain in a general population: results from 
the Southern Pain Prevalence Study. J Pain 
2007;8(5):430-436.
6. Pradalier A, Willer JC, Boureau F, Dry J. Pain 
and obesity. Lancet 1980;1(8177):1090-1091.
7. Ursini F, Naty S, Grembiale RD. Fibromyalgia 
and obesity: the hidden link. Rheumatol Int 
2011;31(11):1403-1408.
8. Goekoop-Ruiterman YP, de Vries-
Bouwstra JK, Allaart CF et al. Clinical and 
radiographic outcomes of four different 
treatment strategies in patients with early 
rheumatoid arthritis (the BeSt study): a 
randomized, controlled trial. Arthritis Rheum 
2005;52(11):3381-3390.
9. World Health Organization. BMI classification 
criteria. WHO Website 2011;http://apps.who.
int/bmi/index.jsp?introPage=intro_3.html.
10. Zou G. A modified poisson regression 
approach to prospective studies with binary 

































11. Klotz U, Teml A, Schwab M. Clinical 
pharmacokinetics and use of infliximab. Clin 
Pharmacokinet 2007;46(8):645-660.
12. Blouin RA, Warren GW. Pharmacokinetic 
considerations in obesity. J Pharm Sci 
1999;88(1):1-7.
13. Ajeganova S, Andersson ML, Hafstrom I. 
Association of obesity with worse disease 
severity in rheumatoid arthritis as well as with 
comorbidities: a long-term followup from 
disease onset. Arthritis Care Res (Hoboken) 
2013 Jan;65(1):78-87.
14. Klarenbeek NB, Guler-Yuksel M, van der Heijde 
DM et al. Clinical synovitis in a particular joint 
is associated with progression of erosions and 
joint space narrowing in that same joint, but 
not in patients initially treated with infliximab. 
Ann Rheum Dis 2010;69(12):2107-2113.
15. van der Helm-van Mil AH, van der Kooij SM, 
Allaart CF, Toes RE, Huizinga TW. A high body 
mass index has a protective effect on the 
amount of joint destruction in small joints 
in early rheumatoid arthritis. Ann Rheum Dis 
2008;67(6):769-774.
16. Westhoff G, Rau R, Zink A. Radiographic joint 
damage in early rheumatoid arthritis is highly 
dependent on body mass index. Arthritis 
Rheum 2007;56(11):3575-3582.
17. Backholer K, Wong E, Freak-Poli R, Walls HL, 
Peeters A. Increasing body weight and risk 
of limitations in activities of daily living: a 


































Table S1. Baseline characteristics of patients in groups 1-3 who received delayed treatment with 
methotrexate+infliximab for patients with a BMI<25 and patients with a BMI ≥25.





Female, n (%) 30 (75) 50 (75) 0.97
Age, mean ± SD 46 ± 13 51 ± 12 0.02
BMI,  mean ± SD 22.1 ± 2.2 29.3 ± 3.3 <0.001
Group 1 21 (53) 34 (51) 0.97
Group 2 7 (18) 13 (19)
Group 3 12 (30) 20 (30)
Symptom duration, wks 27 (15-67) 28 (17-56) 0.8
ACPA positive, n (%) 33 (83) 36 (57) 0.004
RF positive, n (%) 36 (90) 44 (66) 0.005
DAS, mean ± SD 4.6 ± 0.8 4.6 ± 0.9 0.96
HAQ, mean ± SD 1.4 ± 0.6 1.4 ± 0.7 0.8
SHS, median (IQR) 2.5 (0.5-10.5) 2.5 (1.0-8.0) 0.8
ESR, median (IQR) 37 (24-62) 33 (21-55) 0.5
CRP, median (IQR) 23 (9-84) 20 (8-59) 0.2
TJC, median (IQR) 14 (9-20) 15 (11-21) 0.3
SJC, median (IQR) 15 (11-20) 13 (10-18) 0.3
VAS global, mean ± SD 50 ± 23 54 ±19 0.8
VAS physician, mean ± SD 58 ± 17 56 ±18 0.5
VAS pain, mean ± SD 56 ± 24 59 ±21 0.5
VAS morning stiffness, mean ± SD 64 ± 22 61 ±21 0.3
Smokers, n (%) 17 (43) 25 (37) 0.6
Alcohol users, n (%) 14 (35) 30 (45) 0.3
ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, DAS: disease activity score, ESR: 
erythrocyte sedimentation rate, TJC: tender joint count, SJC: swollen joint count, VAS global: visual 


































CAN WE PREVENT RAPID RADIOLOGICAL 
PROGRESSION IN PATIENTS 
WITH EARLY ARTHRITIS?
Submitted
L. Heimans, K.V.C. Wevers-de Boer, H.K. Ronday, G. Collée, 
P.B.J. de Sonnaville, B.A.M. Grillet, T.W.J. Huizinga, C.F. Allaart
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ABSTRACT
Aim: Test the performance of a matrix model to predict Rapid Radiological Progression 
(RRP) in a study population of early rheumatoid arthritis (RA) or undifferentiated arthritis 
(UA) patients. 
Methods: A matrix model using baseline CRP, erosion score, autoantibody status and 
initial treatment choice to predict RRP (increase ≥5 points in Sharp-van der Heijde Score 
(SHS) in 1 year) was derived from the BeSt study where patients with active RA (1987-
criteria) were treated with initial monotherapy or combination therapy, aiming at low 
disease activity. In the IMPROVED-study, patients with early RA (2010-criteria) and UA 
were initially treated with methotrexate and prednisone aiming at remission. A receiver 
operating characteristics (ROC) curve was used to assess the discriminative value of the 
model to predict damage progression in the IMPROVED population.
Results: 431/479 patients with RA and 106/122 with UA could be categorized as high, 
intermediate, low or very low risk for RRP. One patient, with a ‘very low’ risk profile, 
showed RRP. Thirty-two other patients (5%) showed radiological progression ≥0.5 point 
SHS, none had a ‘high risk’ profile and 22 a ‘very low risk’ profile. The AUC of the ROC 
curve was 0.56 (95%CI 0.45;0.68).
Conclusion: A matrix model predicting RRP based on risk factors identified in recent 
onset active RA according to the 1987-criteria performed poorly in recent onset RA 
(2010-criteria) and UA. It appears that known risk factors for damage progression lose 
their impact with early remission steered treatment, so that RRP might be considered a 






























Early treatment in patients with rheumatoid arthritis (RA) can prevent joint damage 
progression and thus preserve functional ability.1 Risk factors for rapid progression of 
radiological joint damage can be used to try to predict which patients require more 
progressive initial treatment to prevent damage and in whom the focus can be more 
on symptom reduction alone. To facilitate this, we previously developed a matrix model 
predicting Rapid Radiological Progression (RRP) defined as an increase in Sharp-van der 
Heijde Score (SHS) of ≥5 points in 1 year.2, 3 The model was based on risk factors for RRP 
identified in patients with recent onset active RA (ACR 1987 classification criteria) who 
participated in the BeSt study: baseline ESR or CRP, baseline erosion score, autoantibody 
profile and initial treatment.4 Following up on the BeSt study, in the IMPROVED study we 
included patients with RA (2010 classification criteria) or undifferentiated arthritis (UA) 
clinically suspect for RA, with a more recent symptom onset than the BeSt population. 
Disease activity at baseline was less severe and all started with initial combination 
therapy with methotrexate and a tapered high dose of prednisone, if necessary followed 
up with treatment adjustments until remission was achieved. We investigated how the 
BeSt matrix model performed in the IMPROVED population.
METHODS
The IMPROVED-study is a multi-center clinical trial in which RA and UA patients were 
initially treated with methotrexate (MTX) 25mg/wk and prednisone 60mg/day tapered to 
7.5mg/day in 7 weeks. If patients achieved early remission (Disease Activity Score DAS<1.6 
after 4 months), medication was tapered. Patients not in early remission after 4 months 
were randomized either to MTX 25 mg/wk plus hydroxychloroquine (HCQ) 400mg/day, 
sulphasalazine (SSZ) 2000mg/day and prednisone 7.5mg/day (arm 1) or to MTX 25mg/
wk plus adalimumab (ADA) 40mg/2weeks (arm 2). During follow-up medication was 
increased or switched in case of no remission and tapered or stopped in case of remission.5
Radiographs of hands and feet, blinded for patient identity, were scored for the presence 
of erosions and joint space narrowing in time random order by 2 trained, independent 
readers (LH and KW). Both readers gave similar progression scores (difference <2 points) 
in 83% of all patients. In 54 patients with inter-reader differences ≥2 in progression 
score, a consensus score was reached. 
The matrix model to predict RRP was derived from the BeSt-study. The model visualizes the 
risk for RRP which was predicted based on CRP and number of erosions at baseline, status for 
rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA) and initial treatment 
choice (initial monotherapy or initial combination therapy with prednisone or infliximab).6 
The predicted risk for RRP is indicated by coloured boxes which indicates the ‘risk profile’ of 
a patient; red represents a high risk (≥50% risk of RRP), orange means an intermediate risk 





























To investigate if patients in the IMPROVED-study could be identified as having high, 
intermediate or low risk for RRP, we used the matrix model variant for patients treated 
with initial combination therapy with prednisone and assigned each IMPROVED patient 
according to presence or absence of the various aforementioned risk factors. Then we 
added the number of IMPROVED patients per matrix box, with the number in the coloured 
box indicating the actual number of patients with that combination of risk factors. 
In a separate test, the matrix model was then used to explore if it could help to identify 
patients who showed with any radiological progression (≥0.5 point increase SHS) after 
year 1. Positive and negative predicted values were calculated and the area under 
the curve (AUC) of the receiver operating characteristics (ROC) curve to explore the 
discriminative value of the matrix in predicting radiological progression ≥0.5.
For all analyses SPSS version 20.0 (SPSS Inc., Chicago, IL) was used.
RESULTS
In the IMPROVED-study 610 patients were included, 479 patients with early RA 
(according to the 2010 ACR classification criteria 7) and 122 patients with undifferentiated 
arthritis (UA). Nine patients could not be classified because of insufficient data. For 431 
RA patients and 106 UA patients sufficient baseline characteristics were available to 
categorize them in the matrix model (figure 1). 
Based on the matrix model, no patients were estimated to have high risk for RRP. Thirteen 
patients with RA and no patients with UA were identified as having an intermediate risk 
of RRP. None of those showed RRP, 2 showed progression ≥0.5 SHS. Fifty-eight patients 
with RA and no patients with UA were predicted to have a low risk of RRP, and none of 
those showed RRP, but 5 showed progression ≥0.5 SHS. The remaining 360 patients with 
RA and all 106 patients with UA were identified as having very low risk for RRP. One of 
those patients with RA actually did show RRP and in total 30 RA and 2 UA patients showed 
progression≥0.5 SHS (1 patient who could not be classified also showed progression). The 
median (IQR) progression in SHS was 0 (0-0) in both patients with RA and patients with UA. 
In RA patients the PPV of the matrix model for progression≥0.5 SHS, based on an 
intermediate or higher risk for progression, was 15.4%. The NPV of the matrix model for 
no progression was 98.8%. In UA patients the PPV and NPV could not be calculated since 
all 106 patients had the same risk. The AUC of the ROC curve for progression≥0.5 SHS 
was 0.56 (95%CI 0.45;0.68, p=0.27).
DISCUSSION
A matrix model to predict rapid radiological progression which we previously developed 
based on results of RA patients in the BeSt study, was not useful to predict damage progression 
in patients with UA and early RA who participated in the IMPROVED-study. This is likely due to 





























Baseline disease activity and symptom duration appeared to be lower in the IMPROVED-
study than in the BeSt study. In the BeSt population, only RA patients who fulfilled 
the 1987 classification criteria and who had high disease activity were included. 
Following recommendations to identify and treat RA patients as early as possible, in 
the IMPROVED-study, RA patients were included and treated when they fulfilled the 
2010 classification criteria. Also, patients with UA clinically suspected by the treating 
rheumatologist to have early RA were included.  In addition, all IMPROVED patients 
received initial combination therapy with methotrexate and prednisone, whereas half 
of the BeSt patients had received initial MTX monotherapy. As a consequence, not only 
were baseline disease activity lower and symptom duration shorter in the IMPROVED-




-/- -/+ or +/- +/+
CRP ≥ 35 0 # 0 * 0 * Erosions ≥4
2 4 # 13 * Erosions 1-3
11 19 # 35 # Erosions 0
CRP 10-34.99 0 0 # 0 # Erosions ≥4
2 4 15 Erosions 1-3
23 28 81 (1 patient with RRP) Erosions 0
CRP < 10 0 0 0 # Erosions ≥4
4 5 19 Erosions 1-3




-/- -/+ or +/- +/+
CRP ≥ 35 0 # 0 * 0 * Erosions ≥4
5 0 # 0 * Erosions 1-3
12 0 # 0 # Erosions 0
CRP 10-34.99 0 0 # 0 # Erosions ≥4
3 0 0 Erosions 1-3
32 0 0 Erosions 0
CRP < 10 0 0 0 # Erosions ≥4
3 0 1 Erosions 1-3
46 2 2 Erosions 0
Figure 1. The number of patients with a combination of baseline risk factors in patients with RA and 
patients with UA. The numbers in the boxes represent the actual number of patients with that combination 
of risk factors for patients with A) Rheumatoid Arthritis (RA) and B) Undifferentiated arthritis (UA). Orange 
boxes (*) represent an intermediate risk of Rapid Radiological Progression (RRP) (20-50%), yellow boxes 
(#)  a low risk (10-20%) and green boxes a very low risk (10%). In total, 47 of 479 RA-patients and 16 of 122 





























IMPROVED patients than in the BeSt patients: they had lower CRP values, were less often 
erosive at baseline and less often ACPA and/or RF positive, and none received initial 
MTX monotherapy. Thus rapid radiologic damage progression was less likely in most 
IMPROVED patients, and particularly unlikely in the UA patients. 
Based on the matrix model, thirteen patients had an intermediate risk of RRP. Of those, 
2 showed progression ≥0.5 SHS in year 1, the others showed no progression. This is 
possibly related to targeted treatment aiming at remission (DAS<1.6) in the IMPROVED-
study, which resulted in suppression of disease activity. One patient predicted to have 
low risk actually showed RRP, suggesting that other risk factors for damage progression 
may be present that are not included in the matrix model. 
It appears that by treating arthritis patients earlier and with remission targeted therapy, 
RRP and indeed also minimal radiologic damage progression may be prevented. 
Prediction models based on data from previous trials and patients populations and 
times of less strict treatment strategies to predict joint damage may thus no longer be 
relevant for current and future patients. As it is still possible that residual disease activity 
will affect cartilage and bone in and around arthritic joints, newer techniques to monitor 
these effects may need to be employed or developed, and next, new risk factors for joint 
damage may be identified. 
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FOUR-MONTH METACARPAL BONE MINERAL 
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JOINT DAMAGE PROGRESSION AFTER 1 YEAR 
IN PATIENTS WITH EARLY RHEUMATOID 
ARTHRITIS – EXPLORATORY ANALYSES 
FROM THE IMPROVED-STUDY
Accepted for publication in Annals of the Rheumatic Diseases
K.V.C. Wevers-de Boer, L. Heimans, K. Visser, J. Kälvesten, 
 J.A.P.M. Ewals, E.T.H. Molenaar, J. Groenendael, A. Peeters, 
 I Speyer, G. Collee, T.W.J. Huizinga, C.F. Allaart
ABSTRACT 
Aim: To assess whether in early (rheumatoid) arthritis (RA) patients, metacarpal bone 
mineral density (BMD) loss after 4 months predicts radiological progression after 1 year 
of anti-rheumatic treatment.
Methods: Metacarpal BMD was measured 4 monthly during the first year by digital X-ray 
radiogrammetry (DXR-BMD) in patients participating in the IMPROVED study, a clinical 
trial in 610 patients with recent onset RA (2010 criteria) or undifferentiated arthritis 
(UA), treated according to a remission (DAS<1.6) steered strategy. With Sharp- van der 
Heijde progression ≥0.5 points after 1 year (yes/no) as dependent variable, univariate 
and multivariate logistic regression analyses were performed.
Results: Of 428 patients with DXR-BMD results and progression scores available, 28 (7%) had 
radiological progression after 1 year. Independent predictors for radiological progression 
were presence of baseline erosions (OR (95%CI) 6.5 (1.7-25)) and early DXR-BMD loss (OR 
(95%CI) 1.5 (1.1-2.0)). In 366 (86%) patients without baseline erosions early DXR-BMD loss 
was the only independent predictor for progression (OR (95%CI) 2.0 (1.4-2.9)).
Conclusion: In early (rheumatoid) arthritis patients, metacarpal BMD loss after 4 months 
of treatment is an independent predictor for radiological progression after 1 year. In 




































Early treatment of patients with rheumatoid arthritis (RA) improves disease outcomes 
including radiological joint damage.1-3 Identification of patients who will have a more 
severe disease course may steer early treatment strategies. Since predicting disease 
outcome is currently not possible in a reliable way for all patients, there is a need for 
new predictors to improve existing prediction models.4-7 
Peri-articular osteopenia is one of the earliest radiological manifestations in RA and 
may already be found in the phase of undifferentiated arthritis (UA).8, 9 Metacarpal bone 
mineral density (BMD) loss may therefore be a potentially new predictor of disease 
outcome in patients with early (rheumatoid) arthritis. Previous research showed that 
metacarpal BMD loss is associated with disease activity 10 and metacarpal BMD loss in the 
first year after diagnosis is predictive for radiological damage up to five years in patients 
with early RA.11-13 For clinical practice however, any predictive value of metacarpal BMD 
loss would be greater if it can be measured earlier in the disease course. 
Therefore we investigated whether metacarpal BMD loss after four months of treatment, as 
measured by Digital X-ray Radiogrammetry (DXR-BMD), may be a predictor of radiological 
joint damage progression after one year in patients with undifferentiated or early rheumatoid 
arthritis treated according to a tight control, remission steered treatment strategy. 
PATIENTS AND METHODS
Patients and study design
Data from the IMPROVED study were used, a multicenter, randomized clinical trial in 
610 patients, including 479 (80%) patients with recent onset RA (according to the 2010 
classification criteria for RA 14 with a symptom duration <2 years), 122 patients with UA (having 
at least 1 joint clinically assessed as ‘arthritis’ and 1 other painful joint, clinically suspected  of 
having early RA, regardless of symptom duration) and 9 patients that could not be classified 
because of missing data. Patients were treated according to a tight control strategy, aimed 
at achieving remission, defined as a DAS<1.6 (DAS-remission).15 All patients started with 4 
months of methotrexate (MTX) 25 mg/week and prednisone 60 mg/day tapered to a stable 
dose of 7.5 mg/day in 7 weeks. Patients in DAS-remission after 4 months started tapering 
medication, if possible to drug free (early DAS remission group). Patients not in early DAS-
remission were randomized either to MTX 25 mg/wk plus hydroxychloroquine (HCQ) 400mg/
day, sulphasalazine (SSZ) 2000mg/day and prednisone 7.5mg/day (arm 1) or to MTX 25mg/wk 
plus adalimumab (ADA) 40mg/2weeks (arm 2). Some patient who were not in DAS-remission 
after 4 months, were not randomized and treated outside of protocol (Outside of Protocol 
(OP) group). Full details about the IMPROVED study protocol were previously published.16, 17
In the current analysis we included all patients participating in the IMPROVED study of 
whom radiologic progression data after 1 year and at least 1 DXR-BMD result during the 


































Demographic and clinical variables
At baseline the following variables were collected: age, gender, symptom duration, body 
mass index, current smoking status and alcohol use, calcium intake, postmenopausal 
status, previous fractures, family history on osteoporosis, anti-citrullinated protein 
antibody (ACPA) and Rheumatoid Factor (RF) status. At baseline and every 4 months, the 
following clinical and laboratory variables were collected: Disease Activity Score (DAS), 
including Ritchie Articular Index (RAI), swollen joint count, erythrocyte sedimentation rate 
(ESR, mm/hr) and visual analogue scale (VAS) for global health, and C-reactive protein (CRP). 
During the first year, X-rays of hand and feet were made 4 monthly by digital radiography 
in all patients. Radiological progression, scored using the Sharp/van der Heijde scoring 
method, was assessed by two independent readers blinded for patient identity and time 
order of the radiographs.18 Progression was defined as an increase in Sharp-van der Heijde 
Score (SHS) of ≥0.5 points. Details on inter-reader reliability were previously published.17
Metacarpal BMD measurements
Suitable routine digital X-rays of both hands were used to measure metacarpal BMD using 
Digital X-ray Radiogrammetry (DXR-BMD) measured by DXR-online (Sectra, Linköping, 
Sweden), a computerised method which automatically recognises three regions of 
interest on the second, third and fourth metacarpal bone. At each region, DXR-BMD is 
estimated from multiple measurements of cortical thickness, bone width and porosity.19 
The mean value of both hands was used in all analyses to avoid bias induced by hand 
dominance. ‘DXR-BMD loss’ was defined as a loss in DXR-BMD of ≥1.5 mg/cm2/4months.10
Statistical analysis
Almost half of the available X-rays were found unsuitable for DXR-measurements. This 
resulted in missing DXR-BMD values in 141/428 patients (33%) at baseline, 73/428 (17%) 
after 4 months, 148/428 (35%) after 8 months and 140/428 (33%) after 1 year. To avoid 
possible bias induced by missing data and to increase power, multiple imputation was 
performed. Ten datasets were created in which missing DXR-values were imputed based 
on a linear regression model fitting available patient and disease characteristics and 
DXR-values.20 Estimates obtained from regression analyses were automatically pooled 
by SPSS, other multiple estimates were averaged.  
Median (IQR) DXR-BMD changes were shown because of a skewed distribution. Mann 
Whitney U test was used for comparisons of DXR-BMD changes between patients with 
and without radiological progression. To identify independent predictors of radiological 
progression we performed univariate followed by multivariate regression analyses. From 
previous literature, the following potential predictors for (rapid) radiological progression 
were identified and entered in a univariate logistic regression model with radiologic 
progression (yes/no) as dependent variable: presence of ACPA and/or RF, baseline swollen 


































treatment.4, 6, 7 In addition, we selected age, gender, fulfilling the 2010 ACR/EULAR criteria 
for RA and achieving DAS-remission after 4 months. Next to baseline erosion score we also 
entered presence of erosions, defined as ≥1 erosions, as covariate. Because only 28 (7%) 
patients included in this analysis had radiological progression, multivariate regression 
in the total study population was powered for about three variables.21, 22 Therefore, in 
addition to DXR-BMD loss from baseline to 4 months, those 2 univariate significant 
predictors (using a significance level of 0.10) with the highest effect size were selected 
for multiple regression. As radiologic progression was present in <10% of the patients 
and therefore can be classified as ‘rare’, we argued that Odds Ratios (OR) obtained from all 
logistic regression analyses can be interpreted as relative risks (RR).23




We included 428 patients in the current analysis. Baseline characteristics of these patients 
did not differ significantly from those participating in the IMPROVED study where 
no SHS or DXR data were available (data not shown). Twenty eight (7%) patients had 
radiological progression after 1 year and 400 (93%) had not. Of those with radiological 
progression, median (IQR) progression score was 0.5 (0.5-1.4). One patient had rapid 
radiological progression (progression score ≥5 points) 24 after 1 year (18 points). 
Compared to patients without progression, patients with progression were older, more 
often postmenopausal, ACPA positive, and more often fulfilled the 2010 criteria for RA. 
Furthermore, they had more often ≥1 erosions at baseline and a higher median total 
baseline SHS and, only at 8 months, a slightly higher DAS (table 1).
DXR-BMD change
Table 2 shows absolute DXR-BMD values and DXR-BMD changes during the first year. 
Compared to patients without radiological progression after 1 year, patients with radiological 
progression had lower absolute DXR-BMD values at baseline and after 4, 8 and 12 months 
follow up. From baseline to 4 months, median DXR-BMD changes were significantly larger 
in patients with radiological progression (median (IQR) -9.6 (-15.2;-2.7) than in patients 
without (-2.0 (-7.2;2.5), p=0.007). Twenty four (86%) patients with radiological progression 
had DXR-BMD loss within the first 4 months, compared to 212 (53%) patients without 
radiological progression (p=0.01). The one patient with rapid radiological progression (18 
points after 1 year) had DXR-BMD loss within the first 4 months of 27.4 mg/cm2.
Treatment steps
Seventeen (61%) patients with radiological progression after 1 year had been in early 


































Table 1. Clinical characteristics at baseline and during one year follow up of the total study group and 





Baseline n=428 n=28 n=400
Age, years, mean ± SD 52 ± 13 58 ± 11 52 ± 13 0.01
Female, n (%) 294 (69) 22 (79) 272 (68) 0.2
BMI, kg/m2, mean ± SD 26 ± 4 25 ± 4 26 ± 4 0.6
Current smoking, n (%) 127 (30) 11 (39) 116 (29) 0.3
Current alcohol use, n (%) 250 (58) 17 (61) 233 (58) 0.9
Postmenopausal status, n (%) 156 (53) 17 (89) 139 (58) 0.01
Previous fractures,  n (%) 142 (33) 8 (29) 134 (34) 0.7
Familial osteoporosis, n (%) 72 (17) 6 (21) 66 (17) 0.5
Calcium intake, mg/day,  median (IQR) 800 (600-1050) 875 (725-1069) 778 (600-1030) 0.2
25(OH) Vitamine D, nmol/l,  median (IQR) 55 (38-75) 46 (25-75) 55 (39-75) 0.3
DAS (mean ± SD) 3.2 ± 0.9 3.3 ± 0.9 3.2 ±0.9 0.8
RA(2010), n (%) 344 (80) 26 (93) 318 (80) 0.04
Symptom duration, wks, median (IQR) 18 (9-33) 20 (9-47) 18 (9-32) 0.5
ACPA positive, n (%) 247 (58) 23 (82) 224 (56) 0.008
RF positive, n (%) 241 (56) 18 (64) 223 (56) 0.2
ACPA and RF positive, n (%) 205 (48) 19 (68) 186 (47) 0.04
SHS total score 0 (0-0) 0.5 (0-4.5) 0 (0-0) <0.001
Presence of erosions, n (%) 62 (14) 11 (39) 51 (13) <0.001
4 months
DAS, mean ± SD 1.5 ± 0.9 1.5 ±0.8 1.5 ± 0.9 0.9
Remission, n (%) 275 (64) 17 (61) 258 (65) 0.7
Early remission Group, n (%) 281 (66) 17 (61) 264 (66) 0.6
Arm 1 MTX+SSZ+HCQ+pred, n (%) 60 (14) 4 (14) 56 (14) 0.97
Arm 2 MTX+adalimumab, n (%) 57 (13) 5 (18) 52 (13) 0.5
Outside of Protocol Group, n (%) 30 (7) 2 (7) 28 (7) 0.98
8 months
DAS, mean ± SD 1.5 ± 0.8 1.8 ± 1.0 1.5 ± 0.8 0.05
Remission, n (%) 246 (57) 12 (43) 234 (61) 0.1
1 year
Use of Bisphosphonate, n (%) 129 (30) 9 (32) 120 (30) 0.8
Use of Calcium and/or vitamine D, n (%) 204 (48) 16 (57) 180 (45) 0.2
DAS, mean ± SD 1.6 ± 0.9 1.6 ± 0.9 1.6 ± 0.9 0.7
Remission,  n (%) 235 (55) 16 (57) 219 (55) 0.8
SHS progression, median (IQR) 0 (0-0) 0.5 (0.5-1.4) 0 (0-0) <0.001
BMI: Body Mass Index (kg/m2), DAS: Disease Activity Score, RA (2010): rheumatoid arthritis according 
to the ACR/EULAR 2010 classification criteria, ACPA: anti-citrullinated protein antibody, RF: rheumatoid 
factor, SHS: Sharp- van der Heijde Score, presence of erosions: defined as ≥1 erosions, remission: 
defined as DAS<1.6, early remission group: patients who were in remission after 4 months and started 
tapering medication, arm 1: patients not in early remission who were randomized to arm 1, arm 2: 
patients not in early remission who were randomized to arm2, MTX: methotrexate, SSZ: sulfasalazine, 
HCQ: hydroxychloroquine, pred: prednisone, outside of protocol group: patients not in early remission 


































zero, 9 (32%) had not achieved early remission and were randomized, and 2 were treated 
outside the protocol. Of those 17 in early DAS-remission, 5 patients relapsed after tapering 
prednisone and restarted it, whereas 12 remained in remission and started tapering MTX 
to zero. Six patients relapsed after tapering MTX and restarted it and 6 did not relapse and 
were in drug free remission after 1 year. The median (IQR) early DXR-BMD change of all 17 
patients was -10.9 (-14.5;-2.5) mg/cm2 (corresponding to -2.7 (-3.6;-0.6 mg/cm2/month)), 
compared to -1.8 (-7.3;2.4) mg/cm2 (corresponding to -0.5 (-1.8;0.6 mg/cm2/month) in 258 
patients who achieved early DAS-remission and had no radiological progression after 1 
year (p=0.02). DXR-BMD loss after 4 months was present in 14/17 (82%) patients in early 
DAS-remission who had radiological progression after 1 year, compared to 134 (52%) 
patients in early DAS-remission without radiological progression after 1 year (p=0.053). 
Predictors of radiological progression
Univariate predictive variables for radiologic progression after 1 year were: fulfilling the 
2010 criteria for RA (p=0.07), presence of baseline erosions (yes/no) (p<0.001), presence 
of both ACPA and RF (p=0.03), early DXR-BMD loss after 4 months (p=0.008), baseline 
total SHS score (p=0.07), age (p=0.01), baseline ESR (p=0.06) and TJC (p=0.05). Female 
gender, presence of either ACPA or RF, symptom duration, baseline erosion score and 
CRP level and treatment group were not predictive. Achieving DAS-remission after 4 
months was also not predictive for radiological progression after 1 year (table 3a). 
Together with early DXR-BMD loss, presence of baseline erosions and fulfilling the 2010 
criteria for RA were selected for inclusion in the multivariate regression analysis. Both 
Table 2. DXR-BMD measurements and changes in DXR-BMD during the first study year of the total study 




p-valueYes: n=28 No: n=400
DXR-BMD g/cm2, 
median (IQR)
0 0.593 (0.527-0.640) 0.558 (0.501-0.601) 0.597 (0.529-0.642) 0.03
4 0.590 (0.526-0.637) 0.546 (0.486-0.587) 0.593 (0.529-0.640) 0.008
8 0.590 (0.525-0.639) 0.544 (0.482-0.589) 0.593 (0.528-0.642) 0.009
12 0.585 (0.522-0.636) 0.541 (0.472-0.586) 0.588 (0.524-0.638) 0.008
Change in DXR-BMD 
mg/cm2, median (IQR)
0 - 4 -2.4 (-7.6 ; 2.2) -9.6 (-15.2 ; -2.7) -2.0 (-7.2 ; 2.5) 0.007
4 - 8 -1.1 (-6.0 ; 3.2) -2.2 (-8.1 ; 3.9) -1.1 (-5.8 ; 3.1) 0.5
8 -12 -3.1 (-9.0 ; 1.3) -4.5 (-14.0 ; 0.05) -3.1 (-8.7 ; 1.5) 0.3
0 - 12 -5.7 (-15.4 ; 0.6) -15.8 (-27.4 ; -2.3) -5.4 (-14.2 ; 0.9) 0.007
Change in DXR-BMD, 
% from baseline
0 - 4 -0.4 (-1.3 ; 0.4) -1.7 (-2.9 ; -0.5) -0.3 (-1.2 ; 0.4) 0.007
4 - 8 -0.2 (-1.1 ; 0.5) -0.4 (-1.5 ; 0.7) -0.2 (-1.0 ; 0.5) 0.5
8 -12 -0.5 (-1.5 ; 0.2) -0.8 (-2.7 ; 0.008) -0.5 (-1.5 ; 0.2) 0.2
0 - 12 -1.0 (-2.7 ; 0.1) -2.8 (-4.9 ; -0.4) -0.9 (-2.4 ; 0.2) 0.006
SHS progression: progression after 1 year ≥0.5 points, DXR-BMD: metacarpal bone mineral density 


































Table 3a. Univariate logistic regression analysis with radiological progression as binomial dependent variable. 
Univariate Logistic regression
Crude OR 95%CI R2
RA according to 2010 criteria 6.5 0.9-48.8 0.04
Presence of baseline erosions 4.4 2.0-10.0 0.07
ACPA/RF
Both negative ref 0.04
One positive 2.6 0.6-11.3
Both positive 3.9 1.1-13.2
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.8 0.13
Female gender 1.7 0.7-4.4 0.01
Erosions score at baseline 1.1 0.99-1.1 0.01
Baseline total SHS 1.1 0.996-1.0 0.02
Age, years 1.0 1.0-1.1 0.04
Baseline ESR 1.0 0.999-1.0 0.02
Baseline CRP 1.0 0.997-1.0 0.01
Baseline TJC 0.97 0.9-1.1 0.003
Treatment Group
Early remission group ref 0.003
Arm 1 MTX+SSZ+HCQ+pred 1.1 0.4-3.4
Arm 2 MTX+adalimumab 1.5 0.5-4.2
Outside of Protocol group 1.1 0.2-5.1
Early DAS-remission 0.8 0.4-1.9 0.001
RA: rheumatoid arthritis (according to the 2010 ACR/EULAR classification criteria), presence of baseline 
erosions: ≥1 erosions, ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, DXR-BMD: 
metacarpal bone mineral density measured by digital X-ray radiogrammetry, erosion score: Sharp-van 
der Heijde erosion score, tSHS: total Sharp-van der Heijde Score, ESR: erythrocyte sedimentation rate 
in mm/hr, CRP: C-reactive protein, TJC: tender joint count, early remission group: patients who were in 
remission after 4 months and started tapering medication, arm 1: patients not in early remission who 
were randomized to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose 
prednisone, arm 2: patients not in early remission who were randomized to MTX plus adalimumab, early 
DAS-remission: remission (DAS<1.6) after 4 months.
presence of baseline erosions and early DXR-BMD loss were predictive for radiological 
progression after one year independent of each other and independent of fulfilling the 
2010 criteria for RA (table 3b). 
In an additional multivariate model including DXR-BMD loss, presence of baseline 
erosions and presence of both ACPA and RF, presence of both ACPA and RF was not 
an independent predictor for radiological progression, whereas DXR-BMD loss and 
presence of baseline erosions both were (data not shown).  
After leaving out the one patient with rapid radiological progression (18 points after 1 


































Patients without baseline erosions 
In 366 (86%) patients no baseline erosions were present, of which 17 patients (5%) showed 
radiological progression after 1 year (61% of all 28 patients with radiological progression) 
and 349 (95%) did not. Median DXR-BMD change from baseline to 4 months was -11.8 
(-16.7;-4.7) in patients with progression and -2.0 (-7.0;2.4) mg/cm2 in patients without 
(corresponding to -2.9 (-4.2;-1.2) and -0.5 (-1.7;0.6) mg/cm2/months, respectively). Univariate 
significant predictors for progression after 1 year in patients without baseline erosions were 
age (p=0.004), baseline total SHS (in these patients reflecting baseline joint space narrowing) 
(p=0.009), baseline ESR level (p=0.096) and early DXR-BMD loss (p=0.02) (table 4a). 
Early DXR-BMD loss and total baseline SHS were selected for entering in the multivariate 
regression analysis. Early DXR-BMD loss was predictive for radiological progression after 
1 year independent of baseline total SHS in patients without baseline erosions (table 4b).
DISCUSSION
In patients with early rheumatoid or undifferentiated arthritis, metacarpal BMD loss 
measured by DXR after four months of treatment with MTX and a tapered high dose 
of prednisone is predictive for future joint damage after 1 year of remission steered 
treatment. In patients without baseline erosions (86%) metacarpal BMD loss was the 
main predictor for future joint damage. 
These data suggest that DXR measurements over a period of 4 months from baseline can 
help to decide which patients with early arthritis should start anti-rheumatic treatment 
to prevent joint damage or damage progression, one of the main goals in treatment 
of RA.25 Early treatment and suppression of disease activity has been shown to be 
associated with better suppression of radiological damage progression.1-3 To facilitate 
this, in 2010 new classification criteria for RA have been formulated.14 In the IMPROVED 
trial we included patients with RA (according to the 2010 classification criteria) but also 
patients with UA, who were judged to represent RA in an early phase of the disease by 
the treating rheumatologist. Starting treatment this early in disease course carries the 
risk of overtreatment of patients who are misdiagnosed as RA, but a treatment delay 
means risking irreversible joint damage progression. 
Table 3b. Multivariate logistic regression with radiologic progression as binomial dependent variable. 
Multivariate logistic regression Adjusted OR 95%CI
Presence of baseline erosions 3.9 1.6-9.5
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.7
RA according to 2010 criteria 4.9 0.6-37
DXR-BMD, metacarpal bone mineral density measured by digital X-ray radiogrammetry; Presence of 
baseline erosions, defined as ≥1 erosions, RA, rheumatoid arthritis according to the 2010 ACR/EULAR 


































Table 4a. Univariate logistic regression analysis with radiological progression as binomial dependent 
variable in patients without baseline erosions.
Univariate Logistic regression
Crude OR 95%CI R2
RA according to 2010 criteria 4.1 0.5-31.3 0.02
ACPA/RF
Both negative ref 0.03
One positive 3.0 0.5-17
Both positive 3.2 0.7-15
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.9 0.13
Female gender 2.1 0.6-7.5 0.01
Baseline total SHS 1.3 1.1-1.6 0.06
Age, years 1.1 1.0-1.1 0.08
Baseline ESR, mm/hr 1.0 0.997-1.0 0.02
Baseline CRP 1.0 0.99-1.0 0.002
Baseline TJC 0.97 0.9-1.1 0.004
Treatment Group
Early remission group ref 0.01
Arm 1 MTX+SSZ+HCQ+pred 1.6 0.4-5.9
Arm 2 MTX+adalimumab 1.7 0.5-6.6
Outside of Protocol group 1.8 0.4-8.8
Early DAS-remission 0.6 0.2-1.7 0.007
RA: rheumatoid arthritis (according to 2010 ACR/EULAR classification criteria), ACPA: anti-citrullinated 
protein antibody, RF: rheumatoid factor, DXR-BMD: metacarpal bone mineral density measured by 
digital X-ray radiogrammetry, SHS: Sharp-van der Heijde Score, ESR: erythrocyte sedimentation rate 
in mm/hr, CRP: C-reactive protein, TJC: tender joint count, early remission group: patients who were in 
remission after 4 months and started tapering medication, arm 1: patients not in early remission who 
were randomized to methotrexate (MTX), sulfasalazine (SSZ), hydroxychloroquine (HCQ) and low dose 
prednisone, arm 2: patients not in early remission who were randomized to MTX plus adalimumab, early 
DAS-remission: remission (DAS<1.6) after 4 months.
Table 4b. Multivariate logistic regression with radiologic progression as binomial dependent variable in 
patients without baseline erosions
Multivariate logistic regression Adjusted OR 95%CI
Early DXR-BMD loss, mg/cm2/month 1.4 1.1-1.8
Baseline total SHS 1.3 1.0-1.6
DXR-BMD: metacarpal bone mineral density measured by digital X-ray radiogrammetry, SHS: Sharp-van 
der Heijde Score, OR: odds ratio, CI: confidence interval.
To individualize treatment, predictive factors for damage progression have been 
identified and prediction models build.4, 6, 7 But in particular in patients without baseline 
damage, predicting who will develop joint damage may be difficult. We looked at 


































progression in patients with early and established RA, and metacarpal BMD loss after 1 
year has been shown to have predictive value additional to known predictors.11, 12 Our 
paper is the first to report metacarpal BMD changes already after 4 months, and we 
found that changes indeed occur. 
Ideally, an outcome predictor can be identified already at baseline. In this early arthritis 
population, presence of baseline erosions was the only independent baseline predictor for 
radiological progression after 1 year besides metacarpal BMD loss after 4 months. Another 
obvious outcome after 4 months, remission yes or no, was not predictive of progression after 
1 year. Some patients who had radiological joint damage after 1 year even were in remission 
throughout the whole year and tapered all medication according to the study protocol. Our 
results indicate that after 4 months, a strong predictor of progression may help to decide if 
adjustments of the chosen treatment strategy should be made in patients with early arthritis. 
One limitation of this study may be the fact that, due to the inclusion of patients 
with early and relatively mild disease, progressively treated with the aim of achieving 
remission, only very few patients had radiological damage progression. Our results 
however reached statistical significance, although we acknowledge that the damage 
scores are hardly of clinical relevance this early in the disease phase. But as RA treatment 
more and more aims at achieving total  disease and damage control in an early phase of 
the disease, we think that our findings may be relevant for daily practice. 
Another limitation was that we found many of the ‘routinely’ acquired radiographs 
unsuitable for DXR. To handle missing metacarpal BMD data we performed multiple 
imputation20 to account for potential bias caused by data ‘missing at random’, meaning 
that missingness depends on other observed patient characteristics than on the fact 
that metacarpal BMD measurements were possible or not. 
A third possible limitation may be that, as DXR-measurements in this study were done in 
retrospect on X-rays made in 12 different hospitals using imaging protocols not adjusted 
to DXR, precision of the method may be lower than previously published. DXR-BMD has 
been shown to have a very high short and long term precision in both in vitro cadaver 
studies (coefficients of variation (CV) of 0.22 to 1%) and in one cohort study and one 
clinical trial (CV of 0.25 to 0.46%).26-29 However, supported by the consistency of our 
results, precision in this study may still be considered as high. 
If metacarpal BMD will be applied in clinical practice using the DXR online method, 
neither low precision or missing values may be problematic, as X-rays will then be 
made according to a predefined protocol (Sectra, Sweden). Precision may reach values 
described above, and in case of mal positioning, direct feedback will be given, which 
makes it more suitable for use in clinical practice. 
In conclusion, we showed that loss of metacarpal bone mineral density measured by 
DXR after the first 4 months of treatment is an independent predictor of future bone 


































metacarpal BMD measurements could help to guide treatment decisions in individual 
patients or may be added to improve the predictive value of existing prediction models 
for disease outcome in RA.   
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ABSTRACT
Objectives: To assess depressive symptoms severity and dispositional optimism in 
patients with recent onset arthritis both before and after 4 months treatment. 
Methods: Two hundred twenty-two patients with recent onset RA and undifferentiated 
arthritis in the IMPROVED study filled out the Beck Depression Inventory (BDI-II) to 
assess depressive symptoms severity and the Life Orientation Test Revised (LOT-R) to 
measure optimism before and after 4  months of treatment. All patients were treated 
with methotrexate 25 mg/week and prednisone 60 mg/day (tapered to 7.5 mg/day in 
7  weeks). Linear regression analysis was used to assess the association between the 
disease activity score (DAS) and its components (tender joint count, general well-being 
measured with a visual analogue scale (VAS), swollen joint count, and erythrocyte 
sedimentation rate) with the BDI-II an LOT-R scores. 
Results: In general, depressive symptoms were mild. The DAS was an independent 
predictor of depressive symptoms scores both at baseline and after 4 months follow-
up, in particular tender joint count and VAS global health. Disease activity was not 
associated with the level of optimism. Nevertheless, patients who achieved clinical 
remission improved significantly more in both depression score and optimism score 
than patients who did not. 
Conclusion: Patients with early arthritis report improvement in depressive symptoms 
and optimism with improvement in disease activity and achieving clinical remission. 
Depression scores are associated with pain and unwell being but not with swollen joint 


















Depressive symptoms are more common in patients with rheumatoid arthritis (RA) 
compared to healthy individuals.1-4 The etiology of the association between RA and 
depressive symptoms is poorly understood.2 Pain and disability may negatively affect 
mood (and vice versa), but inflammatory processes itself may also play a role in inducing 
depressive symptoms.5, 6 Suppression of disease activity might improve depressive 
symptoms.3 However, anti-rheumatic treatment with oral corticosteroids, in particular 
in higher dosages, may also induce psychiatric disorders including depression, anxiety, 
delirium and (hypo)mania.7-10 To investigate the relationship between disease activity and 
mood, we assessed levels of depressive symptoms and dispositional optimism11 in patients 
with recent onset arthritis who were treated with methotrexate and a high tapered dose 
of prednisone with the aim to induce clinical remission in the IMPROVED-study.
PATIENTS AND METHODS
The IMPROVED-study is a multicenter investigator driven clinical trial among patients 
with recent onset arthritis, designed and conducted by rheumatologists in 12 
cooperating hospitals in the western part of the Netherlands. The Medical Ethics 
Committee of each participating center approved the study protocol, and all patients 
gave written informed consent. Patients with undifferentiated arthritis (UA) and recent 
onset RA were included. Recent onset RA was defined according to the ACR/EULAR 
2010 classification criteria12 with a duration of symptoms ≤2 years. UA patients had at 
least one joint clinically assessed as ‘arthritis’ and at least one other tender joint, in the 
opinion of the rheumatologist clinically suspected to represent early RA but not fulfilling 
the 2010 ACR/EULAR criteria. All patients that were recruited between March 2007 and 
September 2010 were at least 18  years old, disease modifying anti-rheumatic drug 
naïve, and had a disease activity score (DAS) ≥1.6. Exclusion criteria included pregnancy, 
malignancy within the last 5  years, bone marrow hypoplasia, elevated liver enzyme 
levels (AST and/or ALT >3 times normal value), serum creatinine level >150 umol/l or 
estimated creatinine clearance of <75 %, uncontrolled diabetes mellitus, uncontrolled 
hypertension, heart failure (NYHA class III/IV), alcohol or drug abuse, serious infections 
in the previous 3 months or chronic infectious disease, opportunistic infections within 
previous 2 months, active or latent hepatitis B, HIV infection or AIDS, lymphoproliferative 
diseases, and multiple sclerosis.
All patients received initial treatment for the first 4 months with methotrexate 25 mg/
week and prednisone 60 mg/day, tapered to 7.5 mg/day in 7 weeks.
At baseline and after 4 months, a trained assessor performed a full joint evaluation and 
calculated a DAS. The patients were asked to fill out a visual analogue scale (VAS) for 
global well-being, the Health Assessment Questionnaire (HAQ),13 and questionnaires on 

















obtained for additional questionnaires, the Beck Depression Inventory II (BDI-II) and the 
Life Orientation Test Revised (LOT-R).14, 15
The BDI-II is a 21-item questionnaire to assess depressive symptoms severity according 
to the diagnostic criteria as stated by the DSM-IV. It is scored as the sum of scores (0–3). 
Missing values, e.g., unanswered questions (12 questions in the baseline questionnaire, 
15 questions in the 4-month questionnaire) were replaced with zero. This is the neutral 
answer in all questions; in case of the question about ‘sadness’, 0 means ‘I don’t feel sad’. 
Patients with a total score of 0–13 are defined as having minimal depressive symptoms, 
a score of 14–19 denotes mild depressive symptoms, 20–28 moderate depressive 
symptoms, and 29–63 severe depressive symptoms.14
Dispositional optimism was assessed by using the LOT-R. The LOT-R is a 10-item 
continuous scale to measure optimism.15 The questionnaire consists of six score items 
and four filler items, answered on a 0−4 Likert scale (0 strongly disagree, 4 strongly 
agree). Three items are keyed in a positive direction and three in a negative direction, 
and negatively worded items (i.e., items 3, 7, and 9) are reversely coded. The total score 
is calculated as the sum of the score items (i.e., items 1, 3, 4, 7, 9, and 10), with a range 
between 0 and 24 and higher scores indicate greater optimism. Low dispositional 
optimism has previously been defined as a total score <12 (often yielding ±20  % of 
the subjects with the lowest scores).16 Missing values were replaced with the rounded 
mean of the remaining score items if at least four of the six score items were filled out.17 
Previously, college students in the USA scored a mean (standard deviation (SD)) LOT-R 
score of 14.3 (4.3); patients after bypass surgery scored 15.2 (4.1).15
Statistical analyses
Comparison between participants of IMPROVED who filled out the BDI-II and LOT-R and 
participants who did not were analyzed using the independent t  test, the Wilcoxon rank 
sum tests, and the χ2 test at the 5 % level. Linear regression analysis was used to assess 
the relationship between DAS scores and depressive symptoms severity scores, both at 
baseline and at 4 months follow-up. We adjusted for age, gender, and alcohol use (yes/no) 
because these characteristics are known to be related to depressive symptoms as well as 
(changes in) disease activity. Given the possible association between the questionnaire 
outcomes on the one hand and marital status (not married and living alone, not married 
and living together, married, divorced, widow(er)), having children (yes/no), level of 
education (highest level of education: primary school, secondary education, vocational 
education, or university), employment (yes/no), and tobacco use (yes/no); on the other 
hand, the analyses were repeated with these covariates included in the model. The 
analyses to assess the relationship at follow-up were also adjusted for baseline disease 
activity and baseline questionnaire scores. Subsequently, separate analyses were done for 
the components of the DAS: tender joint count and patients’ sense of general well-being, 

















sedimentation rate (ESR) as objective components. Univariate and multivariate analyses 
were done separately for tender joint count and swollen joint count because of collinearity. 
The regression analyses were also done for the LOT-R questionnaire.
Finally, questionnaire outcomes were compared at baseline and after 4 months using 
the paired t   test at the 5 % level. Differences in change scores of the BDI-II and LOT-R 
between patients who achieved remission (defined as a DAS <1.618) and those who did 
not were evaluated with an ANCOVA model with remission achievement (yes/no) as 
factor and the baseline values of BDI-II or LOT-R as a covariate. Statistical analyses were 
conducted with SPSS for Windows version 20.0 (SPSS Inc., Chicago, IL).
RESULTS
Characteristics of participants
Six hundred ten patients were included in the IMPROVED-study of whom 222 patients 
gave informed consent to also fill out the questionnaires and filled out at least one of 
the questionnaires at baseline or after 4 months. Of these, 211 patients completed the 
LOT-R and 215 patients completed the BDI-II both at baseline and follow-up. Patient 
characteristics are presented in table 1. Among patients who filled out the BDI-II and 
LOT-R questionnaires, a higher percentage was ACPA positive (p=0.050) and had children 
(p=0.03) compared to those who did not fill out the questionnaires (table 1).
Eight of 610 patients (1.3  %) reported having a depression in their medical history. 
None of these patients reported having ongoing symptoms, three reported using 
antidepressants and two patients reported being under care of a psychologist/
psychiatrist. Seven other patients reported using antidepressants without mentioning 
having a depression in their medical history.
Depressive symptoms severity over time
Disease activity was at both time points independently positively associated with depressive 
symptoms severity (baseline beta, 0.26, p<0.001 and 4  months, beta 0.31, p<0.001). The 
results did not change after adjustment for marital status, having children, level of education, 
employment, and tobacco use. At baseline, the DAS component VAS for global well-being 
and after 4 months, both tender joint count and VAS for global well-being, but not swollen 
joint count or ESR, were independently associated with BDI-II score (table 2).
After 4 months of treatment with methotrexate and prednisone, there was a significant 
decrease in mean BDI-II score in the entire group from 8.5 (SD 7.7) at baseline to 7.0 (SD 
7.2) (95% CI -2.3; -0.6,  p=0.001). Depressive symptoms after treatment were minimal, 
only 21 out of 215 (9.8 %) had mild depressive symptoms (BDI-II score 14−19), 11 out 
of 215 (5.1  %) had moderate (BDI-II score 20−28), and 5 out of 215 patients (2.3  %) 
had severe depressive symptoms (BDI-II >29). After 4 months, 138 patients (66 %) had 

















Table 1. Baseline characteristics of 222 patients who filled out BDI-II and optimism questionnaires 
compared to all patients included in the IMPROVED study.
Patients who filled out the 




Age (years) 51.4 ± 12.5 52.2 ± 14.7 0.45
Female sex 157 (71) 257 (66) 0.25
Married 143 (64) 237 (61) 0.40
Children 184 (83) 300 (77) 0.03
Higher education 73 (33) 177 (29) 0.12
Working 121 (55) 199 (51) 0.10
Disease characteristics:
DAS 3.2 ± 0.9 3.2 ± 0.9 0.51
Duration of symptoms (weeks) 18 (9-36) 18 (9-32) 0.49
ACPA positive 134 (60) 199 (51) 0.050
ESR 24 (11-37) 25 (11-41) 0.21
Tender Joint count 6 (4-9) 6 (4-9) 0.96
Swollen joint count 6 (3-10) 5 (2-10) 0.38
VAS global health 44 ± 24 47 ± 23 0.10
HAQ 1.1 ± 0.7 1.2 ± 0.7 0.28
BDI-II 8.5 ± 7.7 - -
LOT-R 16.7 ± 4.0 - -
Health related factors:
Smoking 63 (28) 114 (29) 0.79
Alcohol 130 (59) 232 (60) 0.67
Data are presented as means ± standard deviations (SD), medians and interquartile ranges (IQR), or 
numbers and percentages (%) when appropriate. DAS: disease activity score, ACPA: anti-citrullinated 
protein antibody, ESR: erythrocyte sedimentation rate, VAS: visual analogue scale, HAQ: health 
assessment questionnaire, BDI-II: Beck Depression Inventory II, LOT-R: Life Orientation Test Revised.
*Data of patients who filled out at least one of the questionnaires, at one of the time points.
were significantly decreased in patients who achieved remission (mean (SD) 6.9 (6.4) to 
4.8 (5.0), 95% CI -3.1; -1.2, p<0.001), but not in patients who did not achieve remission 
(mean (SD) 11.2 (8.9) to 11.0 (8.7), 95% CI -1.96;1.6, p=0.83). In patients who did achieve 
remission, the mean change in BDI-II was 4.0 (SE 0.8) points lower than in the patients 
who did not (p<0.001, figure 1).
Optimism over time
At baseline, disease activity was not associated with optimism scores as assessed with the 
LOT-R (beta 0.001, p=0.99). After 4 months, DAS score and LOT-R score (beta -0.14, p=0.02) 
were inversely associated, but this association disappeared after adjustment for age, 
gender, marital status, having children, level of education, employment, and alcohol 

















At baseline, the optimism score was 16.7 and after 4  months 16.5 (95% CI, -0.7; 
0.3,  p=0.42) in the entire group. The LOT-R scores for optimism and BDI-II scores for 
depressive symptoms severity were significantly associated both at baseline and after 
4  months (beta -0.51,  p<0.001) at baseline and (beta -0.44,  p<0.001) after 4  months. 
Patients with higher optimism scores had less depressive symptoms.
Of the 211 patients who filled out the questionnaire twice, 138 (65.7  %) achieved 
remission after 4 months (mean (SD) DAS 0.9 (0.4)). LOT-R scores remained stable from 
baseline to 4  months, whether remission was achieved (mean (SD) 17.0 (4.1) to 17.1 
(3.5), 95% CI -0.4; 0.7, p=0.08) or not (16 (3.9) to 15.2 (3.7), 95% CI -1.6; 0.1, p=0.68). Yet, 
the mean change in LOT-R was 1.4 (SE 0.4) points higher than in the patients who did 
not achieve remission (p=0.001, figure 1). In all patients, LOT-R scores were above the 
cut-off of 12.
DISCUSSION
In patients with recent onset rheumatoid and undifferentiated arthritis, disease activity 
showed a relationship with depressive symptoms severity. In patients who achieved 
clinical remission after 4  months of treatment with methotrexate and prednisone, 
Table 2. The association between DAS-components and BDI-II, separately for tender joint count and 
swollen joint count.
Crude beta (p-value) Adjusted beta1,2 (p-value)
Baseline
Tender Joint Count 0.27 (<0.001) 0.12 (0.08)1
ESR -0.004 (0.96) 0.02 (0.75)1
VAS 0.33 (<0.001) 0.31 (<0.001)1
4 months
Tender Joint Count 0.41 (<0.001) 0.14 (0.04)2
ESR 0.04 (0.53) 0.04 (0.57)2
VAS 0.47 (<0.001) 0.30 (<0.001)2
Baseline
Swollen Joint Count 0.11 (0.27) 0.04 (0.57)1
ESR -0.004 (0.96) 0.01 (0.85)1
VAS 0.33 (<0.001) 0.34 (<0.001)1
4 months
Swollen Joint Count 0.14 (0.04) 0.04 (0.79)2
ESR 0.04 (0.53) 0.04 (0.54)2
VAS 0.47 (<0.001) 0.35 (<0.001)2
1. Beta adjusted for: age, gender, alcohol consumption yes/no. 2. Beta adjusted for: age, gender, alcohol 
consumption yes/no, Disease Activity Score at baseline, outcome BDI-II at baseline.

















both depression scores and optimism scores improved significantly more compared to 
patients who did not achieve remission.
Our intention was to monitor possible mood changes that might occur during treatment 
with the high tapered dose of prednisone used to try to induce remission of early arthritis in 
our patients. Depression, as well as mania, could be induced by corticosteroids.10 Although 
we do not have a control group to compare the effect of corticosteroids, the finding that 
none of the patients in the IMPROVED-study expressed extreme values on either the 
depression or the optimism questionnaire, it is unlikely that prednisone greatly influenced 
depressive symptoms or optimism. More likely, the changes in mood scores that we saw are 
related to a previously described association between rheumatoid arthritis and depression.4 
The patients in the current study had early and relatively mild arthritis and did not carry 
the extra burden of joint destruction and the comorbidity of advanced rheumatoid arthritis, 
which may explain why only few patients had more than minimal depressive symptoms.
It has previously been hypothesized that the occurrence of depressive symptoms in 
RA is related to inflammatory processes and immune activation. This was based on the 
finding that in patients with depression, increased serum levels of cytokines IL-1, IL-6, 
and TNF-alpha were found.5, 6 In our study, it appears that the depressive symptoms 
depended mostly on the presence and extent of joint tenderness on examination and 
reported global well-being as measured with a visual analogue scale rather than on 
joint swelling and increased erythrocyte sedimentation rate as signs of inflammation. 
Therefore, our results do not support the hypothesis on inflammation and depression 
but point into the direction of a relation between mood and pain.
Figure 1. Difference between the patients with and without remission. The size of each square is 
proportional to the number of patients. Univariate regression lines are shown. P-values by analysis of 
covariance for the group difference, while adjusting for baseline values. Continuous values were used 
throughout the statistical analyses; categorization of baseline BDI-II and optimism scores was done for 

















This relation may be bidirectional, as already at baseline patients with more severe pain 
had more severe depressive symptoms, which is consistent with previous findings,19 
while patients who have more severe depressive symptoms may also be more susceptible 
for and report more pain.20-22 Even if inflammation is well suppressed with prednisone 
and methotrexate, residual or non-inflammatory pain can prevent that the patient will 
be assessed as being in remission. This may explain why patients who did not achieve 
remission after 4 months had higher depression scores. And this in turn may be related to 
the fact that patients who did not achieve remission had significantly higher depression 
scores at baseline than patients who did achieve remission. Since all patients knew that 
the treatment goal in the IMPROVED trial was to achieve remission, after which medication 
would be tapered and finally discontinued, it may be that not achieving remission and 
therefore having to intensify medication also influenced feelings of depression.3
Changes in disease activity or arthritic symptoms in general were not related to level of 
optimism as measured with the LOT-R questionnaire which did not significantly change 
over time. This is possibly related to the fact that optimism levels at baseline were above 
the cut-off for low optimism in the majority of our patients. Also, in contrast to depressive 
symptoms, which are considered to be an affliction or reaction to events, optimism is a 
relative stable trait and one of the components of personality. Any differences in reported 
optimism over time appear to be limited and reverberate around what can be called an 
internal ‘thermostat’ of optimism.23 Although the level of optimism after treatment in general 
did not significantly change in our patients, increase in LOT-R score was significantly higher 
in those who achieved remission compared to those who did not. Therefore, there may be 
a small state component to dispositional optimism. Our results also suggest that optimistic 
patients suffered less from depressive symptoms which in turn were influenced by arthritis 
related symptoms, especially pain and unwell being. Also, optimism influences pain and 
therefore possibly symptoms of arthritis. In general, baseline optimism has been related to 
slower disease progression and more efficient adjustment and coping strategies.17, 24, 25
A limitation of our study is that we chose self-report questionnaires to assess depressive 
symptoms severity and optimism because they are easy to answer and little time 
consuming. With the use of a structured psychiatric interview, the assessment of depressive 
symptoms in relation to RA disease activity might have been more extensive. The BDI-II 
provides a numerical score that makes it easy to assess improvement or reduction of the 
severity of depressive symptoms over time and a means to classify depressive symptoms 
severity. In view of the generally minimal reported depressive symptoms, we believe that 
the results are of scientific interests rather than of clinical significance.
We looked at optimism as a different focus on mood and chose the LOT-R to assess whether 
scores increase or decrease over time or in relation to changes in disease activity. However, 
although there are numerous reports on baseline optimism in relation to changes in aspects 
of (coping with) chronic illnesses, the literature on changes in repeated measurements of 

















are scarce. Previous studies on dispositional optimism in rheumatoid arthritis had cross-
sectional designs, which therefore could not analyze effects on optimism in time.26-28
In conclusion, among these patients with early RA, treated with methotrexate and a 
tapered high dose of prednisone, generally already minimal depressive symptoms 
severity decreased with lower disease activity and was significantly lower in patients 
who achieve remission than in patients who do not. This appears to be mostly due to the 
relationship of depression severity with symptoms of arthritis (pain and unwell being) 
rather than signs of inflammation. Dispositional optimism scores in general stay stable 
over time, although there appeared to be significantly more improvement in optimism 
when remission was achieved. Our data suggest that depressive symptoms in RA patients 
may improve if, by targeted treatment, symptoms of RA are optimally suppressed.
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ABSTRACT
Purpose: To investigate patient reported outcomes (PROs) of functional ability and 
health related quality of life (HRQoL) in patients with early (rheumatoid) arthritis during 
1 year of remission steered treatment. 
Methods: 610 patients with early rheumatoid (RA) or undifferentiated arthritis (UA) 
were treated with methotrexate (MTX) and tapered high dose of prednisone. Patients in 
early remission (Disease Activity Score (DAS) <1.6 after 4 months) tapered prednisone 
to zero and when in persistent remission, also tapered MTX. Patients not in early 
remission were randomized to either MTX+hydroxychloroquine+sulphasalazine+pred
nisone (arm 1) or to MTX+adalimumab (arm 2). Every 4 months, patients filled out the 
Health Assessment Questionnaire (HAQ) and the McMaster-Toronto Arthritis Patients 
Preference Questionnaire (MACTAR), the Short Form 36 (SF-36) and visual analogue 
scales (VAS). Change scores were compared between treatment groups. The association 
with achieving remission was analyzed using linear mixed models. 
Results: During year 1, patients who achieved early remission had the most improvement 
in PROs with scores comparable to the general population. Patients in the randomization 
arms showed less improvement. Scores were comparable between the arms. There was 
a significant association between achieving remission and scores of HAQ, MACTAR and 
physical HRQoL.
Conclusion: In early arthritis, PROs of functional ability and HRQoL after 1 year remission 
steered treatment reach normal values in patients who achieved early remission. 
In patients not in early remission who were randomized to two strategy arms PROs 
























In rheumatoid arthritis (RA) treatment with disease modifying anti-rheumatic drugs 
(DMARDs) is targeted at achieving optimal suppression of disease activity. With that, 
clinical symptoms as well as radiological joint damage (progression) are prevented 
and patient reported outcomes (PROs) such as pain and health related quality of life 
(HRQoL), physical and mental wellbeing, improve.1 Earlier studies have suggested that 
the better disease activity is suppressed, the better the outcomes of functioning and 
radiological joint damage progression.2, 3 Achieving clinical remission would ideally be 
associated with achieving PROs comparable to those in the general population. 
In the IMPROVED study, anti-rheumatic treatment was targeted at remission. Patients 
with early (rheumatoid) arthritis were treated with initial combination therapy of 
methotrexate (MTX) and prednisone. If clinical remission (disease activity score (DAS) 
<1.6) was not achieved after 4 months, patients were randomized into two treatment 
arms:  either starting with a combination of non-biologic DMARDs with low dose 
prednisone or with MTX and TNF-alpha inhibitor adalimumab. The aim of this sub-
analysis was to measure change in functional ability and HRQoL during the first year of 
remission-steered treatment, to compare outcomes between the randomization arms 
and to compare study-patients with the general population.
METHODS
Study design
The IMPROVED-study (acronym for Induction therapy with Methotrexate and 
Prednisone in Rheumatoid Or Very Early arthritic Disease) is a multicenter, randomized, 
single-blinded trial comparing two combination therapies in patients with recent-
onset arthritis aiming at clinical remission, defined as a DAS<1.6. The IMPROVED 
trial was designed and conducted by rheumatologists in the Foundation for Applied 
Rheumatology Research (FARR) and was registered in the ISRCTN Register (number 
11916566) and the EudraCT (number 2006-006186-16). 
Patients were recruited between March 2007 and September 2010 in 12 hospitals in the 
Western part of the Netherlands. The Medical Ethics Committee of each participating 
center approved the study protocol and all patients gave written informed consent. 
Patients with rheumatoid arthritis (RA) and patients with undifferentiated arthritis 
(UA) were included. RA was diagnosed according to the 2010 American College of 
Rheumatology and the European League Against Rheumatism (ACR/EULAR) classification 
criteria4 with symptom duration of <2 years. UA was defined as ‘arthritis’ in at least 
one joint and one other painful joint in which no definitive diagnosis could be made, 
considered to have very early RA according to the treating rheumatologist, regardless 
of symptom duration. All patients were ≥18 years old with a DAS≥1.6. Detailed inclusion 























All patients were initially treated for 4 months with MTX 25 mg/week and a tapered 
high dose of prednisone, starting with 60 mg/day, tapered to 7.5 mg/day in 7 weeks. 
Patients in early remission (DAS<1.6 after 4 months) tapered prednisone to 0 and when 
still in remission after 8 months, also tapered MTX to 0. Patients not in early remission 
(DAS≥1.6) were randomized using variable block randomization stratified per center 
to ensure numerical equality of the two treatment groups. Randomization sequence 
was obtained by computer. At the local centres, allocation was performed by drawing 
opaque envelopes from separate boxes for UA and RA.  Patients were randomized to 
either a combination of either MTX 25 mg/wk, hydroxychloroquine (HCQ) 400mg/day, 
sulphasalazine (SSZ) 2000mg/day and prednisone 7.5mg/day (arm 1) or a combination 
of adalimumab (ADA) 40mg/2weeks and MTX 25mg/wk (arm 2). When patients did not 
achieve remission after 8 months, patients in arm 1 switched to ADA+MTX and patients 
in arm 2 increased ADA to 40mg/week. If patients achieved remission after 8 months, 
patients in both arms tapered to MTX monotherapy. Patients who did not achieve 
remission but were not randomized were analyzed in a separate group, theoutside of 
protocol subgroup (the OP group).6 
Outcomes
Functional ability was assessed every 4 months with the Health Assessment Questionnaire 
(HAQ).7 The HAQ score of a general (Finnish) population is 0.25.8
The McMaster-Toronto Arthritis Patients Preference Questionnaire (MACTAR) also 
measures functional ability. Patients have to rank five activities that are impaired because 
of their arthritis. Over time, improvement or deterioration of these five activities can be 
measured. The MACTAR is sensitive to change and useful to detect small differences. 
Compared to the baseline score, a higher score denotes improvement and a lower score 
means deterioration. The MACTAR interview from Canada was translated into Dutch in 
collaboration with the author of the original MACTAR. The translation was first used in 
the COBRA study, validated and judged as highly responsive. 9-11 
HRQoL was assessed using the Short-Form 36 (SF-36) focusing on 8 domains of health; 
physical functioning, role limitations due to physical or due to emotional functioning, 
bodily pain, general health, vitality, social functioning, mental health. The total score 
ranges from 0 (worst) to 100 (best). Two summary components scores, the mental 
component score (MCS) and the physical component scores (PCS), can be calculated 
from the 8 domains. These component scores are standardized, based on the worldwide 
population norm, to a mean of 50 and a standard deviation of 10.12, 13 The minimum 
clinically important difference to assess improvement or deterioration is a 5-10 point 
difference from baseline for the subscales and 2.5-5 points for the component scores.14
Various visual analogue scales (VAS) were used and patients had to indicate on a scale 
from 0 to 100 millimeters (0 means none, 100 means the worst) their appreciation of global 
























All outcomes were calculated according to the intention-to-treat (ITT) principle. All 
mean outcomes after 4 months, 8 months and 1 year were tested between arms 1 and 2 
using the students t-test and to test the difference in remission rates we used the χ2 test.
HAQ- and MACTAR scores, MCS, PCS and VAS measurements were reported separately 
for patients who achieved early remission and those randomized, and were compared 
between the randomization arms. The results of the study population were compared 
with those in the general population, if available. 
Mean change scores over time were tested between the randomization arms using an 
independent Student’s t-test. Clinically relevant improvement or deterioration after 1 year in 
HRQoL was assessed per treatment group, using the minimum clinically important difference.
To assess the relationship between achieving remission and the PROs SF36-PCS, 
SF36-MCS, HAQ and MACTAR a linear mixed model (with an unstructured covariance 
structure) was used. The analyses were first performed with an interaction term for 
remission achievement and treatment (early remission, arm 1, arm 2, OP group) because 
the different treatment strategies might influence remission achievement (as fixed 
effects were entered into the model: time (study visit at 4 months, 8 months and 1 year) 
and mean baseline score of the assessed PRO) In case of a significant interaction term, the 
analyses were stratified for treatment. The association between remission and PROs was 
assessed with and without adjustment for baseline variables anti-citrullinated protein 
antibody (ACPA) status (positive/negative), sex (male/female), DAS at baseline, Tender 
Joint Count and Swollen Joint count. We used these determinants because they were 
identified as predictors for achieving remission after the first 4 months of the study.5 As 
fixed effects were entered into the model: time (study visit at 4 months, 8 months and 
1 year), mean baseline score of the assessed PRO and the determinants for which the 
analyses were adjusted. After the initial analysis defining remission as a DAS<1.6 we re-
analyzed the association with remission defined according to the provisional Boolean 
based, remission definition published by the American College of Rheumatology and 
the European League Against Rheumatism (ACR/EULAR) with a 44 joint count.15 
Statistical analyses were conducted with SPSS for Windows version 20.0 (SPSS Inc., 
Chicago, Ill).
RESULTS
In total, 610 patients were included. During the first year, 32 patients left the trial (23 withdrew 
consent, 3 discontinued because of a revised diagnosis, 6 because of co-morbidity). 
After 4 months, 387 achieved early remission (DAS<1.6). Of the 221 patients who did 
not achieve early remission, 161 patients were randomized; 83 patients into arm 1 (poly-
DMARD), 78 to arm 2 (ADA+MTX). Fifty patients did not achieve remission but were not 























lower mean baseline DAS, lower values of all DAS-components, had shorter symptom 
duration, included fewer females and more patients positive for ACPA (table 1).5 
After 1 year, remission was most often achieved by patients in the early remission group 
(68%). Fewer patients randomized to arm 1 achieved remission after 1 year than patients 
randomized to arm 2 (respectively 25% and 40%, p=0.01) (table 2). 
Functional ability
HAQ scores in the early remission group were lower, indicating better functional ability, 
than in the randomization arms, both at baseline and after 1 year (figure 1) Functional 
ability improved the most during the first 4 months in all patients (figure 1). The mean 
improvement in HAQ during the first year was comparable between arm 1 and 2 (mean 
difference -0.005, 95%CI -0.3;0.2). In the early remission group the mean HAQ-score after 
1 year of 0.38 was closest to the general population mean of 0.25 (compared to a mean 
HAQ of 0.87 in arm 1 and 0.88 in arm 2) (figure 1 and table 2). 
Functional ability as measured by the MACTAR, which is more sensitive to change than 
the HAQ, improved in all groups together with continuous improvements in mean DAS 










Age (years), mean ± SD 52 ± 14 48 ± 14 51 ± 14 54 ± 14
Female, n (%) 239 (62) 63 (76) 64 (82) 42 (84)
Symptom duration (weeks), median (IQR) 17 (9-30) 22 (9-40) 21 (8-29) 18 (9-42)
ACPA positive, n (%) 225 (58) 40 (48) 36 (46) 25 (50)
RA2010, n (%) 297 (77) 66 (80) 64 (82) 40 (80)
Erosive disease, n (%) 63 (16) 10 (12) 13 (17) 3 (6)
DAS, mean ± SD 3.0 ± 0.9 3.6 ± 0.9 3.6 ± 1.0 3.6 ± 0.9
Tender Joint Count, median (IQR) 5 (2-9) 6 (3-10) 8 (4-12) 7 (3-13)
Swollen Joint Count, median (IQR) 5 (3-8) 8 (6-13) 9 (6-13) 8 (6-14)
HAQ, mean ± SD 1.0 ± 0.7 1.4 ± 0.6 1.4 ± 0.65 1.3 ± 0.7
MCS, mean ± SD 51.2 ± 10.2 46.1 ± 12.4 48.8 ± 11.5 46.5± 13.3
PCS, mean ± SD 37.6 ± 9.3 33.0 ± 8.8 32.9 ± 8.9 35.2± 8.5
MACTAR, mean ± SD 50.1 ± 4.5 47.7 ± 4.6 48.1 ± 4.6 47.7 ± 5.2
VAS global (mm), mean ± SD 43 ± 24 54 ± 20 54 ± 22 51 ± 22
VAS disease activity (mm), mean ± SD 56 ± 25 66 ± 19 67 ± 22 66 ± 20
VAS pain (mm) , mean ± SD 50 ± 24 63 ± 19 61 ± 20 60 ± 24
VAS morning stiffness  (mm), mean ± SD 56 ± 27 69 ± 21 62 ± 25 54 ± 30
Data are presented as means and standard deviations (SD), medians and interquartile ranges (IQR), or 
numbers and percentages (%). OP group: outside of protocol group, ACPA: anti-citrullinated protein antibody, 
RA2010: rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria22, DAS: disease activity 
score, HAQ: Health Assessment Questionnaire, MCS: Mental Component Score, PSC: Physical Component 























(table 1 and 2). The mean change in MACTAR in year 1 was not significantly different 
between arm 1 and 2 (mean difference -1.1, 95%CI -5.2;3.1). The outcomes of the OP 
group were comparable with those in arms 1 and 2.











DAS 0.97 (0.40) 2.49 (0.63) 2.57 (0.68) 0.47 2.31 (0.63)
HAQ 0.23 (0.33) 0.86 (0.57) 0.88 (0.57) 0.77 0.73 (0.68)
MACTAR 58.2 (15.7) 52.8 (15.1) 48.9 (18.8) 0.14 51.6 (14.1)
MCS 52.4 (8.0) 48.8 (9.9) 50.7 (10.8) 0.26 49.8 (10.5)
PCS 51.7 (8.1) 39.4 (9.7) 38.1 (9.4) 0.44 42.5 (9.4)
VAS global (in mm) 14 (14) 37 (21) 39 (21) 0.61 28 (22)
VAS disease activity (in mm) 12 (15) 42 (24) 43 (24) 0.74 32 (25)
VAS pain (in mm) 10 (14) 39 (24) 38 (24) 0.79 27 (24)
VAS morning stiffness (in mm) 11 (17) 40 (27) 39 (27) 0.78 32 (30)
8 months
DAS 1.29 (0.69) 1.97 (0.87) 2.01 (0.91) 0.77 2.02 (0.84)
HAQ 0.35 (0.44) 0.74 (0.61) 0.81 (0.64) 0.51 0.68 (0.59)
MACTAR 56.4 (15.7) 55.8 (14.7) 54.5 (16.1) 0.60 48.9 (19.9)
MCS 52.9 (8.4) 46.6 (17.9) 48.7 (10.3) 0.85 48.5 (13.0)
PCS 48.9 (9.1) 42.8 (10.9) 42.5 (11.0) 0.26 43.7 (9.5)
VAS global (in mm) 20 (20) 33 (23) 34 (21) 0.75 30 (23)
VAS disease activity (in mm) 22 (23) 39 (26) 33 (24) 0.20 35 (25)
VAS pain (in mm) 19 (23) 35 (26) 31 (25) 0.36 32 (24)
VAS morning stiffness (in mm) 24 (26) 34 (29) 37 (28) 0.51 40 (27)
1 year
DAS 1.31 (0.78) 2.07 (0.89) 1.77 (0.90) 0.04 2.20 (0.83)
HAQ 0.38 (0.49) 0.87 (0.66) 0.81 (0.66) 0.60 0.77 (0.65)
MACTAR 63.0 (9.4) 59.2 (10.3) 60.4 (11.9) 0.54 59.7 (11.2)
MCS 53.1 (8.6) 50.5 (10.3) 50.5 (10.1) 0.97 50.4 (11.9)
PCS 48.6 (9.8) 39.9 (10.3) 43.0 (11.4) 0.10 42.6 (10.9)
VAS global (in mm) 20 (21) 33 (23) 27 (20) 0.10 33 (24)
VAS disease activity (in mm) 24 (26) 42 (29) 31 (26) 0.02 34 (27)
VAS pain (in mm) 21 (23) 38 (28) 28 (25) 0.02 28 (25)
VAS morning stiffness (in mm) 25 (26) 41 (31) 33 (27) 0.96 39 (30)
DAS remission (DAS<1.6) 263 (68) 21 (25) 32 (41) 0.01 11 (22)
Data are presented as means and standard deviations (SD), medians and interquartile ranges (IQR), or numbers 
and percentages (%) when appropriate. ACPA: anti-citrullinated protein antibody, RA2010: rheumatoid 
arthritis according to the 2010 American College of Rheumatology classification criteria, DAS: disease activity 
score, HAQ: Health Assessment Questionnaire, MCS: Mental Component Score, PSC: Physical Component 
Score, MACTAR: McMaster-Toronto Arthritis Patients Preference Questionnaire VAS: visual analogue scale. 











































































Health Related Quality Of Life
At baseline, mental HRQoL measured with the mental component score (MCS) was higher 
than physical HRQoL measured by the physical component score (PCS) in all groups (table 
1 and figure 2). Overall, the MCS at baseline was already close to the population average 
of 50, and improvement during the first year was minimal (table 1, figure 2), although 
clinically relevant in the randomization arms based on the minimal clinically important 
difference in component scores of 2.5-5 points (mean (SD) improvement arm 1: 3.8 (11.4), 
arm 2: 2.8 (10.0)). The mean improvement after 1 year was not significantly different 
between arm 1 and 2 (mean difference 1.0, 95%CI -2.8;4.7). The domains in which most 
improvement was seen, were role emotional and social functioning (figure 3). 
For the PCS, baseline scores in all groups were below the population average of 50 (table 
1 and figure 2). The early remission group improved to the population average during 
the first 4 months of treatment and stabilized, whereas the randomization arms also 
improved during the first 4 months and stabilized, but below the population average 
(table 2 and figure 2). The mean improvement in 1 year was clinically relevant in all 
groups based on the minimal clinically important difference of 2.5-5 points: in the early 
remission group 11.1 (SD 11.7), in arm 1 8.0 (10.9) and in arm 2 10.1 (12.8). The mean 
Figure 1. Functional ability as measured by the Health Assessment Questionnaire (HAQ) and the McMaster-
Toronto Arthritis Patients Preference Questionnaire (MACTAR). Scores in the first year in the general 
























































Figure 2. Summary components scores of health as measured by the Short-Form 36 (SF-36). The mental 
component score (MCS) and the physical component score (PCS), can be calculated from the 8 domains 
(physical functioning, role limitations due to physical functioning, bodily pain, general health, vitality, 
social functioning, role limitations due to emotional functioning and mental health) of the SF-36.12, 13 
improvement in 1 year between patients who did and did not achieve early remission 
was significantly higher in patients who achieved early remission (mean difference 
-2.7, 95%CI -4.9;0.5). There was no significant difference between arm 1 and 2 (mean 
difference -2.1, 95%CI -6.3;2.1). The domains in which most improvement was seen, were 
physical functioning, role limitations due to physical functioning and bodily pain (figure 
3). Again, MCS and PCS in the OP group were comparable with those in arms 1 and 2.
Visual analogue scales
Patients who achieved early remission had at baseline and after 1 year lower VAS scores 
(indicating better outcomes) than the randomization arms (table 1 and 2). Patients in 
arm 2 reported lower VAS scores than patients in arm 1 after 1 year (table 2). Only for 
VASda there was more improvement after 1 year in arm 2 than in arm 1 (mean difference 


















































































































































Figure 3. The 8 domains of health as measured by the Short-Form 36 (SF-36; physical functioning, role 
limitations due to physical functioning, bodily pain, general health, vitality, social functioning, role limitations 
due to emotional functioning and mental health). The total score ranges from 0 (worst) to 100 (best).
the randomization arms (mean difference (95%CI) VASgh 7 (-2;16), VASpain 9 (-1;19) and 
VASms 5 (7;16). The OP group showed similar results as patients in arm 1 and 2.
Association of PROs with achieving remission (DAS<1.6)
The analyses of the HAQ and the PCS were stratified for treatment group because there was 























HAQ and achieving remission and between PCS and achieving remission was significant in 
all groups during the first year of the study (table 3). The analyses for MACTAR and MCS 
were not stratified. In the total study group there was a significant association between 
MACTAR and achieving remission. There was also a significant association between MCS 
and achieving remission in the total study group, but after adjustment (for ACPA status 
(positive/negative), sex (male/female), DAS at baseline and Tender Joint Count and Swollen 
Joint count at baseline, this association was no longer found (table 3). Results were the same 
when we used the ACR/EULAR provisional remission definition (data not shown).
As fixed effects were entered: time (study visit at 4 months, 8 months and 1 year) and mean 
baseline score of the assessed PRO. The analyses were also performed with adjustment 
(adjusted beta) for anti-citrullinated protein antibody (ACPA) status (positive/negative), 
sex (male/female), disease activity score (DAS) at baseline, Tender Joint Count and Swollen 
Joint count, these were also entered as fixed variables. For HAQ and PCS there was 
stratification for treatment group (early remission, arm1, arm 2, outside of protocol group) 
because of a significant interaction between treatment group and achieving remission.
DISCUSSION
We assessed patient reported outcomes (PROs) of functional ability and health related 
quality of life (HRQoL) in patients with UA and early RA who were treated with the aim to 
achieve remission (DAS<1.6). Patients who achieved early remission after 4 months had 
the best PROs from baseline through the first year of the study and only in these patients 
PROs reached levels comparable with those measured in the general population. 
Patients who did not achieve early remission and were randomized to multiple DMARDs 
Table 3. Association between the patient reported outcomes and remission achievement during 1 year 
follow up
All Early remission Arm 1 Arm 2 OP group
Crude beta (95%CI)
HAQ - -0.31 (-0.36;-0.26) -0.43 (-0.57;-29) -0.45 (-0.58;-0.32) -0.18 (-0.33;-0.02)
MACTAR 7.8 (6.9;8.9) - - - -
PCS - 6.2 (5.1;7.4) 10.2 (7.5;12.9) 8.9 (5.8;12.0) 4.5 (0.6;8.4)
MCS 0.8 (0.01;1.6) - - - -
Adjusted beta (95%CI)
HAQ - -0.30 (-0.35;-0.25) -0.43 (-0.57;-29) -0.45 (-0.58;-0.32) -0.17 (-0.32;-0.01)
MACTAR 8.1 (7.0;9.2) - - - -
PCS - 6.0 (4.9;7.2) 9.9 (7.1;12.7) 9.1 (6.1;12.1) 4.2 (0.2;8.1)
MCS 0.8 (-0.01;1.7) - - - -
OP: outside of protocol group, CI: confidence interval, HAQ: Health Assessment Questionnaire, MACTAR: 
























with prednisone or combination of methotrexate with adalimumab had lower, and 
between arms comparable, PRO scores during the first year. 
At baseline, the IMPROVED population with a mean age of 52 years scored lower 
on all domains of the physical HRQoL compared to healthy individuals of the Dutch 
population aged >70 years12 and therefore it seems that the disease burden of early 
arthritis is substantial. With treatment, the component score for physical HRQOL showed 
a clinically relevant improvement in all groups, with the most improvement in the early 
remission group during the first 4 months. The mental HRQoL remained stable around 
the population average during the first year of treatment, which suggests that the impact 
of early arthritis is mainly physical. This was also shown in previous published studies.1, 16 
However, improvement of physical HRQoL and HAQ to the population average in the first 
year after diagnosis in a remission steered treatment protocol, was not earlier reported.1, 17
It is generally accepted that remission is the optimal treatment target in rheumatoid 
arthritis. Ideally, this would result in patients having no radiological joint damage 
progression, and no symptoms and no limitations, in other words ‘normality’, functional 
ability and quality of life comparable with the general population. More than disease 
activity scores, patient reported outcomes show whether such improvement can be 
achieved if treatment is steered at achieving remission. The current results indicate that 
scores comparable with the general population can indeed be achieved, but mainly in 
patients who were in early remission after 4 months of initial treatment. There is possibly 
a two-sided relationship between early remission and better PRO scores, since patients 
who achieved early remission had better PRO scores at baseline than patients who did 
not. This indicates that maybe a predisposition to achieve remission determines the 
outcomes. Our results indicate that patients with a milder disease or better predisposition 
to achieve remission benefit from remission steered treatment because this allows 
them to achieve normal levels of functional ability and quality of life, which may have 
a significant impact on their ability to work and personal and societal costs of having 
(rheumatoid) arthritis.18, 19 The magnitude of the association between remission and the 
various PROs is actually bigger in arms 1 and 2 than in the early remission group, which 
had better PROs after 1 year, but also already better PROs at baseline than the patients in 
arms 1 and 2. This suggests that regardless of baseline score, achieving remission itself is 
associated with PRO improvement. 
One may argue that also without treatment the arthritis in these patients would have 
regressed, with function and quality of life restored. However, previously we showed 
that patients who achieved remission were in majority ACPA positive, which makes 
spontaneous remission less likely.5 
Although after 1 year significantly more patients in arm 2 achieved remission than in arm 
1, we found no significant differences in improvement of functional ability, HRQoL and 
VAS results between both arms. Only VAS disease activity as estimated by the patient 























targeted at remission, remission percentages in both arms remained lower than in the 
early remission group. Possibly as a consequence also functional ability and HRQoL in 
the physical domain did not achieve the same levels as the early remission group. In 
particular HAQ was higher in the randomization arms than in the early remission group 
and physical HRQoL did not reach the levels found in the general population. Although 
we found that PROs were associated with achieving remission and significantly more 
patients in arm 2 achieved remission after 1 year than in arm 1, we found no significant 
differences in improvement of functional ability and HRQoL between both arms. 
Only improvement in VAS disease activity was significantly better in patients of arm 2 
compared to patients in arm 1, which can be explained by significantly lower mean DAS 
in arm 2 and it may also be related to higher patient expectations associated with earlier 
introduction of subcutaneous TNF-inhibitor, adalimumab, in this treatment arm.20, 
21 Overall, disease activity was well suppressed in both arms which may explain why 
we have found no differences in improvement in HAQ and HRQoL. The actual disease 
activity score, rather than having a score just above or below the threshold of remission, 
may be the main determinant of PRO outcomes. The patients in the outside of protocol 
subgroup have similar results as patients in arm 1 and 2 which can be explained by the 
comparable response on initial treatment.
In conclusion, in patients with early (rheumatoid) arthritis, there is an association 
between achieving remission and having better functional ability and health related 
quality of life and other PROs, which may in part be bidirectional. Patients who achieve 
early remission improve and remain at levels of the general population. This supports 
the idea that early remission steered treatment could result in complete suppression 
of symptoms with normal functioning and may prevent chronic deterioration also in 
patient reported outcomes. 
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Over the past decades it has become clear that treatment of patients with rheumatoid 
arthritis (RA), preferably combination therapy, has to be initiated in a tight-controlled 
regimen as soon as possible after diagnosis.1 This, in order to restore and maintain 
functional ability and prevent joint damage (progression). Also, health related quality 
of life and the severity of depressive symptoms seem to improve when patients achieve 
(early) remission.2, 3 In addition, it may be possible to reverse the disease process altogether 
and achieve drug free remission (DFR) if effective treatment is initiated very early. 
Undifferentiated arthritis (UA) can have a self-remitting course or progress to RA. In the 
last situation, UA is considered to be an early phase of RA. For these patients, initiation 
of antirheumatic treatment is suggested, not only for symptom relief but to prevent 
progression to RA and even aim for a reversal of disease mechanisms.4, 5 It has been 
shown that methotrexate (MTX), the anchor drug in RA, postpones progression to RA 
in patients with UA who have anti-citrullinated protein antibodies, but for UA patients 
without these autoantibodies MTX appears to be as effective as placebo.6 It has therefore 
been hypothesized that also for patients with UA, initial combination therapy might be 
more effective than initial MTX monotherapy to prevent progression to RA, induce (drug 
free) remission and generally improve disease outcomes.
This thesis focuses on treatment strategies and disease outcomes of patients with RA and 
UA, based on results of three intervention studies. In chapter 1 a general introduction on 
RA, UA, treatment strategies and disease outcomes is given. In the following chapters 
several studies on these subjects are described; the long term disease outcomes of UA 
patients in the PROMPT study (chapter 2), outcomes during 2 years follow-up in the 
IMPROVED-study (chapter 3-5), subanalyses on treatment response in the IMPROVED-
study and the BeSt study (chapter 6 and 7), radiological outcomes (chapter 8 and 9) and 
patient reported outcomes, again in the IMPROVED-study (chapter 10 and 11).
RA VERSUS UA
In the PROMPT study, patients with UA were treated with initial MTX or placebo. After 
30 months it was shown that MTX can postpone, but not prevent, progression from UA 
to RA.6 In chapter 2 of this thesis the long-term outcomes of the PROMPT cohort, after 5 
years follow-up, are reported. Patients initially treated with MTX progressed as often to RA 
(defined according to the 1987 ACR/EULAR classification criteria7) as patients initially treated 
with placebo. Also, joint damage progression was comparable between patients treated 
with MTX and those treated with placebo, as was the percentage of patients who achieved 
DFR. Only patients positive for anti-citrullinated protein antibody (ACPA) benefitted from 
treatment with MTX. However, joint damage progression was more severe in ACPA positives 
regardless of treatment with MTX or placebo. The main conclusion was that there is hardly 
any lasting benefit of a one year course of MTX treatment after 5 years, which suggests that 
early temporary treatment with MTX cannot alter the disease course in UA. This may be due 
















In retrospect, 39% of the patients could have been classified as RA according to the 2010 
classification criteria at baseline, which were formulated to facilitate earlier recognition of 
RA than with the old (1987) criteria. The new criteria suggest that early treatment may be 
started because there is a sufficient risk of persistence of symptoms and structural damage.8 
However, for some of these patients the opportunity to change the disease course might 
have been lost already because of the long duration of symptoms before initiation of 
treatment. On the other hand, the 2010 classification criteria may also recognize self-limiting 
types of arthritis as RA. Twenty-five percent of the PROMPT patients who fulfilled the 2010 
criteria achieved remission after treatment with placebo. Besides initiating treatment too 
late, it is possible that discontinuation of MTX after one year was too early. However, the 
idea of the PROMPT study was to evaluate the effect of early temporary treatment, as 
induction therapy aiming at remission or at least prevention of progression.
It is possible that MTX monotherapy was not the optimal treatment choice to achieve 
these goals. MTX is usually the DMARD of first choice in treatment of RA and has been 
called the anchor drug of antirheumatic treatment. However, it has been shown that 
initial combination therapy of MTX with corticosteroids or with a biologic DMARD leads 
to better outcomes in patients with RA.9-15 In the PROMPT study, 63% of the UA patients 
who could be reclassified as having RA according to the 2010 classification criteria, still 
progressed to RA according to the 1987 classification criteria despite treatment with 
MTX. It may be that with initial combination treatment this could have been prevented. 
These considerations were taken on board when the IMPROVED-study was designed. One 
of the goals of the IMPROVED-study was to compare disease outcomes between patients 
with RA and patients with UA, the results of which are described in chapters 3, 4 and 5. 
Patients with RA according to the 2010 classification criteria and a symptom duration of 
less than 2 years, as well as UA patients were included if they showed any disease activity 
(at least one swollen joint and one other painful joint). All patients were initially treated 
with combination therapy consisting of MTX and a tapered high dose of prednisone. 
Subsequent treatment adjustments when remission was not achieved, were required. 
It was hypothesized that the UA patients would benefit more from the treatment in 
IMPROVED than the RA patients, presuming they were in an earlier phase of the disease or, 
alternatively, they had self-limiting disease. On the other hand, it may be that UA patients, 
with non-RA arthritis, would not respond well to intensive antirheumatic treatment. 
After the first four months of treatment (chapter 3) the remission rates between patients 
with RA and UA were comparable (61% versus 65%). After 1 year (chapter 4) and after 
2 years (chapter 5) there were still no differences in remission rates between patients 
with RA and UA. This, despite the fact that RA patients had a higher disease activity at 
baseline and were more often positive for ACPA, usually associated with worse disease 
outcomes.16 However, in the IMPROVED-study we found that ACPA positivity was one 
of the strongest predictors for remission at 4 months. In addition, the expectation that 
















symptom duration at baseline was comparable with a median duration of 18 weeks in 
RA en 16 weeks in UA. This could indicate that we missed the ‘window of opportunity’, 
the possibility to modulate the disease process with initiation of treatment before 12 
weeks symptom duration,17 in both RA and UA patients and therefore the opportunity to 
alter the disease course. However, at year 1 and also at year 2, UA patients were found to 
have achieved DFR more often than RA patients (chapter 4 and 5). These results suggest 
that although it is possible to achieve remission in comparable rates, the possibility to 
taper and stop medication when remission is achieved, is not. Perhaps this difference 
is related to the significantly lower baseline disease activity in UA patients and the 
majority of patients not having ACPA.18
REMISSION AND DRUG FREE REMISSION
The IMPROVED-study is one of the first studies to steer at remission in patients with 
early RA and the first to taper and stop medication as soon and as long as patients are 
in remission. After 4 months of initial treatment with MTX and a tapered high dose of 
prednisone, 61% of the patients in the IMPROVED-study achieved early remission (chapter 
3). After 1 year the remission rate was 54% (chapter 4) and 49% after 2 years (chapter 5). 
Especially the early remission rate (after the first 4 months) of more than 60%, is quite 
high. This is possibly related to the early initiation of treatment with a proven effective 
combination of antirheumatic drugs, when symptom duration was relatively short and 
disease activity not too far from the treatment goal of remission.19 In addition, some 
patients with UA and even some patients with early RA might have had a self-limiting 
type of disease.5 Also the radiological results are better than previously reported in 
patients with early RA.12, 13, 20, 21 For example, 7-33% of the patients in the BeSt study 
showed progression after 1 year and 20-47% of the patients in the NEO-RACo study 
showed progression after 2 years.12, 22 However, the overall remission rates in the 
IMPROVED-study are only slightly higher than what we observed in the BeSt study.12, 23 
At baseline, those patients had active RA (1987 criteria7) with high disease activity, more 
ACPA positive patients and longer symptom duration. Furthermore, only half of the BeSt 
study population received initial combination therapy and the target of treatment was 
low disease activity (DAS≤2.4) instead of remission (DAS<1.6).
Remission, so easily not achieved due to reported pain or elevated ESR due to other 
causes than RA activity, may be not as readily achieved as low disease activity. It may 
be that treatment tapering and discontinuation came too early, resulting in loss of 
remission where it otherwise might have been consolidated. It is also possible that 
remission was not achieved more often because we missed the ‘window of opportunity’ 
in the IMPROVED-study. Because the median symptom duration before inclusion in our 
patients was 18 weeks, earlier initiation of treatment could have induced higher remission 
rates, at least in some patients. However, we compared the outcomes of patients with a 
















treatment with a combination of MTX and prednisone followed by remission steered 
treatment adjustments is effective, regardless of symptom duration. 
Although actual long term remission was not achieved in as many patients as we had hoped, 
remission steered treatment has resulted in very low disease activity over time in most patients 
and almost total suppression of joint damage progression across the study population. 
INITIAL COMBINATION THERAPY, FOLLOWED BY….?
If, in the IMPROVED-study, the initial combination of MTX and tapered high dose of 
prednisone was not able to induce remission it was more difficult to achieve remission 
with the subsequent treatment steps (chapter 4 and 5). Patients who achieved early 
remission after 4 months were more often in remission and in DFR after 2 years than 
patients who had not achieved early remission and had been randomized to 2 treatment 
strategies. Initially, after 1 year, an early switch from the initial combination of MTX and 
prednisone to MTX with adalimumab resulted in more remission than first expanding 
treatment with sulphasalazine (SSZ) and hydroxychloroquine (HCQ) (chapter 4). This was 
due to more patients losing remission after tapering the combination of DMARDs with 
prednisone to MTX monotherapy and fewer patients achieved remission after switching 
from the combination of MTX, SSZ, HCQ and prednisone to MTX with adalimumab. 
This last finding reflects data from the BeSt study, where infliximab with MTX was less 
effective in patients who had first failed on MTX, SSZ and HCQ or leflunomide, than in 
patients who received infliximab with MTX as initial treatment.24
After 2 years (chapter 6) the two treatment arms resulted in similar percentages of (drug 
free) remission with good preservation of functional ability and hardly any radiological 
damage progression. This may be the effect of continued remission steered treatment 
adjustments with overlap in treatment and prolonged low disease activity that obscures 
initial short-term differences. This was also shown in other studies with patients who, 
after failing on MTX monotherapy, were treated with non-biologic DMARDs or with MTX 
and a biologic agent.21, 25, 26
ACPA
In the PROMPT study (chapter 2) there were differences in outcomes between ACPA positive 
and ACPA negative patients. Time to progression to RA was significantly shorter in ACPA 
positive patients than in ACPA negative patients and APCA positive patients showed more 
radiological damage progression. MTX was effective in ACPA positive patients in so far 
that MTX postponed progression to RA, but did not affect the outcome of ACPA negative 
patients. The absence of ACPA was the only independent predictor of DFR after 5 years. 
Independent predictors of early remission in the IMPROVED-study (chapter 3) were low 
baseline disease activity, low numbers of painful and/or swollen joints, male sex, lower 
















response and disease outcome and therefore it was not expected that ACPA positivity 
would be a predictor of early remission but there are explanations for this finding.18, 27 
The 2010 classification criteria for RA depend on a score that is based on presence and 
severity of arthritis on examination and presence and titer of autoantibodies. Patients 
with a low score for arthritis will still be classified as RA if high autoantibody (ACPA, 
rheumatoid factor) titers are present, patients without autoantibodies require a large 
number of inflamed joints to be classified as RA. Patients not meeting the classification 
criteria (UA patients) only have a few inflamed joints and they are almost all ACPA 
negative. They may have a different type of disease that does not respond as well to 
the initial combination therapy as classified RA patients. ACPA positive RA patients had 
less joint involvement than ACPA negative RA patients, and consequently, the ACPA 
negative RA patients in the IMPROVED-study had a higher disease activity (and they 
also had a longer symptom duration). These differences may explain why ACPA negative 
patients achieved less remission after 4 months than ACPA positive patients.
After 1 year 32% of the patients in the IMPROVED-study achieved drug free remission 
(DFR1year) and in 65% of those, DFR was sustained for at least 4 more months (chapter 
6). Presence of RF, classified RA (2010 classification criteria) and a low tender joint 
count at baseline were associated with achieving DFR1year but none was independently 
associated with DFR1year. Notwithstanding the results after 4 months, ACPA positive 
patients achieved DFR as often as ACPA negative patients, but ACPA positive patients 
less often had sustained DFR. In a previous study, it was reported that absence of ACPA 
was an independent predictor of sustained DFR.18 The comparable DFR1year rates in the 
IMPROVED-study may be explained both by the efficiency of the initial combination of 
MTX and prednisone and the early start of targeted treatment, steered at remission. 
Although achieving DFR1year was achieved in comparable percentages of patients, 
sustaining DFR seems to be a different target. Perhaps, in ACPA positive patients tapering 
came too soon or we should have initiated a different combination of drugs.
The differences in outcomes between ACPA positive and ACPA negative arthritis may 
indicate that these are different diseases with different pathogenic mechanisms leading 
to disease activity. It may be that the effect of treatment depends on which pathogenic 
mechanisms drive disease activity and that therapy should be started and adjusted 
according to this. Current lack of knowledge of the molecular mechanisms that drive 
disease activity may prevent targeted interventions in particular for ACPA negative disease.
REMISSION AND BODY MASS INDEX 
Besides ACPA there are other factors that may influence how patients respond to 
treatment. It was previously reported that patients with a high body mass index (BMI), 
previously treated with at least two DMARDs, responded less well to treatment with fixed-
dose infliximab (IFX).28 It is speculated that this diminished response in patients with a high 
















In the BeSt study, patients with early RA were randomized to initial MTX monotherapy 
or initial combination therapy (with MTX, SSZ and prednisone or with MTX and IFX) and 
the target of treatment was low disease activity (DAS≤2.4).12 In the BeSt population, high 
BMI was associated with failure to achieve low disease activity on antirheumatic therapy. 
The association between high BMI and response to treatment was most noticeable in 
patients treated with combination therapy and we also found that patients with a high 
BMI failed more often on IFX, as initial treatment and also if the dosages were increased 
(chapter 7). Failing was dependent on higher pain and joint tenderness scores. 
Presuming that BMI is associated with higher inflammatory activity, one would expect that 
failure to achieve a DAS≤2.4 in patients with a high BMI would be reflected in increased 
inflammatory parameters. This we did not find. This may be due to small numbers in our 
investigation, as there were not many patients with a BMI above 30 kg/m2. In addition, 
joint evaluation can be a challenge in patients with a high BMI and it is possible that 
joint swelling was underestimated. It was previously shown that local joint tenderness is 
an independent predictor of local joint damage progression,31 and therefore we cannot 
rule out that joint tenderness was an indicator of joint inflammation even in the absence 
of noticeable swelling. However, there were no differences in joint damage progression 
between patients with high or low to normal BMI, suggesting that high BMI patients 
with high pain and joint tenderness scores did not have inflammatory activity. It may be 
that there was a fibromyalgia component responsible for the pain in patients with a high 
BMI.32 It is suggested that there are certain hormones and neurotransmitters that are 
responsible for an association between high BMI and pain.32 Especially musculoskeletal 
pain is experienced more often in patients with a BMI above 30 kg/m2 and often in more 
than one location33, 34 Alternatively, the comparable progression rates may be a result of 
treatment adjustments triggered by high pain and joint tenderness scores, or may reflect 
a protective effect of BMI on joint damage.32, 35, 36 Either way, the association between pain 
and BMI may also explain the decreased functional ability in patients with a high BMI, as it 
was previously reported that pain as well as body size may interfere with daily activities.37
RADIOLOGY
Early treatment and suppression of disease activity leads to better suppression of 
radiological damage progression.38-40 Starting treatment early in disease course brings a 
risk of overtreatment, for instance in patients with self-limiting arthritis, but it also may 
result in prevention or suppression of joint damage progression. 
One of the most significant findings after 2 years remission steered treatment in the 
IMPROVED-study, is the almost complete suppression of joint damage progression 
in the vast majority of patients, whether they were in remission or had not met that 
threshold. Only 50 patients of the original 610 showed progression of at least a 0.5 point 
increase in Sharp-van der Heijde Score (SHS) after 2 years, and only 8 (1%) had damage 
















If combination therapy is started early and treatment is steered at achieving remission, 
then radiological damage progression may be suppressed to the extent that it becomes 
difficult to score. We scored less erosions after 2 years follow-up than after 1 year 
(chapter 5). Minimal joint damage is difficult to distinguish from normal variations. 
Since we scored the radiographs in time random order we were even less likely to score 
progression, as chronological scoring has been shown to be more sensitive to change.41, 42 
Repair as explanation for the lower erosion score is less likely, as this happens mainly in 
damaged joints.43 Despite these differences in scoring, the overall outcome remains that 
radiological joint damage progression was very low, both after 1 and after 2 years. 
Rapid radiological progression (RRP), defined as ≥5 points progression in the first year 
after diagnosis, has been demonstrated to be an early outcome that is associated with 
a bad prognosis regarding further damage progression and functional disability.44A 
prediction model to identify which patient will develop RRP and may need more 
extensive treatment has been developed with data from the BeSt study45 and was 
tested in the IMPROVED-study (chapter 8). The model was not useful to predict damage 
progression in patients with UA and early RA who participated in the IMPROVED-study. 
A matrix model to predict RRP might not be applicable to a study population that showed 
hardly any damage progression and in only one patient RRP. Baseline disease activity and 
symptom duration appeared to be lower in the IMPROVED-study than in the BeSt study. 
In addition, the IMPROVED patients had shorter symptom duration and they all received 
initial combination therapy with MTX and prednisone, whereas half of the BeSt patients 
had received initial MTX monotherapy. As a consequence, not only were baseline disease 
activity lower and symptom duration shorter in the IMPROVED-study, also the risk factors 
used in the matrix model, were less often present in the IMPROVED patients: CRP values 
were lower, they were less often erosive at baseline and less often ACPA and/or RF positive. 
Thus, RRP was less likely in most IMPROVED patients, and particularly unlikely in the UA 
patients. Based on the matrix model, 13 patients had an intermediate risk of RRP and only 
2 of those showed progression of ≥0.5 SHS in year 1, the others showed no progression. 
This is possibly related to targeted treatment aiming at remission in the IMPROVED-study, 
which resulted in suppression of disease activity. One patient, predicted to have low risk 
actually showed RRP. By treating arthritis patients earlier, with remission targeted therapy, 
RRP and indeed also minimal radiologic damage progression may be prevented. Prediction 
models based on data from previous patients populations may thus no longer be relevant 
for current and future patients. Residual disease activity may still have an effect on cartilage 
and bone in and around arthritic joints and newer techniques to monitor these effects may 
need to be employed and next, new risk factors for joint damage may be identified. 
Early in the disease course there are subtle changes in the form of metacarpal osteopenia 
in the bones which are difficult to detect and score by conventional X-rays, the gold 
standard to evaluate joint damage.46 Changes in metacarpal bone mineral density 
















of mBMD during the first year after diagnosis is predictive for radiological damage up 
to 5 years afterwards.47-50 For clinical practice the predictive value of metacarpal BMD 
loss would be greater if it can be measured earlier in the disease course. Therefore we 
measured mBMD loss 4 months after the start of treatment and evaluated if it was a 
predictor of damage after 1 year. Presence of erosions at baseline and mBMD loss after 
4 months were predictive of radiological progression after 1 year (chapter 9). In patients 
without baseline erosions, 86% of the IMPROVED population, mBMD loss after 4 months 
was the only predictor for future joint damage progression. Thus, measuring mBMD 
loss after 4 months may help making treatment decisions early in the disease course. 
As mentioned earlier, only a few patients had radiological damage progression and we 
acknowledge that the value of DXR has to be validated in other studies as well.
PATIENT REPORTED OUTCOMES
Treatment not only improves disease outcomes in terms of remission and radiological 
damage progression, but it also influences how patients judge their quality of life.2 If the 
treatment target in RA is remission, which can be defined as ‘the absence of troublesome 
disease activity’,51 treatment should result in patients having no symptoms and no limitations 
or restrictions in functional ability, psychological wellbeing and quality of life. These so-called 
patient reported outcomes (PROs) can be measured with questionnaires and improving or 
maintaining them becomes more and more important in arthritis patients. 
Depressive symptoms are more common in patients with RA compared to healthy 
individuals.3, 52-54 Based on the finding that increased serum levels of cytokines IL-1, IL-6, 
and Tumour Necrosis Factor alpha (TNF-alpha) were found in patients with depression, 
it has been hypothesized that the relationship between RA and depression is related to 
inflammatory processes.55, 56 In the IMPROVED-study, it appeared that severity of depressive 
symptoms was associated with achieving remission. This association mainly depended on 
changes in joint tenderness and self-reported well-being (measured on a visual analogue 
scale) (chapter 10). An association between mood and pain may be bidirectional: pain 
perception can affect mood, mood can affect pain perception. Patients with higher pain 
scores at baseline may report more severe depressive symptoms and patients with more 
severe depressive symptoms may report more pain.57-59 Non-inflammatory pain can 
prevent patients from achieving remission and that could explain the higher depression 
scores. Furthermore, all patients knew that the treatment goal was remission and that 
medication would be tapered and stopped after achieving remission and it is possible that 
not achieving the treatment goal also influenced feelings of depression.3
All patients were treated with prednisone which can induce extremes in mood like 
depression and also mania.60 Because there was no control group, we were unable to 
evaluate the effect of steroids on mood. On the other hand it is unlikely that prednisone 
had much effect on depressive symptom severity since none of the patients reported being 
















As opposed to depressive symptoms which are considered to be a state of mind, optimism 
is considered a trait and is less variable over time. Indeed, the level of optimism did not 
significantly change after treatment. However, the increase in 4 months in optimism 
scores was significantly higher in patients who achieved remission compared to those 
who did not. This suggests that optimism, as we measured it, is not only a trait and 
that a part may vary over time and may on some level depend on mood. Optimism and 
depressive symptoms were associated with each other and perhaps optimistic patients 
suffered less from depressive symptoms which in turn is related with symptoms like pain 
and unwell being. Furthermore, optimism is one of the factors that influences coping 
strategies and could therefore also have an influence on how patients feel; mood but 
also how fatigued patients are and how much pain they experience.61-63
Overall, the severity of depressive symptoms was minimal and optimism scores were 
only slightly lower than normal. These results were underlined by measurements of 
mental health related quality of life (HRQoL) measured with the Short-Form 36 (SF-36) 
(chapter 11). Fluctuations were minimal and the scores remained stable around the 
population average. However, all domains of physical HRQoL were lower than the Dutch 
population means for healthy individuals who were on average 18 years older64 and 
showed a clinically relevant improvement in all patients. This suggests that the impact 
of early arthritis is mainly physical. Furthermore, it seems that despite the fact that 
treatment was initiated relatively early and almost nobody had radiological damage at 
baseline, the disease burden of early arthritis is substantial. 
Patients who achieved early remission after 4 months had better PRO outcomes than patients 
who did not. This may in part be because already at baseline their scores were better. It appears 
that patients with a milder disease at baseline are predisposed to better disease outcomes 
and they benefit more from remission steered treatment because they are more likely to 
achieve scores as are reported by healthy controls. This has a positive influence on ability to 
work and therefore on personal and societal costs of having (rheumatoid) arthritis.65, 66
In the patients who did not achieve early remission and were randomized, PROs remained 
lower than in the early remission group despite treatment adjustments targeted at 
remission. In particular functional ability was less and physical HRQoL did not reach the 
levels found in the general population. After 1 year the PROs between the randomized 
groups were comparable, although significantly more patients in the MTX plus adalimumab 
group achieved remission than in the DMARDs plus prednisone group. Only self-reported 
disease activity was judged better by the patients in the MTX plus adalimumab group, 
probably because of the significantly lower mean DAS and the higher patient expectations 
of TNF-alpha inhibitor adalimumab.67, 68 For all PROs there was an association between 
achieving remission and an improvement in PRO score. Yet, it is likely that suppression of 
















FUTURE PERSPECTIVES AND CONCLUSION
Where the classification criteria in 1987 were meant to identify patients with established 
RA, the goal of the 2010 criteria is to identify patients who would benefit from early 
initiation of treatment. Since the publication of the new classification criteria for RA in 
2010, the difference between RA and UA has become smaller. Perhaps disease course and 
outcomes will also become more comparable. In the IMPROVED-study, patients with RA 
and UA are somewhat different at baseline; RA patients have a higher disease activity and 
the percentage of ACPA positive patients is higher. The outcomes in both groups, however, 
are comparable except for the number of patients achieving DFR. On the one side, it is 
encouraging that RA patients have the same outcomes as UA patients. On the other hand, 
the ultimate goal of treating patients with UA is trying to change the course of the disease 
and possibly offer ‘a chance for cure’ and this appears not to have been achieved.
The comparability of RA and UA stresses the importance of early identification and 
immediate treatment. But how early is early? According to the ’window of opportunity 
-theory’, ‘early’ means before 12 weeks symptom duration. However, after 2 years 
follow-up in the IMPROVED-study there were no differences in the outcomes of patients 
treated with less or more than 12 weeks symptom duration. This suggests that the 12 
weeks threshold which was identified in a RA patients who for the most part were treated 
with initial monotherapy followed by, at the most, treatment adjustments aiming at low 
disease activity, may not be relevant if patients are treated with more effective initial 
combination therapy. However, with early initiation of treatment in patients with UA or 
even in patients classified as RA, overtreatment is a serious factor to keep in mind. 
Also ACPA positivity has previously been identified as a predictor for a poor treatment 
response and a more severe disease course. ACPA positive and ACPA negative arthritis can 
almost be considered as different disease entities and ideally, therapy should be started 
and adjusted according to those differences.6 In the IMPROVED-study patients were 
initially treated with MTX and prednisone. We found that after 1 year remission steered 
treatment, ACPA positive patients achieved remission as often as ACPA negative patients 
and that in both groups, damage progression was minimal and comparable. The only 
noticeable difference was that ACPA positive patients were less often able to sustain DFR 
and after 2 years they less often achieved DFR. These results may indicate that differences 
in outcomes between patients with a good prognosis and a poor prognosis, become 
smaller. This can be explained by effective treat-to-target treatment strategies resulting 
in better outcomes in general and thus in comparable results between patients with and 
without predictors of a worse disease outcome. It may also indicate that there may be 
other predictors of outcome yet to be identified. All these results indicate that disease 
outcomes in early arthritis have been further improved with treatment strategies like 
those of the IMPROVED-study. Although remission is achieved in a large proportion of 
patients nowadays, ideally DFR would be achieved in more (or preferably all) patients and 
















have to demonstrate predictors of sustained (drug free) remission. Not only remission 
rates, but also well-being and quality of life seem to benefit from early initiation of MTX 
and a tapered high dose of prednisone. Patients reported feeling better with suppression 
of disease activity, especially when remission was achieved early in the disease course. 
Because there may be a bidirectional relationship between several PROs and response to 
treatment, patient care could possibly be further improved with routine assessments of 
PROs which could be taken into account to make treatment decisions.
In the IMPROVED-study, patients who do not achieve early remission, achieved much 
lower remission and drug free remission (DFR) rates compared to patients who achieved 
early remission on initial combination therapy. This, despite continued remission steered 
treatment adjustments including continued use of low dose prednisone and use of 
combinations of drugs including multiple non-biologic DMARDs and biologic agents 
like adalimumab. Perhaps patients respond less well to treatment in case of a relative 
delay in finding the right treatment or they may have a type of illness that requires 
different medication altogether. As in some patients there may be a background of 
augmented perception of pain where stronger anti-inflammatory drugs may not be the 
answer. Identification of new risk factors for not achieving early remission may be a first 
step towards tailor-made treatment for these patients. 
Without losing sight of the benefits of remission steered treatment as was the basis of 
the IMPROVED-study, we should also take into account the possible downsides of such 
a strategy. Early use of adalimumab, or biologic agents in general, comes with high drug 
costs and potential side effects. Also, the high dose of prednisone and continued use 
of low dose prednisone in some patients, may come with a risk for infections and other 
complications. We have recorded all side effects, but without a non-prednisone control 
group we cannot assess the risk of this treatment. There could be alternatives, with a 
lower dose of prednisone.69
In conclusion, in patients with recent onset RA or UA, remission targeted treatment 
results in continued high remission rates and drug free remission rates. Patients who 
achieved remission in an early phase of the disease also achieved more (drug free) 
remission in the long run. Radiological damage progression was almost completely 
suppressed. Also, a good response to treatment may prevent chronic deterioration in 
various patient reported outcomes. 
The results in this thesis suggests that, if diagnosed and treated early, RA may not progress 
to the chronic and destructive autoimmune disease as we knew it. Compared to results in 
older cohorts, the disease outcomes are better regardless of traditional poor prognostic 
factors and up to the point that radiological damage on conventional radiographs has 
become difficult to score and may no longer be clinically relevant. Additional research 
should focus not only on finding early, effective treatment for those patients who did 
not achieve early remission on MTX with prednisone, but also on identifying imaging 
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C H A P T E R  13
NEDERLANDSE SAMENVAT TING

De afgelopen decennia is uit onderzoek gebleken dat patiënten met reumatoïde artritis 
(RA) zo snel mogelijk na het stellen van de diagnose moeten starten met de behandeling, 
bij voorkeur met combinatietherapie. Op deze manier kunnen beperkingen in het 
dagelijks functioneren hersteld worden en kan schade(progressie) aan de gewrichten 
voorkomen worden. Ook de kwaliteit van leven en de stemming lijken te verbeteren 
wanneer de ziekteactiviteit snel onder controle is. Daarnaast is het wellicht mogelijk dat, 
indien de doeltreffende behandeling heel vroeg wordt gestart, het ziekteproces een 
halt kan worden toegeroepen en medicatievrije remissie wordt bereikt.
Ongedifferentieerde artritis (van het Engelse undifferentiated artritis; UA) kan vanzelf 
over gaan, maar kan zich ook ontwikkelen tot RA. In het laatste geval wordt UA beschouwd 
als een vroege fase van RA. Ook bij patiënten met UA wordt een tijdige start met 
antireumatische medicatie aanbevolen. Niet alleen vanwege de symptoomverlichting 
maar ook om progressie naar RA te voorkomen, en wellicht zelfs om het ziekteproces 
te stoppen. Methotrexaat (MTX) is het meest voorgeschreven middel bij patiënten met 
RA, maar ook patiënten met UA die autoantilichamen genaamd ACPA (anti-citrullinated 
protein antibodies, geassocieerd met slechtere ziekte-uitkomsten) in het bloed hebben, 
hebben hier baat bij omdat het de progressie naar RA uitstelt. In UA patiënten zonder 
deze autoantilichamen blijkt MTX echter net zo effectief als placebo. Dit suggereert dat 
patiënten met UA wellicht ook meer baat hebben bij initiële combinatietherapie, in 
plaats van MTX monotherapie, om progressie naar RA te voorkomen, om (medicatievrije) 
remissie te induceren en om de uitkomsten van de ziekte in het algemeen te verbeteren. 
Dit proefschrift richt zich op verschillende behandelstrategieën en uitkomstmaten in patiënten 
met RA en UA, en is gebaseerd op de resultaten van drie interventiestudies. In hoofdstuk 1 
wordt een algemene inleiding gegeven over RA, UA, verschillende behandelingsstrategieën 
en relevante uitkomstmaten. In de daaropvolgende hoofdstukken wordt een aantal studies 
over deze onderwerpen beschreven; de lange termijn uitkomsten van UA patiënten in de 
PROMPT studie (hoofdstuk 2), de uitkomsten van UA en RA patiënten gedurende 2 jaar 
follow-up in de IMPROVED-studie (hoofdstuk 3-5), de respons op de behandeling in de 
IMPROVED-studie en de BeSt studie (hoofdstuk 6 en 7), het voorspellen van radiologische 
gewrichtsschade in de IMPROVED-studie (hoofdstuk 8 en 9), en de visie van de patiënt (de 
zogenaamde patiënt gerapporteerde uitkomsten) op zijn/haar welbevinden en het effect 
van de behandeling, opnieuw in de IMPROVED-studie (hoofdstuk 10 en 11).
RA VERSUS UA
In de PROMPT studie werden UA patiënten initieel behandeld met MTX of placebo 
gedurende 1 jaar. Na 30 maanden bleek dat behandeling met MTX de progressie van UA 
naar RA uitstelde, maar dit niet kon voorkomen. In hoofdstuk 2 van dit proefschrift worden 
de lange termijn resultaten van de PROMPT studie, na 5 jaar, besproken. Bij patiënten die 
initieel behandeld werden met MTX werd even vaak progressie naar RA (gedefinieerd 













en de European League Against Rheumatism (EULAR)) gezien als bij patiënten die werden 
behandeld met placebo. Ook de hoeveelheid gewrichtsschade was vergelijkbaar tussen 
patiënten behandeld met MTX en placebo, evenals het aantal patiënten in medicatievrije 
remissie. Alleen patiënten die positief waren voor ACPA profiteerden van de behandeling met 
MTX omdat progressie naar RA in deze groep werd uitgesteld. Echter, de gewrichtsschade 
was ernstiger in deze groep, ongeacht de behandeling met MTX of placebo. De belangrijkste 
conclusie was dat er na 5 jaar nauwelijks een blijvend effect is van behandeling met MTX 
in het eerste jaar. Dit suggereert dat vroege, maar tijdelijke behandeling met MTX, het 
ziektebeloop in patiënten met UA niet kan veranderen. Dit kan zowel het gevolg kan zijn 
van de timing als van de duur van de behandeling, of de keuze van het geneesmiddel.
Bij enkele patiënten uit de PROMPT studie is het niet gelukt om reeds in een vroeg stadium 
het ziekteproces af te remmen, waarschijnlijk vanwege de lange duur van symptomen 
vóór aanvang van de behandeling. Waar alle patiënten volgens de oude (1987) 
classificatiecriteria nog als UA werden geclassificeerd, kon 39% van deze UA patiënten 
geclassificeerd worden als RA volgens de in 2010 gepubliceerde classificatiecriteria, 
die zijn geformuleerd om sneller de diagnose RA te kunnen stellen dan de oude (1987) 
criteria. Doordat patiënten sneller als  RA geclassificeerd worden met deze nieuwe 
criteria, kan de behandeling ook sneller worden gestart in die patiënten waarbij er een 
grote kans is op persisterende symptomen en gewrichtsschade. De keerzijde is dat er 
met de 2010-criteria ook soorten artritis worden geclassificeerd en behandeld als RA, 
die eigenlijk vanzelf zouden zijn overgegaan; zo bereikte 25% van de PROMPT patiënten 
die aan de 2010-criteria voldeed remissie na behandeling met placebo. 
Naast het ‘(te) laat’ starten van de behandeling is het mogelijk dat het stoppen van MTX 
na 1 jaar te vroeg was. Echter, het doel van de PROMPT studie was om het effect van 
vroege, tijdelijke behandeling te onderzoeken. 
Het is ook mogelijk dat MTX monotherapie niet de optimale behandeling was om 
progressie van de ziekte een halt toe te roepen. MTX is doorgaans het middel van eerste 
keus in de behandeling van RA. Gebleken is dat initiële combinatietherapie bestaande 
uit MTX en corticosteroïden of MTX met een biologisch antireumatisch medicijn 
(middelen die bestaan uit dierlijk of menselijk eiwit en het immuunsysteem remmen) 
leidt tot betere resultaten bij patiënten met RA. In de PROMPT studie trad bij 63% van 
de UA patiënten die op baseline konden worden geclassificeerd als vroege RA volgens 
de 2010-criteria, progressie op naar RA (1987) ondanks behandeling met MTX. Mogelijk 
had dit voorkomen kunnen worden met initiële combinatiebehandeling.
Deze overwegingen zijn meegenomen in het ontwerp van de IMPROVED-studie. Een van 
de doelstellingen van de IMPROVED-studie was het vergelijken van uitkomsten in patiënten 
met RA en patiënten met UA.  Deze resultaten worden beschreven in hoofdstuk 3, 4 en 5. RA 
werd gedefinieerd volgens de 2010-criteria met een symptoomduur van minder dan 2 jaar. 
UA werd gedefinieerd als ten minste één gezwollen gewricht en één ander pijnlijk gewricht, 













combinatietherapie bestaande uit MTX en hoge dosis prednison die snel werd afgebouwd 
naar een lagere dosis en vervolgens gecontinueerd werd als onderhoudsdosering. 
Gedurende de studie werd de behandeling aangepast op basis van de Disease Activity 
Score (DAS), een berekening van de ziekteactiviteit gemeten met het aantal gezwollen 
gewrichten en pijnlijke gewrichten, tekenen van ontsteking in het laboratoriumonderzoek 
en de mening van de patiënt over pijn en welzijn. Een DAS<1,6 geeft aan dat er sprake is 
van remissie, de afwezigheid van ziekteactiviteit. De hypothese van de IMPROVED-studie 
was dat de UA patiënten meer baat zouden hebben bij deze behandeling dan patiënten 
met RA, omdat werd verondersteld dat zij in een vroegere fase van de ziekte zaten en dat 
sommigen wellicht een ziekte hadden die vanzelf over kon gaan. Anderzijds was het ook 
mogelijk dat UA patiënten een ‘niet als RA herkenbare artritis’ hadden en minder goed 
zouden reageren op een intensieve anti-reumatische behandeling.
Na de eerste vier maanden van de behandeling (hoofdstuk 3) waren de remissiepercentages 
vergelijkbaar tussen patiënten met RA en UA (61% versus 65%). Na 1 jaar (hoofdstuk 4) 
en na 2 jaar (hoofdstuk 5) waren er nog steeds geen verschillen. Dit was opvallend omdat 
RA patiënten een hogere ziekteactiviteit hadden bij aanvang van de studie en vaker 
ACPA-positief waren, wat doorgaans wordt geassocieerd met een slechtere klinische en 
radiologische respons. Echter, in de IMPROVED-studie vonden we dat ACPA positiviteit 
één van de sterkste voorspellers was voor het bereiken van vroege remissie na 4 
maanden. Bovendien bleken UA patiënten niet in een veel vroegere fase van de ziekte 
te zitten want de symptoomduur op baseline was vergelijkbaar tussen RA (18 weken) 
en UA (16 weken) patiënten. Dit kan erop wijzen dat we de “window of opportunity”, de 
korte tijdspanne van 12 weken waarin het mogelijk lijkt om de uitkomsten van de ziekte 
gunstig te moduleren indien de behandeling direct wordt gestart, hebben gemist in 
zowel RA als UA patiënten. Na 1 jaar en ook 2 jaar follow-up bleek dat UA patiënten vaker 
medicatievrije remissie bereikten dan RA patiënten (hoofdstuk 4 en 5). Deze resultaten 
suggereren dat, hoewel het mogelijk is om in beide groepen evenveel remissie te 
bereiken, het niet mogelijk is om ook evenveel medicatievrije remissie te bereiken. Een 
mogelijk verklaring voor dit verschil is de significant lagere ziekteactiviteit op baseline 
bij UA patiënten en het feit dat de meesten UA patiënten ACPA negatief zijn.
REMISSIE EN MEDICATIEVRIJE REMISSIE
De IMPROVED-studie is één van de eerste studies die de behandeling stuurt op remissie en de 
eerste studie die medicatie afbouwt en stopt zodra en zolang patiënten in remissie zijn. Na de 
eerste 4 maanden behandeling met MTX en prednison was 61% van de patiënten (RA en UA) 
in vroege remissie (hoofdstuk 3). Na 1 jaar was 54% van de patiënten in remissie (hoofdstuk 
4) en na 2 jaar 49% (hoofdstuk 5). Vooral het percentage vroege remissie, van ruim 60%, is vrij 
hoog en te verklaren door de behandeling met een bewezen effectieve combinatie van anti-
reumatische geneesmiddelen, de relatief korte symptoomduur, en de ziekteactiviteit die op 













Het is wel merkwaardig dat de remissiepercentages na 1 en 2 jaar follow-up in de 
IMPROVED-studie slechts iets hoger waren dan de remissiepercentages beschreven 
in de BeSt studie. De patiënten in de BeSt studie waren gediagnosticeerd met actieve 
RA (1987 criteria) en hadden een hoge ziekteactiviteit op baseline, waren vaker ACPA 
positief, en hadden een langere symptoomduur. Bovendien werd slechts de helft 
van de populatie initieel behandeld met combinatietherapie en was het doel van de 
behandeling gericht op het behalen van lage ziekteactiviteit (DAS≤2,4) en niet op 
het behalen van remissie (DAS<1,6), zoals in de IMPROVED-studie. De radiologische 
schade aan de gewrichten bleek echter wel minder ernstig te zijn in de IMPROVED-
studie dan in de Best studie.
Mogelijk is de medicatie in de IMPROVED-studie te vroeg afgebouwd of gestopt, wat 
resulteerde in verlies van remissie. Een andere verklaring is dat remissie minder vaak 
dan verwacht werd bereikt omdat we de “window of opportunity” hebben gemist in 
een deel van de patiënten. Echter, de resultaten van patiënten met een symptoomduur 
van minder dan 12 weken of met een symptoomduur van 12 weken of meer, waren 
vergelijkbaar. Dit wijst erop dat initiële behandeling met MTX en prednison gevolgd 
door remissie gestuurde behandeling effectief is, ongeacht de symptoomduur.
Ondanks dat niet alle patiënten remissie bereiken op de lange termijn, heeft deze 
remissie gestuurde behandeling wel geleid tot een gemiddeld zeer lage ziekteactiviteit 
en het vrijwel volledige voorkomen van gewrichtsschadeprogressie.
INITIËLE COMBINATIETHERAPIE, GEVOLGD DOOR...?
Als patiënten in de IMPROVED-studie na 4 maanden geen remissie hadden bereikt met 
de combinatie van MTX en prednison, dan was het voor deze patiënten moeilijk  om 
met de volgende behandelstappen alsnog remissie te bereiken (hoofdstuk 4 en 5). De 
groep patiënten die vroege remissie bereikten waren na 2 jaar vaker in remissie en in 
medicatievrije remissie dan patiënten die geen vroege remissie hadden bereikt. 
Als patiënten na 4 maanden niet in remissie waren, dan werden zij gerandomiseerd tussen 
2 behandelingsstrategieën (uitbreiding met twee disease-modifying antirheumatic 
drugs (DMARDs) sulfasalazine (SSZ) en hydroxychloroquine (HCQ) of een switch naar 
MTX+adalimumab). Aanvankelijk, na 1 jaar, resulteerde behandeling met MTX en 
adalimumab vanaf 4 maanden in een hoger remissiepercentage dan wanneer de initiële 
behandeling werd uitgebreid met SSZ en HCQ (hoofdstuk 4). Daarnaast verloren meer 
patiënten remissie na het afbouwen van de combinatie van MTX, SSZ, HCQ en prednison 
naar MTX monotherapie en bereikten minder patiënten remissie na het overstappen van 
de combinatie van MTX, SSZ, HCQ en prednison naar de combinatie MTX en adalimumab. 
Deze laatste bevinding weerspiegelt resultaten van de BeSt studie, waarbij infliximab met 
MTX minder effectief was bij patiënten die eerst hadden gefaald op MTX, SSZ en HCQ of 













Na 2 jaar (hoofdstuk 6) lieten de twee behandelstrategieën soortgelijke percentages 
(medicatievrije) remissie zien, met een goed behoud van functioneren en nauwelijks 
radiologische schadeprogressie. Dit kan, in ieder geval deels, verklaard worden door de 
remissiegestuurde behandeling en de uiteindelijke overlap van de behandeling in de 
twee armen. Bovendien is het mogelijk dat langdurige lage ziekteactiviteit de verschillen 
op korte termijn teniet doet. Deze resultaten werden ook gezien in andere studies.
ACPA
De PROMPT studie (hoofdstuk 2) liet zien dat er verschillen waren in uitkomsten tussen 
ACPA positieve en ACPA negatieve patiënten. Progressie van UA naar RA ging significant 
sneller bij ACPA positieve patiënten en er was meer radiologische schadeprogressie in 
deze groep. Daarnaast bleek MTX alleen effectief bij ACPA positieve patiënten; progressie 
van UA naar RA werd alleen in deze groep uitgesteld en MTX had geen effect in ACPA 
negatieve patiënten. Als laatste werd gevonden dat de afwezigheid van ACPA de enige 
onafhankelijke voorspeller was voor medicatievrije remissie na 5 jaar.
Onafhankelijke voorspellers voor vroege remissie in de IMPROVED-studie (hoofdstuk 
3) waren; lage ziekteactiviteit op baseline, weinig pijnlijke en/of gezwollen 
gewrichten, mannelijk geslacht, lagere ‘body mass index’ (BMI) en ACPA positiviteit. 
De laatstgenoemde lag niet in de lijn der verwachting omdat ACPA meestal wordt 
geassocieerd met slechtere uitkomsten en een slechtere respons op de behandeling. Een 
verklaring voor deze bevinding kan gevonden worden in de criteria die gesteld zijn voor 
de classificatie van RA. Volgens de 2010-criteria is de classificatie van RA gebaseerd op 
de ernst van een artritis en op de aanwezigheid en de titer van autoantilichamen (ACPA 
en reumafactor (RF)). Patiënten met een milde artritis maar met een hoge titer auto-
antilichamen, worden aangemerkt als RA en patiënten zonder autoantilichamen hebben 
een groter aantal ontstoken gewrichten ‘nodig’ om te kunnen worden geclassificeerd als 
RA. De ACPA positieve RA patiënten in IMPROVED hadden inderdaad minder betrokken 
gewrichten dan ACPA negatieve RA patiënten en als gevolg daarvan hadden de ACPA 
negatieve RA patiënten een hogere baseline ziekteactiviteit (ze hadden tevens een 
langere symptoomduur). Dit kan verklaren waarom ACPA negatieve patiënten minder 
vaak remissie bereikten na 4 maanden dan ACPA positieve patiënten. 
Na 1 jaar was 32% van de patiënten in de IMPROVED-studie in medicatievrije remissie en 
in 65% van deze patiënten hield dit gedurende ten minste 4 maanden stand (hoofdstuk 
6). Aanwezigheid van RF, geclassificeerde RA (volgens de 2010-criteria), en een laag aantal 
pijnlijke gewrichten op baseline waren geassocieerd met het bereiken van medicatievrije 
remissie na 1 jaar. Echter, geen van de variabelen was onafhankelijk geassocieerd met 
medicatievrije remissie. ACPA positieve patiënten bereikten net zo vaak medicatievrije 
remissie als ACPA negatieve patiënten, maar ACPA positieve patiënten konden minder 
vaak in medicatievrije remissie blijven. In een eerdere studie werd al gerapporteerd dat 













medicatievrije remissie. Dat in een vergelijkbaar percentage ACPA positieve en ACPA 
negatieve patiënten medicatievrije remissie bereikt werd in IMPROVED kan verklaard 
worden door zowel de efficiëntie combinatie van MTX en prednison, en de tijdige start 
van doelgerichte behandeling. Hoewel vergelijkbare percentages in het behalen van 
medicatievrije remissie werden gevonden, lijkt het behouden van medicatievrije remissie 
iets anders. Wellicht hebben ACPA positieve patiënten een andere behandelstrategie nodig 
dan ACPA negatieve patiënten; bij ACPA positieve patiënten zou misschien minder snel 
afgebouwd moeten  worden of juist gestart met een andere combinatie van medicijnen.
De verschillen in uitkomsten tussen ACPA positieve en ACPA negatieve artritis kunnen 
erop wijzen dat dit verschillende ziekten zijn met verschillende pathofysiologische 
mechanismen die leiden tot ziekteactiviteit. Mogelijk is het effect van de behandeling 
afhankelijk van deze pathofysiologische mechanismen en moet de behandeling worden 
aangepast aan deze mechanismen. Het huidige gebrek aan kennis van de moleculaire 
mechanismen die ten grondslag liggen aan ziekteactiviteit maakt dat gerichte 
interventies, in het bijzonder voor ACPA negatieve ziekte, (nog) niet mogelijk zijn.
REMISSIE EN BMI 
Naast ACPA zijn er ook andere factoren die van invloed zijn op de behandelrespons. Uit 
eerder onderzoek is gebleken dat patiënten met een hoog BMI die eerder behandeld 
waren met ten minste twee DMARDs, minder goed reageerden op de behandeling met 
infliximab (IFX). De hypothese die hier aan ten grondslag ligt is dat deze verminderde 
respons bij patiënten met een hoog BMI verklaard kan worden door een hoog aantal 
‘ontstekingsbevorderende stoffen’ (pro-inflammatoire cytokinen) vanuit vetcellen.
In de BeSt studie werden patiënten met vroege actieve RA behandeld met initiële MTX 
monotherapie of initiële combinatietherapie (combinatie van MTX, SSZ en prednison of 
de combinatie van MTX en IFX) waarbij het doel het bereiken van lage ziekteactiviteit 
(DAS≤2,4) was. In de BeSt populatie bleek een hoog BMI geassocieerd te zijn met 
het minder vaak bereiken van lage ziekteactiviteit na behandeling (falen), en deze 
associatie was het meest uitgesproken bij patiënten die behandeld werden met initiële 
combinatietherapie (hoofdstuk 7). Falen, het niet bereiken van lage ziekteactiviteit, was 
afhankelijk van hogere pijn scores en een groter aantal pijnlijke gewrichten.
Ervan uitgaande dat BMI is geassocieerd met inflammatoire parameters, zou men 
verwachten dat het niet bereiken van een DAS≤2,4 bij patiënten met een hoog BMI 
veroorzaakt wordt door verhoogde inflammatoire parameters. De resultaten lieten 
dit echter niet zien.  Dit zou onder andere verklaard kunnen worden door het kleine 
aantal patiënten met een BMI>30 kg/m2. Bovendien kan het gewrichtsonderzoek soms 
een uitdaging zijn bij patiënten met een hoog BMI en daardoor is gewrichtszwelling 
in deze patiënten mogelijk onderschat. In de BeSt studie werd eerder aangetoond 













datzelfde gewricht en daarom is het niet uitgesloten dat gewrichtspijn een indicator 
is van gewrichtsontsteking, zelfs in de afwezigheid van (objectiveerbare) zwelling. 
Echter, de mate van gewrichtsschade tussen patiënten met een hoog BMI en een laag/
normaal BMI was vergelijkbaar, en dus lijkt het waarschijnlijk dat patiënten met een 
hoog BMI en veel pijnlijke gewrichten toch geen hogere ontstekingsactiviteit hadden. 
De vergelijkbare progressie in de verschillende BMI categorieën kan ook het gevolg zijn 
van gecontinueerde DAS-gestuurde behandeling, waarbij veel pijn leidt tot een hogere 
score voor ziekteactiviteit en dus een intensievere behandeling. De vergelijkbare 
gewrichtsschade kan ook verklaard worden door een eerder beschreven beschermend 
effect van BMI op gewrichtsschade. Mogelijk speelt fibromyalgie een rol in de pijn bij 
patiënten met een hoog BMI. In de literatuur is beschreven dat bepaalde hormonen en 
neurotransmitters verantwoordelijk zijn voor een verband tussen een hoog BMI en pijn, 
en met name musculoskeletale pijn wordt dan vaker aangegeven op meerdere locaties. 
De associatie tussen pijn en BMI geeft een ook verklaring voor de verminderde functionele 
capaciteit bij patiënten met een hoog BMI, daar zowel pijn als lichaamsgrootte kunnen 
interfereren met de dagelijkse bezigheden.
RADIOLOGIE
Vroege en doelgerichte behandeling, waarmee de ziekteactiviteit onderdrukt wordt, kan 
radiologische schadeprogressie voorkomen. Wanneer behandeling vroeg in het ziekteproces 
wordt gestart bestaat er echter wel een risico op overbehandeling, bijvoorbeeld in patiënten 
met ongedifferentieerde artritis die ook zonder behandeling over was gegaan. 
Eén van de belangrijkste bevindingen na 2 jaar remissiegestuurde behandeling in de 
IMPROVED-studie is het bijna volledig voorkomen van gewrichtsschade in de overgrote 
meerderheid van de patiënten, los van het feit of deze patiënten in remissie waren of niet. 
Slechts 51 patiënten (8%), van de oorspronkelijke 610, hadden progressie van minimaal een 
0,5 punt in de Sharp-van der Heijde Score (SHS) na 2 jaar en slechts 8 patiënten (1%) hadden 
progressie  van ≥5 punten, gedefinieerd als het minimale klinisch relevante verschil. 
Wanneer combinatietherapie vroeg wordt gestart en de behandeling wordt gestuurd op 
remissie, wordt radiologische schadeprogressie onderdrukt tot het punt dat elke vorm van 
schade moeilijk te detecteren is en bovendien ook lastig te onderscheiden van normale 
variatie. In de IMPROVED-studie werden minder erosies gevonden na 2 jaar follow-up 
dan na 1 jaar (hoofdstuk 5). Marginale gewrichtsschade is moeilijk te onderscheiden van 
normale variaties in het radiologisch beeld. Aangezien de röntgenfoto’s in willekeurige 
volgorde zijn gescoord (en niet in chronologische volgorde), is het lastig om progressie 
te detecteren. Repair, het helen van reeds ontstane erosies, als verklaring voor het minder 
aantal gevonden erosies na 2 jaar follow-up is niet heel waarschijnlijk, aangezien dit 
vooral optreedt in beschadigde gewrichten. Het meest belangrijk is echter dat, ondanks 













Snelle toename van radiologische schade (zogenaamd rapid radiological progression 
(RRP)), gedefinieerd als ≥5 punten progressie in het eerste jaar na diagnose, is 
geassocieerd met een slechte prognose met betrekking tot verdere schadeprogressie en 
de functionele capaciteit. In de BeSt studie is een voorspelmodel ontwikkeld waarmee 
het risico op RRP  kan worden vastgesteld (door middel van erosies op baseline, de 
mate van ontsteking in het bloed en de aanwezigheid van autoantilichamen)zodat de 
initiële behandeling kan worden aangepast aan dat risico. Dit model is in de IMPROVED-
studie getest (hoofdstuk 8) en bleek niet van toepassing op de IMPROVED populatie, 
waarschijnlijk door verschillen in inclusiecriteria in beide studies.
Baseline ziekteactiviteit bleek lager te zijn en symptoomduur korter in de IMPROVED-
studie dan in de BeSt studie. In de BeSt populatie werden alleen RA patiënten geïncludeerd 
die voldeden aan de 1987 classificatie criteria met een hoge ziekteactiviteit. In de 
IMPROVED-studie werden patiënten, volgens de huidige aanbevelingen, zo vroeg mogelijk 
geclassificeerd als RA volgens de 2010-criteria of als UA met een klinische verdenking 
op vroege RA. Daarnaast werden alle IMPROVED patiënten behandeld met initiële 
combinatietherapie bestaande uit MTX en prednison, terwijl in BeSt de helft van de patiënten 
aanvankelijk MTX monotherapie kregen. Niet alleen was de baseline ziekteactiviteit lager 
en de symptoomduur korter in de IMPROVED-studie, ook de risicofactoren van het matrix 
model waren minder vaak aanwezig in de IMPROVED patiënten: patiënten hadden lagere 
CRP waardes, minder vaak erosieve gewrichtsschade op baseline en ze waren minder 
vaak ACPA en/of RF-positief. Bovendien werd niemand initieel behandeld met MTX 
monotherapie. Om deze redenen was RRP minder waarschijnlijk in de meeste IMPROVED 
patiënten en bijzonder onwaarschijnlijk in de UA patiënten.
Gebaseerd op het model hadden 13 patiënten een gemiddeld risico (20% - 50%) op 
RRP. Van die 13, waren er 2 patiënten met progressie (≥0,5 SHS) in jaar 1, de anderen 
hadden geen progressie. Waarschijnlijk is dit te verklaren door de behandeling gericht 
op remissie in de IMPROVED-studie, waardoor de ziekteactiviteit efficiënt wordt 
onderdrukt. Eén patiënt met een laag risico op RRP volgens het model had na 1 jaar wél 
RPP. Waarschijnlijk spelen andere risicofactoren voor schadeprogressie, die niet in het 
model zijn opgenomen, een rol.
Voorspellingsmodellen voor RRP op basis van gegevens van eerdere studies en 
patiëntenpopulaties uit de tijd van minder strenge behandelstrategieën, lijken niet 
meer relevant voor de huidige en voor toekomstige patiënten. Omdat in deze groep 
patiënten nog wel resterende, nauwelijks meetbare, ziekteactiviteit kan zijn en dit 
invloed kan hebben op het kraakbeen van de gewrichten, zullen nieuwere technieken 
moeten worden ontwikkeld. Uiteindelijk zal moeten worden gezocht naar nu nog 
onbekende risicofactoren voor gewrichtsschade.
Naast röntgenfoto’s kunnen andere beeldvormende technieken gebruikt worden 
om het (vroege) effect van ziekteactiviteit op het bot te bekijken. Met Digitale X-ray 













de botdichtheid van de middenhandsbeentjes (mBMD) worden gedetecteerd. Verlies van 
mBMD in het eerste jaar na diagnose blijkt voorspellend te zijn voor radiologische schade 
na 5 jaar follow-up. Voor de klinische praktijk zou een vroege detectie van veranderingen 
in de botdichtheid van de waarde kunnen zijn om de behandeling daarop aan te passen. 
In IMPROVED is de voorspellende waarde van botdichtheidsverlies na 4 maanden 
behandeling onderzocht en veranderingen in de botdichtheid bleken radiologische 
schade na 1 jaar te kunnen voorspellen (hoofdstuk 9). De aanwezigheid van erosies op 
baseline was tevens voorspellend voor radiologische schadeprogressie na 1 jaar follow-up. 
Bij patiënten die geen erosies op baseline hadden (86% van de patiënten), was verlies van 
de botdichtheid na 4 maanden behandeling zelfs de enige voorspeller voor toekomstige 
gewrichtsschade. Het meten van botdichtheidsverlies na 4 maanden follow-up lijkt dus 
waardevol en kan helpen bij de besluitvorming omtrent de behandeling. Echter, zoals 
eerder vermeld, slechts een paar patiënten in IMPROVED hadden schadeprogressie en de 
waarde van de DXR zal daarom verder gevalideerd moeten worden in andere studies.
PATIËNT GERAPPORTEERDE UITKOMSTEN
Behandeling heeft niet alleen invloed op het bereiken van remissie en voorkomen 
van radiologische schadeprogressie, maar beïnvloedt ook hoe patiënten hun kwaliteit 
van leven beoordelen. Het behandeldoel in de IMPROVED-studie is remissie, wat kan 
worden gedefinieerd als ‘de afwezigheid van hinderlijke ziekteactiviteit’. Daarmee 
dient de behandeling niet alleen te leiden tot afwezigheid van symptomen, maar 
ook tot afwezigheid van beperkingen in functioneren, psychische klachten, en 
tot een toename of herstel van de kwaliteit van leven. Deze zogenaamde patiënt 
gerapporteerde uitkomstmaten worden gemeten met behulp van vragenlijsten. In de 
huidige behandeling van patiënten met artritis speelt het verbeteren en/of handhaven 
van deze uitkomsten  een steeds grotere rol. Depressie komt vaker voor bij patiënten 
met RA in vergelijking met de gezonde populatie. In patiënten met een depressie 
werden in eerder onderzoek verhoogde waarden gevonden van de cytokinen IL-1, 
IL-6 en Tumor Necrose Factor (TNF) alfa. Er wordt gesuggereerd dat de associatie 
tussen RA en depressie verklaard kan worden door deze inflammatoire processen. In 
de IMPROVED-studie bleek dat patiënten meer depressieve symptomen rapporteerden 
wanneer geen remissie werd bereikt, wat voornamelijk afhankelijk was van het aantal 
pijnlijke gewrichten en het gevoel van welzijn (gemeten op een visueel analoge 
schaal) (hoofdstuk 10). De associatie tussen de stemming en pijn werkt waarschijnlijk 
twee kanten op: pijn kan de stemming beïnvloeden, maar de stemming kan ook de 
pijnperceptie beïnvloeden. Patiënten met hogere pijnscores op baseline rapporteerden 
meer depressieve symptomen, waarbij het uiteraard mogelijk is dat de patiënten met 
meer depressieve symptomen geneigd zijn tot het rapporteren van meer pijn. Pijn die 
niet gerelateerd is aan een ontsteking kan een hoge DAS veroorzaken en dat kan er 













meer depressieve symptomen. Bovendien was het voor alle patiënten duidelijk dat het 
behandeldoel remissie was en dat medicatie daarna afgebouwd en zelfs gestopt kon 
worden. Het niet bereiken van remissie, en dus het niet bereiken van het behandeldoel, 
kan ook van invloed geweest zijn op de stemming.
In de IMPROVED-studie werden alle patiënten behandeld met prednison, wat extremen 
kan veroorzaken in stemming zoals depressie maar ook manie. Vanwege het ontbreken 
van een  controlegroep, kan het daadwerkelijke effect van de prednison niet worden 
geëvalueerd. Het lijkt echter onwaarschijnlijk dat prednison veel effect heeft gehad 
op de stemming, omdat geen van de patiënten extremen in de stemming heeft 
gerapporteerd, en de onderhoudsdosis prednison slechts 7,5 mg per dag was.
Als tegenhanger van depressieve symptomen, die fluctueren over de tijd, wordt optimisme 
beschouwd als een karaktereigenschap die relatief stabiel is over de tijd. In de IMPROVED-
studie bleek dat het niveau van optimisme niet significant was veranderd na de eerste 4 
maanden behandeling. Zelfs de patiënten die remissie bereikten na 4 maanden hadden 
geen significant hoger niveau van optimisme dan patiënten die geen remissie bereikten. 
Dit zou kunnen betekenen dat optimisme, zoals  gemeten in deze studie, toch ook over de 
tijd kan variëren en op een bepaald niveau afhankelijk is van de stemming. In IMPROVED 
waren optimisme en depressieve symptomen met elkaar geassocieerd; optimistische 
patiënten hadden minder last van depressieve symptomen die op hun beurt weer 
geassocieerd zijn met pijn, welbevinden en remissie. Bovendien is optimisme één van de 
factoren die invloed heeft op coping en het is daarom plausibel dat optimisme op die 
manier invloed heeft gehad op hoe patiënten zich voelden, op hun stemming, maar ook 
op de vermoeidheid van patiënten en de hoeveelheid pijn die ze hadden.
Gedurende het eerste jaar van de IMPROVED-studie werden nog meer patiënt 
gerapporteerde uitkomsten gemeten; de gezondheidsgerelateerde kwaliteit van leven, 
gemeten met de Short-Form 36 (SF-36), het functioneren in het dagelijks leven (met 
de health assessment questionnaire (HAQ)), de mate van pijn, ochtendstijfheid en 
welbevinden, en de eigen inschatting van de ziekteactiviteit (op een visual analogue 
scale (VAS), een schaal van 0 tot 100 mm) (hoofdstuk 11). 
Op baseline bleken met name de fysieke domeinen van gezondheidsgerelateerde 
kwaliteit van leven aangedaan te zijn en gemiddeld een stuk lager te liggen dan 
in gezonde personen uit de Nederlandse populatie. Ondanks dat de behandeling 
relatief vroeg werd gestart en bijna geen enkele patiënt radiologische schade had op 
baseline, bleek de ziektelast van vroege artritis aanzienlijk. In alle patiënten werd na de 
behandeling een klinisch relevante verbetering gezien. 
Patiënten die vroege remissie hadden bereikt, hadden opnieuw betere uitkomsten 
(gezondheidsgerelateerde kwaliteit van leven, functioneren, pijn, ochtendstijfheid, 
welbevinden, en de eigen inschatting van de ziekteactiviteit) dan patiënten die 













behaalden op baseline al beter waren, kan geconcludeerd worden dat patiënten met 
een mildere ziekte op baseline waarschijnlijk voorbestemd zijn voor betere uitkomsten 
en daarom hebben ze meer baat bij remissiegestuurde behandeling omdat de patiënt 
gerapporteerde uitkomsten in deze groep vergelijkbaar zijn met de gezonde populatie. 
Dit heeft een positieve invloed op het vermogen om te kunnen werken en dus op de 
persoonlijke en maatschappelijke kosten van het hebben van (reumatoïde) artritis.
Bij de patiënten die geen vroege remissie bereikten en werden gerandomiseerd, waren 
alle patiënt gerapporteerde uitkomsten lager dan in de vroege remissie groep. Tussen 
de gerandomiseerde groepen waren de uitkomsten na 1 jaar bijna geheel vergelijkbaar. 
Alleen de onderdrukking van de ziekteactiviteit werd in de MTX plus adalimumab groep 
beter beoordeeld, waarschijnlijk vanwege de lagere DAS en de hogere verwachtingen 
ten aanzien van TNF-alfa antagonist adalimumab. 
Uit de IMPROVED-studie blijkt dat alle PROs waren geassocieerd met het bereiken van 
remissie. Omdat dit effect ook te zien was in de verschillende randomisatie armen is het 
waarschijnlijk dat onderdrukking van ziekteactiviteit, ook al is het niet tot het niveau van 
remissie, toch de belangrijkste determinant is van patiënt gerapporteerde uitkomsten.
TOEKOMSTPERSPECTIEVEN EN CONCLUSIE
De classificatiecriteria uit 1987 waren bedoeld om patiënten met gevorderde RA te 
identificeren. Het doel van de 2010-criteria is om in een vroeg stadium te identificeren 
welke patiënten mogelijk een progressiever ziektebeloop krijgen en baat hebben 
bij een gerichte behandeling. Sinds de publicatie van de nieuwe criteria, is het 
verschil tussen RA en UA kleiner geworden. Daarmee worden het ziektebeloop en de 
uitkomsten waarschijnlijk ook meer en meer vergelijkbaar. In de IMPROVED-studie 
waren er enkele verschillen tussen patiënten met RA en UA op baseline; in RA patiënten 
was de gemiddelde ziekteactiviteit en het percentage ACPA positieve patiënten 
hoger. De resultaten wat betreft remissie waren in beide groepen vergelijkbaar, met 
uitzondering van het aantal patiënten dat medicatievrije remissie behaalde. Aan de 
ene kant is het bemoedigend dat RA patiënten dezelfde uitkomsten hebben als UA 
patiënten. Anderzijds is het uiteindelijke doel van de behandeling van UA patiënten 
om te proberen om het beloop van de ziekte zodanig te veranderen dat zij mogelijk 
genezen kunnen worden. Helaas lijkt dit doel niet bereikt te zijn in de IMPROVED-studie.
De vergelijkbaarheid van de uitkomsten tussen patiënten met RA en UA benadrukt 
het belang van vroege herkenning en directe behandeling. Maar hoe vroeg is vroeg? 
Volgens de ‘window of opportunity-theorie’ betekent vroeg dat de behandeling vóór 12 
weken symptoomduur geïnitieerd moet worden. Na 2 jaar follow-up in de IMPROVED-
studie bleken er geen verschillen te zijn in de percentages behaalde remissie van de 
patiënten met meer of minder dan 12 weken symptoomduur. De 12 weken drempel, die 













door behandeling gericht op lage ziekteactiviteit, is waarschijnlijk niet meer relevant 
wanneer patiënten worden behandeld met een efficiëntere initiële combinatietherapie 
en DAS- en/of remissiegestuurde behandeling. Echter, met de vroege start van de 
behandeling bij patiënten met UA of zelfs bij patiënten met geclassificeerde RA, 
is overbehandeling een belangrijke factor om rekening mee te houden. Toch is 
overbehandeling vaak tijdelijk, omdat bij de meeste patiënten de medicatie afgebouwd 
en zelfs gestopt kan worden bij een goede klinische respons.
De aanwezigheid van ACPA wordt beschouwd als voorspeller voor een slechte respons 
op behandeling en een ernstiger ziekteverloop. ACPA positieve artritis en ACPA 
negatieve artritis kunnen daarom worden beschouwd als verschillende ziekte entiteiten 
en idealiter moet de behandeling worden gestart en aangepast aan deze verschillen. In 
de IMPROVED-studie werden patiënten aanvankelijk behandeld met MTX en prednison. 
Na 1 jaar remissiegestuurde behandeling waren ACPA positieve en ACPA negatieve 
patiënten even vaak in remissie en de schade progressie was in beide groepen minimaal 
en vergelijkbaar. Het enige verschil was dat ACPA positieve patiënten minder vaak 
langere tijd in medicatievrije remissie  konden blijven. De verschillen tussen patiënten 
met een goede prognose (ACPA negatief ) en een slechte prognose (ACPA positief ) lijken 
kleiner te worden. Dit kan deels worden verklaard door de dynamische behandelstrategie 
binnen de IMPROVED-studie, in dit geval remissiegestuurd, die er in het algemeen voor 
zorgt dat zowel patiënten met een goede prognose als patiënten met een slechte 
prognose zo snel mogelijk de voor hun meest effectieve behandeling krijgen. Het kan 
ook betekenen dat andere factoren een rol spelen en dat deze mogelijk nog niet zijn 
geïdentificeerd. De resultaten in dit proefschrift geven aan dat de ziekteuitkomsten 
van vroege artritis verder zijn verbeterd door behandelingsstrategieën zoals die in 
de IMPROVED-studie. Hoewel in de meeste patiënten al wel remissie werd bereikt, is 
het ideaalbeeld toch dat er ook medicatievrije remissie wordt bereikt in meer (of bij 
voorkeur alle) patiënten, voor langere tijd. Toekomstige studieresultaten, waaronder die 
van de IMPROVED-studie, moeten onderzoeken welke factoren voorspellend zijn voor 
aanhoudende (medicatievrije) remissie. 
Ook de kwaliteit van leven en het algemeen welzijn van de patiënten lijken te verbeteren 
door de vroege start met combinatietherapie, vooral wanneer remissie vroeg in het 
ziekteproces werd bereikt. Wellicht kan het routinematig monitoren van patiënt 
gerapporteerde uitkomsten van pas komen in de dagelijkse praktijk en mee worden 
genomen in behandelbeslissingen.
In de IMPROVED-studie haalden de patiënten die geen vroege remissie (na 4 maanden) 
bereikt hadden, veel minder vaak remissie en medicatievrije remissie tijdens follow-up. 
Gecontinueerde remissiegestuurde behandeling lijkt hier dus geen effect op te hebben. 
Mogelijk is de respons op behandeling minder goed wanneer het langer duurt om het 
juiste middel of de juiste combinatie van middelen te vinden. Bij sommige patiënten 













geen oplossing voor bieden. Identificatie van onbekende risicofactoren voor het niet 
bereiken van vroegtijdige remissie is een stap in de richting van behandeling op maat.
Zonder de voordelen van remissiegestuurde behandeling uit het oog te verliezen, 
moeten we ook rekening houden met de mogelijke nadelen. Het starten van adalimumab, 
of biologische middelen in het algemeen, vroeg in het ziektebeloop gaat gepaard met 
hoge kosten en mogelijke bijwerkingen. De initiële hoge dosis prednison, weliswaar 
voortgezet in een lage dosering in sommige patiënten, geeft een verhoogd risico op 
infecties en andere complicaties. Echter, zonder een non-prednison controlegroep 
kunnen we het risico van deze behandeling niet goed beoordelen. Wellicht is MTX met 
een lagere startdosering prednison net zo effectief.
Samenvattend, bij patiënten met vroege RA of UA leidt remissiegestuurde behandeling 
tot relatief hoge percentages remissie en medicatievrij remissie. Patiënten die remissie 
bereiken in een vroege fase van de ziekte, bereiken ook vaker (medicatievrije) remissie 
op de lange termijn. Bijna alle patiënten toonden een goede onderdrukking van 
radiologische schadeprogressie. Bovendien voorkomt een goede respons op de 
behandeling verslechtering van verschillende patiënt gerapporteerde uitkomsten, zoals 
depressie en kwaliteit van leven.
De resultaten in dit proefschrift onderstrepen dat, als de diagnose vroeg wordt gesteld en 
er direct wordt gestart met de behandeling, RA niet meer de chronische en destructieve 
ziekte is die het vroeger was. Vergeleken met de resultaten in oudere cohorten zijn de 
uitkomsten met de huidige behandelstrategieën beter, ongeacht de aanwezigheid 
van prognostische factoren die traditioneel als slecht te boek staan, tot aan het punt 
dat radiologische schade op conventionele röntgenfoto’s dusdanig moeilijk te scoren 
is en misschien niet meer klinisch relevant. Toekomstig onderzoek zal zich niet alleen 
moeten gaan richten op het vinden van vroege, effectieve behandelingsstrategieën 
voor patiënten die geen vroege remissie bereiken op MTX en prednison, maar ook op 
het toetsen van beeldvormende technieken die voldoende gevoelig en betrouwbaar 
zijn om toe te kunnen passen bij de evaluatie van de behandeling. Ook zal er gericht 
onderzoek gedaan moeten worden naar nieuwe prognostische factoren die bijdragen 
aan individuele behandelingsstrategieën die de behandeling en uitkomsten van 
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zus bent, fantastisch dat je mijn paranimf wilt zijn!
Lieve papa, heel veel dank voor het vertrouwen en de mogelijkheden die jij en mama 
me gegeven hebben. Dat mama dit niet heeft mogen meemaken is een groot gemis.
Ik dank jou en Yvonne voor jullie steun en verregaande interesse tijdens de afgelopen jaren.
En ten slotte natuurlijk Jeroen, mijn allerliefste. Mijn dank aan jou is buitengewoon 
groot; voor je interesse in de dingen die ik doe, je luisterend oor in tijden van klagen, 
je relativeringsvermogen en humor als je met me meedenkt en bovenal voor je liefde. 
Samen met jou kan ik alles aan, ik kijk enorm uit naar onze toekomst!
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